CA2528119A1 - Cis-2,4,5-triaryl-imidazolines - Google Patents
Cis-2,4,5-triaryl-imidazolines Download PDFInfo
- Publication number
- CA2528119A1 CA2528119A1 CA002528119A CA2528119A CA2528119A1 CA 2528119 A1 CA2528119 A1 CA 2528119A1 CA 002528119 A CA002528119 A CA 002528119A CA 2528119 A CA2528119 A CA 2528119A CA 2528119 A1 CA2528119 A1 CA 2528119A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- trifluoromethyl
- chloro
- bis
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 131
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims abstract description 18
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims abstract description 18
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 230000003993 interaction Effects 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 441
- 125000003545 alkoxy group Chemical group 0.000 claims description 188
- 125000000623 heterocyclic group Chemical group 0.000 claims description 167
- 125000001424 substituent group Chemical group 0.000 claims description 128
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 123
- 125000004043 oxo group Chemical group O=* 0.000 claims description 99
- 125000001072 heteroaryl group Chemical group 0.000 claims description 80
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 68
- 125000003118 aryl group Chemical group 0.000 claims description 58
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 36
- -1 cyano, hydroxy Chemical group 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000000565 sulfonamide group Chemical group 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- PMKOHDFNHIQHEU-UHFFFAOYSA-N 1-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-oxoethyl]-n,n-diethylpiperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CC(CCC2)C(=O)N(CC)CC)CC1 PMKOHDFNHIQHEU-UHFFFAOYSA-N 0.000 claims description 2
- ZNZKQJWQOKNGIO-UHFFFAOYSA-N 1-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetyl]-n,n-diethylpiperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CC(CCC2)C(=O)N(CC)CC)CC1 ZNZKQJWQOKNGIO-UHFFFAOYSA-N 0.000 claims description 2
- IFZDTJNREFBQTR-UHFFFAOYSA-N 1-[2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-2-oxoethyl]-n,n-diethylpiperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CC(CCC2)C(=O)N(CC)CC)CC1 IFZDTJNREFBQTR-UHFFFAOYSA-N 0.000 claims description 2
- ZAWFJNDMMRRTMD-UHFFFAOYSA-N 1-[2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-2-oxoethyl]piperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CC(CCC2)C(N)=O)CC1 ZAWFJNDMMRRTMD-UHFFFAOYSA-N 0.000 claims description 2
- GJOIYISPAKKBDK-UHFFFAOYSA-N 1-[2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CCC(CC2)C(N)=O)CC1 GJOIYISPAKKBDK-UHFFFAOYSA-N 0.000 claims description 2
- LGQBICOQRLJALZ-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-(dimethylamino)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN(C)C)CC1 LGQBICOQRLJALZ-UHFFFAOYSA-N 0.000 claims description 2
- YXPRNTPQPZRLEF-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[2-(dimethylamino)ethylamino]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CNCCN(C)C)CC1 YXPRNTPQPZRLEF-UHFFFAOYSA-N 0.000 claims description 2
- SXVYOQHGEIBTGB-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[methyl-(1-methylpyrrolidin-3-yl)amino]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN(C)C2CN(C)CC2)CC1 SXVYOQHGEIBTGB-UHFFFAOYSA-N 0.000 claims description 2
- ZPMWMBBYMBLEOL-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-methoxyethanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)COC)CC1 ZPMWMBBYMBLEOL-UHFFFAOYSA-N 0.000 claims description 2
- GWXFDEKTMYHREF-UHFFFAOYSA-N 1-[4-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]sulfonylpiperazin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCN(CC2)C(C)=O)CC1 GWXFDEKTMYHREF-UHFFFAOYSA-N 0.000 claims description 2
- SIRRGYOWMNYEGB-UHFFFAOYSA-N 1-[4-[[4-[4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCN(C(C)=O)CC1 SIRRGYOWMNYEGB-UHFFFAOYSA-N 0.000 claims description 2
- YVUAWTINQHPMBG-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCC3(CC2)OCCO3)CC1 YVUAWTINQHPMBG-UHFFFAOYSA-N 0.000 claims description 2
- LNJVNRIFSMVMBJ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-[4-(2-hydroxyethyl)piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCC(CCO)CC2)CC1 LNJVNRIFSMVMBJ-UHFFFAOYSA-N 0.000 claims description 2
- XWSILZLDAKXQSK-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-[4-(hydroxymethyl)piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCC(CO)CC2)CC1 XWSILZLDAKXQSK-UHFFFAOYSA-N 0.000 claims description 2
- GUFQMXVXIWTNOX-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-[4-(trifluoromethyl)piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCC(CC2)C(F)(F)F)CC1 GUFQMXVXIWTNOX-UHFFFAOYSA-N 0.000 claims description 2
- IPONKTFQLKPTGG-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-pyrrolidin-1-ylethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCCC2)CC1 IPONKTFQLKPTGG-UHFFFAOYSA-N 0.000 claims description 2
- YGOXRDOHYBSCHA-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-thiomorpholin-4-ylethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCSCC2)CC1 YGOXRDOHYBSCHA-UHFFFAOYSA-N 0.000 claims description 2
- MQMZUIHFOFNBJQ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n,n-bis(2-methoxyethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(CCOC)CCOC)CC1 MQMZUIHFOFNBJQ-UHFFFAOYSA-N 0.000 claims description 2
- VWUWYTDXGJFOGO-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n,n-diethylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(CC)CC)CC1 VWUWYTDXGJFOGO-UHFFFAOYSA-N 0.000 claims description 2
- SRBBJOUGKVHQQN-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(1,3-dioxolan-2-ylmethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)CC2OCCO2)CC1 SRBBJOUGKVHQQN-UHFFFAOYSA-N 0.000 claims description 2
- RHOQXHDPMWCDRH-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(2-hydroxyethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)CCO)CC1 RHOQXHDPMWCDRH-UHFFFAOYSA-N 0.000 claims description 2
- OWYVHASFWKEOJJ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(furan-2-ylmethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)CC=2OC=CC=2)CC1 OWYVHASFWKEOJJ-UHFFFAOYSA-N 0.000 claims description 2
- HNKROGOWIIXEAQ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-[(5-methylfuran-2-yl)methyl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCC=2OC(C)=CC=2)CC1 HNKROGOWIIXEAQ-UHFFFAOYSA-N 0.000 claims description 2
- HNOOCMSVOYKNLF-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-cyclopropylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NC2CC2)CC1 HNOOCMSVOYKNLF-UHFFFAOYSA-N 0.000 claims description 2
- NGJOSVSANIDIAK-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-ethoxyacetamide Chemical compound C1CN(CC(=O)NOCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 NGJOSVSANIDIAK-UHFFFAOYSA-N 0.000 claims description 2
- FHLUHUAVLUVQDQ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-methyl-n-propan-2-ylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)C(C)C)CC1 FHLUHUAVLUVQDQ-UHFFFAOYSA-N 0.000 claims description 2
- TWDQXWQGTUWDMO-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NC)CC1 TWDQXWQGTUWDMO-UHFFFAOYSA-N 0.000 claims description 2
- CQLDSBZXVVUVNB-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-phenylmethoxyacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NOCC=2C=CC=CC=2)CC1 CQLDSBZXVVUVNB-UHFFFAOYSA-N 0.000 claims description 2
- LCQJPQHYYVXJSP-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetonitrile;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC#N)CC1 LCQJPQHYYVXJSP-UHFFFAOYSA-N 0.000 claims description 2
- ULTUCEUWZCEGDC-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(1-methoxypropan-2-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NC(C)COC)CC1 ULTUCEUWZCEGDC-UHFFFAOYSA-N 0.000 claims description 2
- GDDCHSMTZROILQ-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NCC(F)(F)F)CC1 GDDCHSMTZROILQ-UHFFFAOYSA-N 0.000 claims description 2
- CODMIFWNDYMESN-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(2-methoxyethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NCCOC)CC1 CODMIFWNDYMESN-UHFFFAOYSA-N 0.000 claims description 2
- GPEZKHJBESZSIU-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(cyanomethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N(C)CC#N)CC1 GPEZKHJBESZSIU-UHFFFAOYSA-N 0.000 claims description 2
- BHLFBHMJNDFAFF-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-methoxyacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NOC)CC1 BHLFBHMJNDFAFF-UHFFFAOYSA-N 0.000 claims description 2
- GYOXIZRKEWGRAZ-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NC)CC1 GYOXIZRKEWGRAZ-UHFFFAOYSA-N 0.000 claims description 2
- XPYOFGQFWWNUBO-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-phenylmethoxyacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NOCC=2C=CC=CC=2)CC1 XPYOFGQFWWNUBO-UHFFFAOYSA-N 0.000 claims description 2
- AZFCHKRYFQIJDY-UHFFFAOYSA-N 2-amino-n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN)CC1 AZFCHKRYFQIJDY-UHFFFAOYSA-N 0.000 claims description 2
- KZGMKPKDEDWOIT-UHFFFAOYSA-N 3-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-1,1-dimethylurea Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)N(C)C)CC1 KZGMKPKDEDWOIT-UHFFFAOYSA-N 0.000 claims description 2
- XGMBBXAABINRKU-UHFFFAOYSA-N 3-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]propanenitrile;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCC#N)CC1 XGMBBXAABINRKU-UHFFFAOYSA-N 0.000 claims description 2
- LSLMBRARXLZGPW-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n,n-bis(2-methoxyethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(CCOC)CCOC LSLMBRARXLZGPW-UHFFFAOYSA-N 0.000 claims description 2
- IFKASQXBCRCOSA-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(2-hydroxyethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCO IFKASQXBCRCOSA-UHFFFAOYSA-N 0.000 claims description 2
- KLIFJIOVFXEYGQ-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(furan-2-ylmethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCC1=CC=CO1 KLIFJIOVFXEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- LVSSXNRWEFFGQH-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(furan-2-ylmethyl)-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CC1=CC=CO1 LVSSXNRWEFFGQH-UHFFFAOYSA-N 0.000 claims description 2
- XJCSXLINKZBYBN-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[(2-hydroxyphenyl)methyl]-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CC1=CC=CC=C1O XJCSXLINKZBYBN-UHFFFAOYSA-N 0.000 claims description 2
- CRVVGQZGVRNDRO-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[(3-methoxyphenyl)methyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCC1=CC=CC(OC)=C1 CRVVGQZGVRNDRO-UHFFFAOYSA-N 0.000 claims description 2
- OVYZOSNOYGXIRL-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[(4-sulfamoylphenyl)methyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCC1=CC=C(S(N)(=O)=O)C=C1 OVYZOSNOYGXIRL-UHFFFAOYSA-N 0.000 claims description 2
- GQFHCWSUFLQQML-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCC1N(C)CCC1 GQFHCWSUFLQQML-UHFFFAOYSA-N 0.000 claims description 2
- AGJQPMIWRKRFAK-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[2-(2-oxoimidazolidin-1-yl)ethyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCN1C(=O)NCC1 AGJQPMIWRKRFAK-UHFFFAOYSA-N 0.000 claims description 2
- NJQKQSHAGFJUHN-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methoxy-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NOC NJQKQSHAGFJUHN-UHFFFAOYSA-N 0.000 claims description 2
- QIKPBGRNLSUJDC-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-n-(1-methylpiperidin-4-yl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)C1CCN(C)CC1 QIKPBGRNLSUJDC-UHFFFAOYSA-N 0.000 claims description 2
- DBMFSVNODSANEL-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-n-(1-methylpyrrolidin-3-yl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)C1CN(C)CC1 DBMFSVNODSANEL-UHFFFAOYSA-N 0.000 claims description 2
- UNKGINWJIXGLGX-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-n-pyridin-2-yl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)C1=CC=CC=N1 UNKGINWJIXGLGX-UHFFFAOYSA-N 0.000 claims description 2
- VFXPSIGPFVGJJD-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-n-(1,3-dioxolan-2-ylmethyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CC1OCCO1 VFXPSIGPFVGJJD-UHFFFAOYSA-N 0.000 claims description 2
- HVXVOZYNRWLUMH-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-n-(2,5-dimethoxyphenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NC1=CC(OC)=CC=C1OC HVXVOZYNRWLUMH-UHFFFAOYSA-N 0.000 claims description 2
- OUIQLYQRPBBFEL-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-n-(2-cyanoethyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CCC#N OUIQLYQRPBBFEL-UHFFFAOYSA-N 0.000 claims description 2
- WRKSGUVUMJZNDV-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-n-(cyanomethyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CC#N WRKSGUVUMJZNDV-UHFFFAOYSA-N 0.000 claims description 2
- LPRIGQVWNVGIFF-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-n-ethoxy-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCONC(=O)N1C(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N=C1C1=CC=C(C(F)(F)F)C=C1OCC LPRIGQVWNVGIFF-UHFFFAOYSA-N 0.000 claims description 2
- ZLJWFWOWIYJOPB-UHFFFAOYSA-N 4-[2-[[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]sulfonyl]ethyl]piperazin-2-one;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1S(=O)(=O)CCN1CC(=O)NCC1 ZLJWFWOWIYJOPB-UHFFFAOYSA-N 0.000 claims description 2
- SUXWXKITNSSWTE-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-1-(2-morpholin-4-ylethyl)piperazin-2-one;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)N(CCN2CCOCC2)CC1 SUXWXKITNSSWTE-UHFFFAOYSA-N 0.000 claims description 2
- BRPDKOYUZAZSLL-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n,n-bis(2-methoxyethyl)piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N(CCOC)CCOC)CC1 BRPDKOYUZAZSLL-UHFFFAOYSA-N 0.000 claims description 2
- VNBGONALGBTMRP-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n,n-dimethylpiperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N(C)C)CC1 VNBGONALGBTMRP-UHFFFAOYSA-N 0.000 claims description 2
- YYVZBFWNELRMCJ-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-(2,2,2-trifluoroethyl)piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NCC(F)(F)F)CC1 YYVZBFWNELRMCJ-UHFFFAOYSA-N 0.000 claims description 2
- ZGLGALKEKHIVFE-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-(2-cyanoethyl)-n-methylpiperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N(C)CCC#N)CC1 ZGLGALKEKHIVFE-UHFFFAOYSA-N 0.000 claims description 2
- YIJLDBXYLWVXDX-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-[2-(dimethylamino)ethyl]piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NCCN(C)C)CC1 YIJLDBXYLWVXDX-UHFFFAOYSA-N 0.000 claims description 2
- LXRRWILFQKZGOA-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-methylpiperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NC)CC1 LXRRWILFQKZGOA-UHFFFAOYSA-N 0.000 claims description 2
- VOTDQHRMFGDQEK-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(N)(=O)=O)CC1 VOTDQHRMFGDQEK-UHFFFAOYSA-N 0.000 claims description 2
- DAGNTHYPINFNDS-UHFFFAOYSA-N 4-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]sulfonylpiperazin-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CC(=O)NCC2)CC1 DAGNTHYPINFNDS-UHFFFAOYSA-N 0.000 claims description 2
- RIRZNUVMUFRDRS-UHFFFAOYSA-N 4-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]methyl]piperazin-2-one;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(CN2CC(=O)NCC2)CC1 RIRZNUVMUFRDRS-UHFFFAOYSA-N 0.000 claims description 2
- FMRIDCDGOMMYLI-UHFFFAOYSA-N 4-[[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]piperazin-2-one;hydrochloride Chemical compound Cl.CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CC(=O)NCC1 FMRIDCDGOMMYLI-UHFFFAOYSA-N 0.000 claims description 2
- FGFHXGCYEIACES-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-pyrazin-2-ylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2N=CC=NC=2)CC1 FGFHXGCYEIACES-UHFFFAOYSA-N 0.000 claims description 2
- YSAFOIILDHRZSP-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-pyrimidin-2-ylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2N=CC=CN=2)CC1 YSAFOIILDHRZSP-UHFFFAOYSA-N 0.000 claims description 2
- BCRXVTIICGAQSG-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-thiophen-3-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=CSC=C2)CC1 BCRXVTIICGAQSG-UHFFFAOYSA-N 0.000 claims description 2
- OPYWECJIKLJLGC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-ethoxyethyl)piperazin-1-yl]methanone Chemical compound C1CN(CCOCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 OPYWECJIKLJLGC-UHFFFAOYSA-N 0.000 claims description 2
- MKWZOCOMXIXIHZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCOC)CC1 MKWZOCOMXIXIHZ-UHFFFAOYSA-N 0.000 claims description 2
- OUGPFVFFNNPCDX-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCOC)CC1 OUGPFVFFNNPCDX-UHFFFAOYSA-N 0.000 claims description 2
- ZBIZRPTWKDPGON-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2C=C(OC)C=C(OC)C=2)CC1 ZBIZRPTWKDPGON-UHFFFAOYSA-N 0.000 claims description 2
- XRYPQDXFWZERNP-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3-hydroxypiperidin-1-yl)sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CC(O)CCC2)CC1 XRYPQDXFWZERNP-UHFFFAOYSA-N 0.000 claims description 2
- YRLQJUVSNRSRMP-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3-methoxypropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCCOC)CC1 YRLQJUVSNRSRMP-UHFFFAOYSA-N 0.000 claims description 2
- WXPUTFIZBWJHEZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(4-fluorophenyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2C=CC(F)=CC=2)CC1 WXPUTFIZBWJHEZ-UHFFFAOYSA-N 0.000 claims description 2
- ZHZKRKMEDDRNFU-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCC(CC2)N2CCCC2)CC1 ZHZKRKMEDDRNFU-UHFFFAOYSA-N 0.000 claims description 2
- CFDTYCNQCXVVQW-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(5-chlorothiophen-2-yl)sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C=2SC(Cl)=CC=2)CC1 CFDTYCNQCXVVQW-UHFFFAOYSA-N 0.000 claims description 2
- MNRSILSXEFWHLZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(piperazin-1-ylmethyl)piperidin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(CN2CCNCC2)CC1 MNRSILSXEFWHLZ-UHFFFAOYSA-N 0.000 claims description 2
- FUNAOJIRVXDUMK-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=C(ON=C2C)C)CC1 FUNAOJIRVXDUMK-UHFFFAOYSA-N 0.000 claims description 2
- AGUJPMSOQCRQRS-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN(C)C)CC1 AGUJPMSOQCRQRS-UHFFFAOYSA-N 0.000 claims description 2
- NJMZSGKHDFHEFC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[2-[di(propan-2-yl)amino]ethyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN(C(C)C)C(C)C)CC1 NJMZSGKHDFHEFC-UHFFFAOYSA-N 0.000 claims description 2
- QJWCCFBVMHMPCP-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCN(CCO)CC2)CC1 QJWCCFBVMHMPCP-UHFFFAOYSA-N 0.000 claims description 2
- VVMZUOLGUJFDQF-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(diethylaminomethyl)phenyl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C1=CC=C(CN(CC)CC)C=C1 VVMZUOLGUJFDQF-UHFFFAOYSA-N 0.000 claims description 2
- JGCGRBGCQKSDRZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(morpholin-4-ylmethyl)phenyl]methanone Chemical compound CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCOCC1 JGCGRBGCQKSDRZ-UHFFFAOYSA-N 0.000 claims description 2
- GBWGBEJPLFJORW-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]phenyl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCC(N2CCCC2)CC1 GBWGBEJPLFJORW-UHFFFAOYSA-N 0.000 claims description 2
- HLFWHMPQNPTCNV-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCN(CCO)CC1 HLFWHMPQNPTCNV-UHFFFAOYSA-N 0.000 claims description 2
- OSPXDEOYPPCUHS-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(morpholin-4-ylmethyl)phenyl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCOCC1 OSPXDEOYPPCUHS-UHFFFAOYSA-N 0.000 claims description 2
- VDZWKQHTAXLIMD-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCN(CCO)CC1 VDZWKQHTAXLIMD-UHFFFAOYSA-N 0.000 claims description 2
- GFLVMDJMSBFNQV-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(1,5-dimethylpyrazol-3-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=NN(C)C(C)=C2)CC1 GFLVMDJMSBFNQV-UHFFFAOYSA-N 0.000 claims description 2
- ALXLMBKMYZDLIM-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(3,5-dimethyl-1,2-oxazol-4-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=C(ON=C2C)C)CC1 ALXLMBKMYZDLIM-UHFFFAOYSA-N 0.000 claims description 2
- CWPYLWWBADPYPY-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(4-methylthiadiazol-5-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=C(N=NS2)C)CC1 CWPYLWWBADPYPY-UHFFFAOYSA-N 0.000 claims description 2
- AXTHQJXVOMITRP-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(furan-3-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=COC=C2)CC1 AXTHQJXVOMITRP-UHFFFAOYSA-N 0.000 claims description 2
- MKLIKEOAEZXBJE-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(oxolan-2-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2OCCC2)CC1 MKLIKEOAEZXBJE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- WDAXYOUAHWVMJS-UHFFFAOYSA-N ethyl 1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidine-2-carboxylate Chemical compound CCOC(=O)C1CCCCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 WDAXYOUAHWVMJS-UHFFFAOYSA-N 0.000 claims description 2
- RSNRCWOIVNOSCQ-UHFFFAOYSA-N ethyl 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 RSNRCWOIVNOSCQ-UHFFFAOYSA-N 0.000 claims description 2
- UMGYZKMHTDCUBS-UHFFFAOYSA-N methyl 1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]pyrrolidine-2-carboxylate Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1C(C(=O)OC)CCC1 UMGYZKMHTDCUBS-UHFFFAOYSA-N 0.000 claims description 2
- YFTNAFWQFPPLOP-UHFFFAOYSA-N methyl 1-[[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1C(C(=O)OC)CCC1 YFTNAFWQFPPLOP-UHFFFAOYSA-N 0.000 claims description 2
- STBXVEIMIGNANG-UHFFFAOYSA-N methyl 3-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]sulfonylthiophene-2-carboxylate Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=C(SC=C2)C(=O)OC)CC1 STBXVEIMIGNANG-UHFFFAOYSA-N 0.000 claims description 2
- QGUHPQDVTOBVOR-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-(3-hydroxypiperidin-1-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CC(O)CCC2)CC1 QGUHPQDVTOBVOR-UHFFFAOYSA-N 0.000 claims description 2
- WGKDMLSGGRRUPH-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-(3-oxopiperazin-1-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CC(=O)NCC2)CC1 WGKDMLSGGRRUPH-UHFFFAOYSA-N 0.000 claims description 2
- KLPNGRRRAHCMLX-UHFFFAOYSA-N n-[1-[[4-[4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]piperidin-4-yl]acetamide;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCC(NC(C)=O)CC1 KLPNGRRRAHCMLX-UHFFFAOYSA-N 0.000 claims description 2
- IIKFXOLJMNWWCH-UHFFFAOYSA-N piperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)CC1 IIKFXOLJMNWWCH-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 4
- NTSDJVFOVNGESW-UHFFFAOYSA-N 1-(4-acetylpiperazin-1-yl)-2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCN(CC2)C(C)=O)CC1 NTSDJVFOVNGESW-UHFFFAOYSA-N 0.000 claims 1
- RRRGLTISNLQCMJ-UHFFFAOYSA-N 1-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-3-methylthiourea Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=S)NC)CC1 RRRGLTISNLQCMJ-UHFFFAOYSA-N 0.000 claims 1
- RAIZKZVXLRAXNS-UHFFFAOYSA-N 1-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-3-phenylthiourea Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=S)NC=2C=CC=CC=2)CC1 RAIZKZVXLRAXNS-UHFFFAOYSA-N 0.000 claims 1
- VXTBVLQZHFRXOP-UHFFFAOYSA-N 1-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-oxoethyl]piperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CC(CCC2)C(N)=O)CC1 VXTBVLQZHFRXOP-UHFFFAOYSA-N 0.000 claims 1
- ZPXHTINOYDOZEJ-UHFFFAOYSA-N 1-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CCC(CC2)C(N)=O)CC1 ZPXHTINOYDOZEJ-UHFFFAOYSA-N 0.000 claims 1
- HINGKKKFIYTTGE-UHFFFAOYSA-N 1-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetyl]piperidine-3-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CC(CCC2)C(N)=O)CC1 HINGKKKFIYTTGE-UHFFFAOYSA-N 0.000 claims 1
- YMLLKWUILYYKOD-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-(2-hydroxyethylamino)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CNCCO)CC1 YMLLKWUILYYKOD-UHFFFAOYSA-N 0.000 claims 1
- WAMDOIWVJLGUAY-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-(2-methoxyethylamino)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CNCCOC)CC1 WAMDOIWVJLGUAY-UHFFFAOYSA-N 0.000 claims 1
- VWXMQZICDXSSKF-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-(3-hydroxypiperidin-1-yl)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CC(O)CCC2)CC1 VWXMQZICDXSSKF-UHFFFAOYSA-N 0.000 claims 1
- UZKAHAPQWFBQFA-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-(methylamino)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CNC)CC1 UZKAHAPQWFBQFA-UHFFFAOYSA-N 0.000 claims 1
- YJNUMKBPOCKUIU-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[1,3-dioxolan-2-ylmethyl(methyl)amino]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN(C)CC2OCCO2)CC1 YJNUMKBPOCKUIU-UHFFFAOYSA-N 0.000 claims 1
- FELIVOLRHFFPFT-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[4-(hydroxymethyl)piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CCC(CO)CC2)CC1 FELIVOLRHFFPFT-UHFFFAOYSA-N 0.000 claims 1
- OINOXAKBYKWQPE-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[bis(2-hydroxyethyl)amino]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN(CCO)CCO)CC1 OINOXAKBYKWQPE-UHFFFAOYSA-N 0.000 claims 1
- IHTYVRVGRGXIHY-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-[bis(2-methoxyethyl)amino]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN(CCOC)CCOC)CC1 IHTYVRVGRGXIHY-UHFFFAOYSA-N 0.000 claims 1
- DQEROOWICKPTND-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-methoxyethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)COC)CC1 DQEROOWICKPTND-UHFFFAOYSA-N 0.000 claims 1
- REXMXXBLUIZYQT-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazine-1-carbonyl]piperidine-4-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)N2CCC(CC2)C(N)=O)CC1 REXMXXBLUIZYQT-UHFFFAOYSA-N 0.000 claims 1
- NQPNQJZMBXRNCW-UHFFFAOYSA-N 1-benzyl-4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)N(CC=2C=CC=CC=2)CC1 NQPNQJZMBXRNCW-UHFFFAOYSA-N 0.000 claims 1
- LBGQGYKSBSHYEA-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)-1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CCN(CC2)C(C)=O)CC1 LBGQGYKSBSHYEA-UHFFFAOYSA-N 0.000 claims 1
- BAVQQMYMRMKNON-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)-n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CCN(CC2)C(C)=O)CC1 BAVQQMYMRMKNON-UHFFFAOYSA-N 0.000 claims 1
- INXKEGMXCZBZMY-UHFFFAOYSA-N 2-[4-[2-[[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]sulfonyl]ethyl]piperazin-1-yl]ethanol;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1S(=O)(=O)CCN1CCN(CCO)CC1 INXKEGMXCZBZMY-UHFFFAOYSA-N 0.000 claims 1
- KFJJVBPTPGFRCO-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-(3-hydroxypiperidin-1-yl)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CC(O)CCC2)CC1 KFJJVBPTPGFRCO-UHFFFAOYSA-N 0.000 claims 1
- KOIMCAPFHQFBHV-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-piperidin-1-ylethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCCCC2)CC1 KOIMCAPFHQFBHV-UHFFFAOYSA-N 0.000 claims 1
- YNRACKVTYHOPIG-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n,n-dimethylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)C)CC1 YNRACKVTYHOPIG-UHFFFAOYSA-N 0.000 claims 1
- QIGJYOMVPRYMHB-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n,n-dimethylethanesulfonamide;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCS(=O)(=O)N(C)C)CC1 QIGJYOMVPRYMHB-UHFFFAOYSA-N 0.000 claims 1
- ATEJZMYSUKZDSN-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(1-hydroxy-4-methylpentan-2-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NC(CO)CC(C)C)CC1 ATEJZMYSUKZDSN-UHFFFAOYSA-N 0.000 claims 1
- XXZAHFLSKCUSOH-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(1-methoxypropan-2-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NC(C)COC)CC1 XXZAHFLSKCUSOH-UHFFFAOYSA-N 0.000 claims 1
- KQSGNXWNJJCIPQ-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(2,2,2-trifluoroethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCC(F)(F)F)CC1 KQSGNXWNJJCIPQ-UHFFFAOYSA-N 0.000 claims 1
- ILDNRBKSBADBSR-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(2-cyanoethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)CCC#N)CC1 ILDNRBKSBADBSR-UHFFFAOYSA-N 0.000 claims 1
- QBVKSPYMQCEKRG-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(2-methoxyethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCCOC)CC1 QBVKSPYMQCEKRG-UHFFFAOYSA-N 0.000 claims 1
- HCVFRXGWSQSNTE-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(2-methylpropyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCC(C)C)CC1 HCVFRXGWSQSNTE-UHFFFAOYSA-N 0.000 claims 1
- QBLUEPJSLLJNQD-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(3-hydroxypropyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCCCO)CC1 QBLUEPJSLLJNQD-UHFFFAOYSA-N 0.000 claims 1
- ZXQRROQQVXOKIH-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(cyanomethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)CC#N)CC1 ZXQRROQQVXOKIH-UHFFFAOYSA-N 0.000 claims 1
- XKWMLLCLSSLJAR-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-(oxolan-2-ylmethyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NCC2OCCC2)CC1 XKWMLLCLSSLJAR-UHFFFAOYSA-N 0.000 claims 1
- AXFCNUVWDCCBOI-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-methoxy-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N(C)OC)CC1 AXFCNUVWDCCBOI-UHFFFAOYSA-N 0.000 claims 1
- GSCHYMHIPYLQEB-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-methoxyacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)NOC)CC1 GSCHYMHIPYLQEB-UHFFFAOYSA-N 0.000 claims 1
- RLGDRYOGAMOMCS-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-n-propylacetamide Chemical compound C1CN(CC(=O)NCCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 RLGDRYOGAMOMCS-UHFFFAOYSA-N 0.000 claims 1
- AENZBYISSGOZDI-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(N)=O)CC1 AENZBYISSGOZDI-UHFFFAOYSA-N 0.000 claims 1
- LBVCBDILDVPPOO-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]ethanesulfonamide;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCS(N)(=O)=O)CC1 LBVCBDILDVPPOO-UHFFFAOYSA-N 0.000 claims 1
- MOATXUKIKTWTKP-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2C(=CC=CN=2)C#N)CC1 MOATXUKIKTWTKP-UHFFFAOYSA-N 0.000 claims 1
- SPMCVMOJJXEZSU-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-1-(3-hydroxypiperidin-1-yl)ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N2CC(O)CCC2)CC1 SPMCVMOJJXEZSU-UHFFFAOYSA-N 0.000 claims 1
- VLAHBHZQBPWVLV-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-1-[4-(trifluoromethyl)piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N2CCC(CC2)C(F)(F)F)CC1 VLAHBHZQBPWVLV-UHFFFAOYSA-N 0.000 claims 1
- PNNVHVBOVLOBRS-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(1-hydroxy-4-methylpentan-2-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NC(CO)CC(C)C)CC1 PNNVHVBOVLOBRS-UHFFFAOYSA-N 0.000 claims 1
- IQCPDPHGEWITPU-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(2-cyanoethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N(C)CCC#N)CC1 IQCPDPHGEWITPU-UHFFFAOYSA-N 0.000 claims 1
- LFDQTBXTDLBOIL-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(2-hydroxyethyl)-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N(C)CCO)CC1 LFDQTBXTDLBOIL-UHFFFAOYSA-N 0.000 claims 1
- IQXDZQYVAZQWBA-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-(2-methylpropyl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NCC(C)C)CC1 IQXDZQYVAZQWBA-UHFFFAOYSA-N 0.000 claims 1
- MRBWIPLARHRXHS-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-[(5-methylfuran-2-yl)methyl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)NCC=2OC(C)=CC=2)CC1 MRBWIPLARHRXHS-UHFFFAOYSA-N 0.000 claims 1
- FZVLWLJYWZKHAC-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-methoxy-n-methylacetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NCC(=O)N(C)OC)CC1 FZVLWLJYWZKHAC-UHFFFAOYSA-N 0.000 claims 1
- ORWDRQGNASMTJL-UHFFFAOYSA-N 2-[[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]amino]-n-propylacetamide Chemical compound C1CC(NCC(=O)NCCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 ORWDRQGNASMTJL-UHFFFAOYSA-N 0.000 claims 1
- DIYOAFOOTUNZJN-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]sulfonyl]-n,n-diethylethanamine;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1S(=O)(=O)CCN(CC)CC DIYOAFOOTUNZJN-UHFFFAOYSA-N 0.000 claims 1
- GBEWNNRCXVTBHZ-UHFFFAOYSA-N 3-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 GBEWNNRCXVTBHZ-UHFFFAOYSA-N 0.000 claims 1
- HARPEZGBOPBKKK-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(1-methoxypropan-2-yl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NC(C)COC HARPEZGBOPBKKK-UHFFFAOYSA-N 0.000 claims 1
- GKYXLJBDFMPMLF-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(2-hydroxyethyl)-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)CCO GKYXLJBDFMPMLF-UHFFFAOYSA-N 0.000 claims 1
- AEJMYUVWCMZRON-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(2-methoxyethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCOC AEJMYUVWCMZRON-UHFFFAOYSA-N 0.000 claims 1
- GLUQEDUKBIZHPI-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(2-pyridin-2-ylethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCC1=CC=CC=N1 GLUQEDUKBIZHPI-UHFFFAOYSA-N 0.000 claims 1
- JCGOSNURLUPGIP-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(3-hydroxypropyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCCO JCGOSNURLUPGIP-UHFFFAOYSA-N 0.000 claims 1
- FOMFABDEFZKSHH-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(3-imidazol-1-ylpropyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCCCN1C=NC=C1 FOMFABDEFZKSHH-UHFFFAOYSA-N 0.000 claims 1
- AQLBJTDAHDNQPN-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-(pyridin-3-ylmethyl)-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCC1=CC=CN=C1 AQLBJTDAHDNQPN-UHFFFAOYSA-N 0.000 claims 1
- LHZWMTIERCWSEH-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-[(1-ethylpyrrolidin-2-yl)methyl]-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NCC1N(CC)CCC1 LHZWMTIERCWSEH-UHFFFAOYSA-N 0.000 claims 1
- AMQDVMNSFPLZRM-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methoxy-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N(C)OC AMQDVMNSFPLZRM-UHFFFAOYSA-N 0.000 claims 1
- IQOFQSGQBFVBNT-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-n-methyl-4,5-dihydroimidazole-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)NC IQOFQSGQBFVBNT-UHFFFAOYSA-N 0.000 claims 1
- MBTRQLAEOBOYRO-UHFFFAOYSA-N 4-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-oxoethyl]piperazin-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CN2CC(=O)NCC2)CC1 MBTRQLAEOBOYRO-UHFFFAOYSA-N 0.000 claims 1
- YEKLFMLKZXWMMY-UHFFFAOYSA-N 4-[2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]acetyl]piperazin-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CC(=O)NCC2)CC1 YEKLFMLKZXWMMY-UHFFFAOYSA-N 0.000 claims 1
- MYIAAVVOARILMW-UHFFFAOYSA-N 4-[2-[[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]sulfonyl]ethyl]morpholine;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1S(=O)(=O)CCN1CCOCC1 MYIAAVVOARILMW-UHFFFAOYSA-N 0.000 claims 1
- HJVWVSNQXSAAQJ-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-1-(2-methoxyethyl)piperazin-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)N(CCOC)CC1 HJVWVSNQXSAAQJ-UHFFFAOYSA-N 0.000 claims 1
- IEAJTKVIBAKADZ-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-(2-methoxyethyl)piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NCCOC)CC1 IEAJTKVIBAKADZ-UHFFFAOYSA-N 0.000 claims 1
- YEQJREIXODTFNO-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-(2-methylpropyl)piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NCC(C)C)CC1 YEQJREIXODTFNO-UHFFFAOYSA-N 0.000 claims 1
- KVDNVNFGTTXVFE-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-(oxolan-2-ylmethyl)piperazine-1-sulfonamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)NCC2OCCC2)CC1 KVDNVNFGTTXVFE-UHFFFAOYSA-N 0.000 claims 1
- HDWAWXHTRJAHRX-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-methylpiperazine-1-carbothioamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=S)NC)CC1 HDWAWXHTRJAHRX-UHFFFAOYSA-N 0.000 claims 1
- VCJLCHZOCWJUNP-UHFFFAOYSA-N 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]-n-phenylpiperazine-1-carbothioamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=S)NC=2C=CC=CC=2)CC1 VCJLCHZOCWJUNP-UHFFFAOYSA-N 0.000 claims 1
- OIMJCEYUFFYQSQ-UHFFFAOYSA-N 4-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazine-1-carbonyl]piperazin-2-one Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)N2CC(=O)NCC2)CC1 OIMJCEYUFFYQSQ-UHFFFAOYSA-N 0.000 claims 1
- JQEHIFIBJWHIFW-UHFFFAOYSA-N 4-[[4-[4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]piperazin-2-one;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CC(=O)NCC1 JQEHIFIBJWHIFW-UHFFFAOYSA-N 0.000 claims 1
- YCHBIEKEWNEPIX-UHFFFAOYSA-N 6-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2N=CC(=CC=2)C#N)CC1 YCHBIEKEWNEPIX-UHFFFAOYSA-N 0.000 claims 1
- WSDWKCIUJGQZFE-UHFFFAOYSA-N [1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-methyl-1-oxopropan-2-yl] acetate Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C(C)(C)OC(C)=O)CC1 WSDWKCIUJGQZFE-UHFFFAOYSA-N 0.000 claims 1
- TVTLQEQPTUOKGT-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC2(OCCO2)CC1 TVTLQEQPTUOKGT-UHFFFAOYSA-N 0.000 claims 1
- GOHWZWUGBHXOGV-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-butylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)CCCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 GOHWZWUGBHXOGV-UHFFFAOYSA-N 0.000 claims 1
- ODUFUQGOMHVBET-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-morpholin-4-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCOCC2)CC1 ODUFUQGOMHVBET-UHFFFAOYSA-N 0.000 claims 1
- BSMVNJNBGDPLJO-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-phenylpiperidin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(C=2C=CC=CC=2)CC1 BSMVNJNBGDPLJO-UHFFFAOYSA-N 0.000 claims 1
- WMDMSSWUZRXHTG-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-piperidin-1-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCCCC2)CC1 WMDMSSWUZRXHTG-UHFFFAOYSA-N 0.000 claims 1
- XUMOWPYPPBBYGC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-propan-2-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C(C)C)CC1 XUMOWPYPPBBYGC-UHFFFAOYSA-N 0.000 claims 1
- AGXGFLVIFZYEPO-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-pyridin-4-ylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2C=CN=CC=2)CC1 AGXGFLVIFZYEPO-UHFFFAOYSA-N 0.000 claims 1
- XHTVWKWDMXEDAZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-pyrrolidin-1-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)N2CCCC2)CC1 XHTVWKWDMXEDAZ-UHFFFAOYSA-N 0.000 claims 1
- BMOXVSPXJAECSB-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-(4-thiophen-2-ylsulfonylpiperazin-1-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C=2SC=CC=2)CC1 BMOXVSPXJAECSB-UHFFFAOYSA-N 0.000 claims 1
- HPPBFVDOYBMGRS-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2,5-dichlorothiophen-3-yl)sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=C(SC(Cl)=C2)Cl)CC1 HPPBFVDOYBMGRS-UHFFFAOYSA-N 0.000 claims 1
- PAHOPVLKVGUHGH-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-methylsulfonylethyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCS(C)(=O)=O)CC1 PAHOPVLKVGUHGH-UHFFFAOYSA-N 0.000 claims 1
- KMEDWOHVELFZGS-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN2CCOCC2)CC1 KMEDWOHVELFZGS-UHFFFAOYSA-N 0.000 claims 1
- ANVAHHLBXHTMLW-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-piperidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN2CCCCC2)CC1 ANVAHHLBXHTMLW-UHFFFAOYSA-N 0.000 claims 1
- HVHXOWJMRXYOCP-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN2CCCC2)CC1 HVHXOWJMRXYOCP-UHFFFAOYSA-N 0.000 claims 1
- IENPFQYAANHLIH-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3,3,3-trifluoro-2-hydroxypropyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(O)C(F)(F)F)CC1 IENPFQYAANHLIH-UHFFFAOYSA-N 0.000 claims 1
- VTODHAYKVICOKB-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCC(F)(F)F)CC1 VTODHAYKVICOKB-UHFFFAOYSA-N 0.000 claims 1
- KJFQJCIJRMMCJI-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCCN2CCCCC2)CC1 KJFQJCIJRMMCJI-UHFFFAOYSA-N 0.000 claims 1
- HWVOEJWMPGKSCQ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3-pyrrolidin-1-ylpropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCCN2CCCC2)CC1 HWVOEJWMPGKSCQ-UHFFFAOYSA-N 0.000 claims 1
- SZIUGQAOGWXIDC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)N2C(=NC(C2C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C=2C(=CC(=CC=2)C(F)(F)F)OCC)CC1 SZIUGQAOGWXIDC-UHFFFAOYSA-N 0.000 claims 1
- UHTZUSOEDCHFRN-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylpiperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=C(N(C)N=C2C)Cl)CC1 UHTZUSOEDCHFRN-UHFFFAOYSA-N 0.000 claims 1
- HYSCMEGJZMGCLW-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(oxolan-2-ylmethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC2OCCC2)CC1 HYSCMEGJZMGCLW-UHFFFAOYSA-N 0.000 claims 1
- LGXDPMUBIGIGQG-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(pyridin-4-ylmethyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC=2C=CN=CC=2)CC1 LGXDPMUBIGIGQG-UHFFFAOYSA-N 0.000 claims 1
- KQPXLFKTKFUEFZ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(trifluoromethylsulfonyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C(F)(F)F)CC1 KQPXLFKTKFUEFZ-UHFFFAOYSA-N 0.000 claims 1
- RTCPQZJEAKVSFG-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[(1-methylpiperidin-3-yl)methyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC2CN(C)CCC2)CC1 RTCPQZJEAKVSFG-UHFFFAOYSA-N 0.000 claims 1
- UGGKGXFEVHJJCV-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(S(=O)(=O)C2=C(N=C(C)S2)C)CC1 UGGKGXFEVHJJCV-UHFFFAOYSA-N 0.000 claims 1
- IUFNDDQDOBQUPA-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[2-(diethylamino)ethyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCN(CC)CC)CC1 IUFNDDQDOBQUPA-UHFFFAOYSA-N 0.000 claims 1
- IBZXBAGFPOOVFD-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[2-(dipropylamino)ethyl]piperazin-1-yl]methanone Chemical compound C1CN(CCN(CCC)CCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 IBZXBAGFPOOVFD-UHFFFAOYSA-N 0.000 claims 1
- NJROZHSIDXNWOA-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[3-(diethylamino)propyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCCN(CC)CC)CC1 NJROZHSIDXNWOA-UHFFFAOYSA-N 0.000 claims 1
- QRNSLQCDKUKGGQ-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[3-(dimethylamino)propyl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CCCN(C)C)CC1 QRNSLQCDKUKGGQ-UHFFFAOYSA-N 0.000 claims 1
- JYJHDPXRHVGMTC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[3-(dipropylamino)propyl]piperazin-1-yl]methanone Chemical compound C1CN(CCCN(CCC)CCC)CCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 JYJHDPXRHVGMTC-UHFFFAOYSA-N 0.000 claims 1
- BPPOPIKNOBHFLF-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C=2N=CC(=CC=2)C(F)(F)F)CC1 BPPOPIKNOBHFLF-UHFFFAOYSA-N 0.000 claims 1
- UCGNVNNLBFIATN-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(diethylaminomethyl)phenyl]methanone;hydrochloride Chemical compound Cl.C1=CC(CN(CC)CC)=CC=C1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OC(C)C)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 UCGNVNNLBFIATN-UHFFFAOYSA-N 0.000 claims 1
- BYEDKQWZDVQUKY-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(piperazin-1-ylmethyl)phenyl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCNCC1 BYEDKQWZDVQUKY-UHFFFAOYSA-N 0.000 claims 1
- YWCVPNHASCELHD-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]phenyl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCC(N2CCCC2)CC1 YWCVPNHASCELHD-UHFFFAOYSA-N 0.000 claims 1
- AQORZULZMPNHDF-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-[[2-(hydroxymethyl)piperidin-1-yl]methyl]phenyl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1C(CO)CCCC1 AQORZULZMPNHDF-UHFFFAOYSA-N 0.000 claims 1
- GIXDXKFKNRGDRF-UHFFFAOYSA-N [4-[(4-aminopiperidin-1-yl)methyl]phenyl]-[4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]methanone;hydrochloride Chemical compound Cl.CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C(C=C1)=CC=C1CN1CCC(N)CC1 GIXDXKFKNRGDRF-UHFFFAOYSA-N 0.000 claims 1
- GRTRICISKIPFQP-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2OC3=CC=CC=C3OC2)CC1 GRTRICISKIPFQP-UHFFFAOYSA-N 0.000 claims 1
- RTXIAHIHLNKSAI-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(2,5-dichlorothiophen-3-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=C(SC(Cl)=C2)Cl)CC1 RTXIAHIHLNKSAI-UHFFFAOYSA-N 0.000 claims 1
- ITADBKAAYQFMBH-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(2,5-dimethylfuran-3-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=C(OC(C)=C2)C)CC1 ITADBKAAYQFMBH-UHFFFAOYSA-N 0.000 claims 1
- OIOXXEAFLDNPPJ-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C=2OC=CC=2)CC1 OIOXXEAFLDNPPJ-UHFFFAOYSA-N 0.000 claims 1
- MBWSRQPGPPWUGB-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-pyridin-4-ylmethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C=2C=CN=CC=2)CC1 MBWSRQPGPPWUGB-UHFFFAOYSA-N 0.000 claims 1
- KEQQOWBTQSHSKX-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-thiophen-2-ylmethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C=2SC=CC=2)CC1 KEQQOWBTQSHSKX-UHFFFAOYSA-N 0.000 claims 1
- DLJSPKRDWBJMDG-UHFFFAOYSA-N [4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-thiophen-3-ylmethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2=CSC=C2)CC1 DLJSPKRDWBJMDG-UHFFFAOYSA-N 0.000 claims 1
- AGFUSWVFBAPXEM-UHFFFAOYSA-N ethyl 1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidine-3-carboxylate Chemical compound C1C(C(=O)OCC)CCCN1C(=O)N1C(C=2C(=CC(=CC=2)C(F)(F)F)OCC)=NC(C=2C=CC(Cl)=CC=2)C1C1=CC=C(Cl)C=C1 AGFUSWVFBAPXEM-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- OCJNCKPZMYMQPW-UHFFFAOYSA-N methyl 1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidine-4-carboxylate Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(C(=O)OC)CC1 OCJNCKPZMYMQPW-UHFFFAOYSA-N 0.000 claims 1
- PSKWYMGDLOHCOJ-UHFFFAOYSA-N methyl 1-[[4-[4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]phenyl]methyl]pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CCCN1CC1=CC=C(C(=O)N2C(=NC(C2C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C=2C(=CC(=CC=2)C(F)(F)F)OC(C)C)C=C1 PSKWYMGDLOHCOJ-UHFFFAOYSA-N 0.000 claims 1
- HZTMLJLCAPPFDV-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CCC3(CC2)OCCO3)CC1 HZTMLJLCAPPFDV-UHFFFAOYSA-N 0.000 claims 1
- HQZBIQHTOHZTPE-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-(dimethylamino)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN(C)C)CC1 HQZBIQHTOHZTPE-UHFFFAOYSA-N 0.000 claims 1
- SWDYPEDVVHRLMH-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-(methylamino)acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CNC)CC1 SWDYPEDVVHRLMH-UHFFFAOYSA-N 0.000 claims 1
- YKJLSOQWRNRPFT-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-[1,3-dioxolan-2-ylmethyl(methyl)amino]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN(C)CC2OCCO2)CC1 YKJLSOQWRNRPFT-UHFFFAOYSA-N 0.000 claims 1
- NXMIYADOTCPWNS-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-[4-(hydroxymethyl)piperidin-1-yl]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN2CCC(CO)CC2)CC1 NXMIYADOTCPWNS-UHFFFAOYSA-N 0.000 claims 1
- BUCQZHGYHATTNQ-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-[bis(2-hydroxyethyl)amino]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN(CCO)CCO)CC1 BUCQZHGYHATTNQ-UHFFFAOYSA-N 0.000 claims 1
- DXURKBNFYMONJI-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-2-[bis(2-methoxyethyl)amino]acetamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)CN(CCOC)CCOC)CC1 DXURKBNFYMONJI-UHFFFAOYSA-N 0.000 claims 1
- YFIGDCAZBCVILF-UHFFFAOYSA-N n-[1-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperidin-4-yl]-3-oxopiperazine-1-carboxamide Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(NC(=O)N2CC(=O)NCC2)CC1 YFIGDCAZBCVILF-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 129
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- ZDIXPTCKIMQEGQ-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1 ZDIXPTCKIMQEGQ-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002462 imidazolines Chemical class 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- PTHFWXYYHUSNFM-UHFFFAOYSA-N 1-[2-[2-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]ethenylsulfonyl]ethenyl]-4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole Chemical compound ClC1=CC=C(C=C1)C1N=C(N(C1C1=CC=C(C=C1)Cl)C=CS(=O)(=O)C=CN1C(=NC(C1C1=CC=C(C=C1)Cl)C1=CC=C(C=C1)Cl)C1=C(C=C(C=C1)C(F)(F)F)OCC)C1=C(C=C(C=C1)C(F)(F)F)OCC PTHFWXYYHUSNFM-UHFFFAOYSA-N 0.000 description 2
- UZHRUOKQPUKJCH-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-chloroethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CCl)CC1 UZHRUOKQPUKJCH-UHFFFAOYSA-N 0.000 description 2
- LCXAFSYDJOFYKE-UHFFFAOYSA-N 1-propan-2-ylsulfonylpiperazine Chemical compound CC(C)S(=O)(=O)N1CCNCC1 LCXAFSYDJOFYKE-UHFFFAOYSA-N 0.000 description 2
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- UQGXPWHUTFHDEC-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl chloride Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(Cl)=O UQGXPWHUTFHDEC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QXYSFGLEOFHNSK-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-piperazin-1-ylmethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCNCC1 QXYSFGLEOFHNSK-UHFFFAOYSA-N 0.000 description 2
- MWCSBVYRVMTWLM-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-piperazin-1-ylmethanone;hydrochloride Chemical compound Cl.CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCNCC1 MWCSBVYRVMTWLM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- PKBOYBKUIIQFGB-UHFFFAOYSA-N ethyl 2-ethoxy-4-(trifluoromethyl)benzenecarboximidate;hydrochloride Chemical compound Cl.CCOC(=N)C1=CC=C(C(F)(F)F)C=C1OCC PKBOYBKUIIQFGB-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- QJFHSLQYLVARMM-UHFFFAOYSA-N tert-butyl 4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazine-1-carboxylate Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1 QJFHSLQYLVARMM-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UNRBEYYLYRXYCG-UHFFFAOYSA-N (1-ethylpyrrolidin-2-yl)methanamine Chemical compound CCN1CCCC1CN UNRBEYYLYRXYCG-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- QDGJAAOFBIEXOC-UHFFFAOYSA-N 1-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-2-thiophen-2-ylethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)CC=2SC=CC=2)CC1 QDGJAAOFBIEXOC-UHFFFAOYSA-N 0.000 description 1
- ZSHRJBMPUVRXKC-UHFFFAOYSA-N 1-[4-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazine-1-carbonyl]piperidin-1-yl]ethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(C(=O)C2CCN(CC2)C(C)=O)CC1 ZSHRJBMPUVRXKC-UHFFFAOYSA-N 0.000 description 1
- BNPCRHWMJSUKDM-UHFFFAOYSA-N 1-benzylpiperazin-2-one Chemical compound O=C1CNCCN1CC1=CC=CC=C1 BNPCRHWMJSUKDM-UHFFFAOYSA-N 0.000 description 1
- IDUUIDSBIFYYIO-UHFFFAOYSA-N 1-benzylpiperazin-2-one;hydrochloride Chemical compound Cl.O=C1CNCCN1CC1=CC=CC=C1 IDUUIDSBIFYYIO-UHFFFAOYSA-N 0.000 description 1
- NXMXETCTWNXSFG-UHFFFAOYSA-N 1-methoxypropan-2-amine Chemical compound COCC(C)N NXMXETCTWNXSFG-UHFFFAOYSA-N 0.000 description 1
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 1
- SDGHXWKVBZYHRR-UHFFFAOYSA-N 2-(1h-imidazol-2-ylsulfonyl)-1h-imidazole Chemical compound N=1C=CNC=1S(=O)(=O)C1=NC=CN1 SDGHXWKVBZYHRR-UHFFFAOYSA-N 0.000 description 1
- WEDUREKGKXARTL-UHFFFAOYSA-N 2-[4-[4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl]piperazin-1-yl]-1-morpholin-4-ylethanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(=O)N2CCOCC2)CC1 WEDUREKGKXARTL-UHFFFAOYSA-N 0.000 description 1
- PYNYHMRMZOGVML-UHFFFAOYSA-N 2-bromopropanenitrile Chemical compound CC(Br)C#N PYNYHMRMZOGVML-UHFFFAOYSA-N 0.000 description 1
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 1
- ZCNXVYPATPFQQN-UHFFFAOYSA-N 2-ethoxy-4-(trifluoromethyl)benzonitrile Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C#N ZCNXVYPATPFQQN-UHFFFAOYSA-N 0.000 description 1
- BQCWLXXZTCLGSZ-UHFFFAOYSA-N 2-nitro-4-(trifluoromethyl)benzonitrile Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1C#N BQCWLXXZTCLGSZ-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- ABZGTIUIMHXVIS-UHFFFAOYSA-N 3-oxopiperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNC(=O)C1 ABZGTIUIMHXVIS-UHFFFAOYSA-N 0.000 description 1
- TYNGBYGPPLFZFV-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carboxylic acid Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(O)=O TYNGBYGPPLFZFV-UHFFFAOYSA-N 0.000 description 1
- YUWLEORZYZXVLN-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1 YUWLEORZYZXVLN-UHFFFAOYSA-N 0.000 description 1
- LRCUFZWUTJIRGF-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl chloride Chemical compound CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(Cl)=O LRCUFZWUTJIRGF-UHFFFAOYSA-N 0.000 description 1
- HUPNRVHWPHWMBZ-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1 HUPNRVHWPHWMBZ-UHFFFAOYSA-N 0.000 description 1
- CFCYJEWFJKRHPK-UHFFFAOYSA-N 4,5-bis(4-chlorophenyl)-2-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazole-1-carbonyl chloride Chemical compound CC(C)OC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(Cl)=O CFCYJEWFJKRHPK-UHFFFAOYSA-N 0.000 description 1
- RCOVTJVRTZGSBP-UHFFFAOYSA-N 4-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=C(C(Cl)=O)C=C1 RCOVTJVRTZGSBP-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- RGPGMLOCLXQVBM-UHFFFAOYSA-N 4-piperazin-1-ylsulfonylmorpholine;hydrochloride Chemical compound Cl.C1COCCN1S(=O)(=O)N1CCNCC1 RGPGMLOCLXQVBM-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- FPLZIIDNOCUDJF-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(3,3,3-trifluoro-2-hydroxypropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCN(CC(O)C(F)(F)F)CC1 FPLZIIDNOCUDJF-UHFFFAOYSA-N 0.000 description 1
- XQHJHXUBGFOPHC-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-4-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(bromomethyl)piperidin-1-yl]methanone Chemical compound CCOC1=CC(C(F)(F)F)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CCC(CBr)CC1 XQHJHXUBGFOPHC-UHFFFAOYSA-N 0.000 description 1
- SJMKPCKLKPXSNR-UHFFFAOYSA-N [4,5-bis(4-chlorophenyl)-2-[2-ethoxy-5-(trifluoromethyl)phenyl]-4,5-dihydroimidazol-1-yl]-[4-(chloromethyl)phenyl]methanone Chemical compound CCOC1=CC=C(C(F)(F)F)C=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)C1=CC=C(CCl)C=C1 SJMKPCKLKPXSNR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZWQHAOJFCRHNNE-UHFFFAOYSA-N butyl 2-oxopiperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCNCC1=O ZWQHAOJFCRHNNE-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- IXQKXEUSCPEQRD-DKRGWESNSA-N cucurbitacin B Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)/C=C/C(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-DKRGWESNSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- CQBWPUJYGMSGDU-UHFFFAOYSA-N ethyl benzenecarboximidate Chemical compound CCOC(=N)C1=CC=CC=C1 CQBWPUJYGMSGDU-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical compound Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XOVUITMHPFXQPN-UHFFFAOYSA-N imidazole-1-carbonyl chloride Chemical compound ClC(=O)N1C=CN=C1 XOVUITMHPFXQPN-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- SFQSZZGLAJRHHB-UHFFFAOYSA-N piperazin-2-one;hydrochloride Chemical compound Cl.O=C1CNCCN1 SFQSZZGLAJRHHB-UHFFFAOYSA-N 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XBMXAAOSSFWPED-UHFFFAOYSA-N tert-butyl 4-morpholin-4-ylsulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)N1CCOCC1 XBMXAAOSSFWPED-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides compounds according to formula (I ) having the designations provided herein, and pharmaceutically acceptable salts and esters thereof These compounds inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.
Description
Cis-2,4,5-Triaryl-imidazolines This invention is related to at least one compound selected from a compound of formula I
X
X~
or pharmaceutically acceptable salts thereof, wherein X1, Xa, X3, and R are described in this application. This compound is believed to inhibit the interaction of MDM2 protein with a p-53-like peptide and have anti-proliferative activity.
p53 is a tumor suppresser protein that plays a central role in protection against development of cancer. It guards cellular integrity and prevents the propagation of permanently damaged clones of cells by the induction of growth arrest or apoptosis. At the molecular level, p53 is a transcription factor that can activate a panel of genes implicated in the regulation of cell cycle and apoptosis. p53 is a potent cell cycle inhibitor which is tightly regulated by MDM2 at the cellular level. MDM2 and p53 form a feedback control loop. MDM2 can bind p53 and inhibit its ability to transactivate p53-regulated genes. In addition, MDM2 mediates the ubiquitin-dependent degradation of p53. p53 can activate the expression of the MDM2 gene, thus raising the cellular level of MDM2 protein. This feedback control loop insures that both MDM2 and p53 are kept at a low level in normal proliferating cells. MDM2 is also a cofactor for E2F, which plays a central role in cell cycle regulation.
The ratio of MDM2 to p53 (E2F) is dysregulated in many cancers. Frequently occurring molecular defects in the pl6INK4/pl9ARF locus, for instance, have been shown to affect MDM2 protein degradation. Inhibition of MDM2-p53 interaction in tumor cells with wild-type p53 should lead to accumulation of p53, cell cycle arrest and/or apoptosis. MDM2 antagonists, therefore, can offer a novel approach to cancer therapy as single agents or in combination with a broad spectrum of other antitumor therapies. The feasibility of this strategy has been shown by the use of different _2_ macromolecular tools for inhibition of MDM2-p53 interaction (e.g. antibodies, antisense oligonucleotides, peptides). MDM2 also binds E2F through a conserved binding region as p53 and activates E2F-dependent transcription of cyclin A, suggesting that antagonists might have effects in p53 mutant cells.
Wells et al. J. Org. Chem., 1972, 37, 2158-2161, report synthesis of imidazolines.
Hunter et al., Can. J. Chem., 1972, Vol. 50, pgs. 669-77, report the preparation of amarine and isoamarine compounds which had previously been studied for chemiluminescence (McCapra et al. Photochem. and Photobiol. 1965, 4, 1111-1121). Zupanc et al.
Bull. Soc.
Cl2em. er Tech. (Yugoslavia) 1980-81, 27/28, 71-80, report the use of triaryl imidazolines as starting materials in the preparation of EDTA derivatives. EP 363 061 to Matsumoto reports imidazoline derivatives useful as immunomodulators. The compounds were indicated to have low toxicity. Treatment and/or prevention of rheumatoid arthritis, multiple sclerosis, systemic lupus, erythemathodes, and rheumatic fever were implicated.
WO 00/78725 to Choueiry et al. report a method for making substituted amidine compounds, and indicate that imidazoline-type compounds may be useful in the treatment of diabetes or related diseases involving impaired glucose disposal.
The present invention provides at least one compound selected from a compound of formula I
X~
H Xs N
N \ CF3 H R
XZ
wherein Xl and XZ are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of I
~ ~ ~ O=S=O
w ~ O Rz~N~O N- 'O N_ 'O
R~ I ~ R3 , , HN~ and Rs Ra R/vS
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R~, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHZ-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
RS is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, SOz-Rl~ and lower alkyl substituted by a substituent selected from R15 and C(O)-Rls;
R6 is selected from the group consisting of Lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower allzyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
L~~ is selected from the group consisting of cyano, hydroxy, Iower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOZNHZ, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CHZ-R9 and CHz-Rlo;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rll;
Rla is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-Iower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, OXO, and lower alkyl substituted with-OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl _g_ substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOZ-NHz, SOZ-N-lower alkyl, heteroaryl, heterocycle;
Rl6 is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkoxy, N-lower alkenyl N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH~, C(O)-N-Lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(O)-NHZ, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, triffuoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In one embodiment, the present invention provides at least one compound selected from a compound of formula I
X
XZ I
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of ~ ~ ~ O=S=O
O R~~N~O N- 'O N- 'O
s R, I r Rs ~ , HN~ and R
Ra R5 wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
Rz is selected from hydrogen and methyl;
R3 is selected from the group consisting of heteroaryl, heterocycle, and CHZ-R~;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHz-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-Rlz, C(O)-R13, SOZ-Ri4 and lower alkyl substituted by a subsdtuent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-Iower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, lower allcoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOzNH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NHZ and C(O)-NH-lower alkyl, CHI-R9 and CHz-RIO;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkOXya C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rln Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NHZ, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and triffuoromethyl;
R12 is selected from the group consisting of lower alkox y, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(Q)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, and oxo;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
Rls is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOZ-NH2, SOZ-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHz, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(~)-NHz C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In preferred embodiments, the two hydrogen of the imadazoline ring are in a cis configuration to each other. The compound may be in a racemic form and may be optically active. The compound maybe an isomer.
The present invention provides cis-imidazolines which are small molecule inhibitors of the MDM2-p53 interaction. In cell-free and cell-based assays, compounds of the present invention are shown to inhibit the interaction of MDM2 protein with a p53-like peptide with a potency that is approximately 100 fold greater than a p53-derived peptide. In cell-based assays, these compounds demonstrate mechanistic activity.
Incubation of cancer cells with wild-type p53 leads to accumulation of pS3 protein, induction of p53-regulated p21 gene, and cell cycle arrest in G1 and G2 phase, resulting in potent antiproliferative activity against wild-type p53 cells in vitro. In contrast, these activities were not observed in cancer cells with mutant p53 at comparable compound concentrations. Therefore, the activity of MDM2 antagonists is likely linked to its mechanism of action. These compounds can be potent and selective anticancer agents.
The present invention provides at least one compound selected from a compound selected from a compound of formula I
H Xs N
N \ CF3 / R
X~
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of w O RZ~N~O N- 'O N- 'O O-S=O
R~ I i R3 ~ , HN,( J and Rs Ra R~''S
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHZ, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen, methyl and lower alkoxy;
_1g_ R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R~, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHz-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C ( S )-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, SOz-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-Rls;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, Iower alkoxy, heteroaryl, hetero cycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOZNHz, lower alkoxy and hydroxy;
R$ is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NHz and C(O)-NH-lower alkyl, CHz-R9 and CHz-Rio;
R9 is selected from the group consisting of NHz, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O )-NH-Rl i;
Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-Iower alkyl, C(O)-NHz, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Ril is selected from lower alkyl, and Iower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
Rlz is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-Iower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, and lower alkyl substituted with -OC(O)CH3;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, triffuoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOz-NHz, SOz-N-lower alkyl, heteroaryl, heterocycle;
RI6 is selected from the group consisting of lower alkoxy, NHz, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by RIB, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
RIB is selected from the group consisting of C(O)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, hydroxy, oxo and Iower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In one embodiment, the present invention provides at least one compound selected from a compound of formula I
X
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of I
~ O RZ~N~O N- 'O N- 'O O=S=O
i R~ I ~ Rs , H ~ and Rs Ra R
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHZ, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen and methyl;
R3 is selected from the group consisting of heteroaryl, heterocycle, and CH2-R~;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHZ-N-lower alkyl, CHZ-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, S02-Ri4 and lower alkyl substituted by a substituent selected from R15 and C(O)-Rl~;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of S02NH2, lower alkoxy and hydroxy;
R$ is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the gxoup consisting of oxo, C(O)-NHZ and C(O)-NH-lower alkyl, CHZ-R9 and CH2-Rio;
R9 is selected from the group consisting of NHZ, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rl l;
Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-Iower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
Rlz is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NHz, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
Ri5 is selected from the group consisting of Iower alkoxy, cyano, trifluoromethyl, N-lower alkyl, S02-lower alkyl, C(O)-lower alkyl, SO2-NH2, SOZ-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and RI$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In preferred embodiments, the two hydrogen of the imadazoline ring are in a cis configuration to each other. The compound may be in a racemic form and may be optically active. The compound may be an isomer.
In another preferred embodiment, Xi and Xz are both chloro; X3 is ethoxy or isopropoxy.
In another preferred embodiment, the trifluoromethyl group is para to the imidazoline ring. The trifluoromethyl group is meta to the imidazoline ring.
The R group is preferred to be C(O)-phenyl-CHZ-Rl, C(O)-NRZR3, C(O)-piperidine substituted by R4, and C(O)-piperazine substituted by R5, SOZ-R6.
In a further preferred embodiment, Xl and XZ are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is para to the imidazoline ring, and R
is C(O)-piperidine substituted by R4.
In yet another preferred embodiment, Xl and X2 are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is para to the imidazoline ring, and R
is C(O)-piperazine substituted by R5.
In yet another preferred embodiment, Xl and X2 are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is ineta to the imidazoline ring, and R
is C(O)-~~iperidine substituted by R4.
In yet another preferred embodiment, Xl and Xa are chloro, X3 is ethoxy or .sopropoxy, the trifluoromethyl group is meta to the imidazoline ring, and R
is C(O)-~iperazine substituted by R5.
In a further preferred embodiment, R5 is lower alkyl substituted by R15.
In yet another preferred embodiment, piperazine is substituted by oxo and lower alkyl substituted by Rls.
In yet another preferred embodiment, Rls is selected from the group consisting of -SOZ-methyl, hydroxy and lower alkoxy.
"Alkoxy" denotes -O-alkyl.
"Alkyl" denotes a straight-chained or branched saturated aliphatic hydrocarbon.
"Lower alkyl" groups denote C1-C6 alkyl groups and include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2-butyl, pentyl, hexyl, and the like. Generally, lower alkyl is preferably C1-C4 alkyl, and more preferably CI-C3 alkyl.
"Aryl" means a monovalent, monocyclic or bicyclic, aromatic carbocyclic hydrocarbon radical, preferably a 6-10 member aromatic ring system. Preferred aryl groups include, but are not limited to, phenyl, naphthyl, tolyl, and xylyl.
"Cycloalkyl" means a non-aromatic, partially or completely saturated monovalent cyclic hydrocarbon radical containing 3 to 8 atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
"Effective amount" means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
"Halogen" means fluorine, chlorine, bromine or iodine, preferably bromine or chlorine.
"Hetero atom" means an atom selected from N, O and S.
"Heteroaryl" means an aromatic heterocyclic ring system containing up to two rings. Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyridine, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole and tetrazolyl.
"Heterocycle" or "heterocyclyl" means a saturated or partially unsaturated, non-aromatic cyclic radical of 3 to 8 ring atoms in which from one to 3 ring atoms are hetero atoms selected from nitxogen, oxygen, S(O)n (where n is an integer from 0 to
X
X~
or pharmaceutically acceptable salts thereof, wherein X1, Xa, X3, and R are described in this application. This compound is believed to inhibit the interaction of MDM2 protein with a p-53-like peptide and have anti-proliferative activity.
p53 is a tumor suppresser protein that plays a central role in protection against development of cancer. It guards cellular integrity and prevents the propagation of permanently damaged clones of cells by the induction of growth arrest or apoptosis. At the molecular level, p53 is a transcription factor that can activate a panel of genes implicated in the regulation of cell cycle and apoptosis. p53 is a potent cell cycle inhibitor which is tightly regulated by MDM2 at the cellular level. MDM2 and p53 form a feedback control loop. MDM2 can bind p53 and inhibit its ability to transactivate p53-regulated genes. In addition, MDM2 mediates the ubiquitin-dependent degradation of p53. p53 can activate the expression of the MDM2 gene, thus raising the cellular level of MDM2 protein. This feedback control loop insures that both MDM2 and p53 are kept at a low level in normal proliferating cells. MDM2 is also a cofactor for E2F, which plays a central role in cell cycle regulation.
The ratio of MDM2 to p53 (E2F) is dysregulated in many cancers. Frequently occurring molecular defects in the pl6INK4/pl9ARF locus, for instance, have been shown to affect MDM2 protein degradation. Inhibition of MDM2-p53 interaction in tumor cells with wild-type p53 should lead to accumulation of p53, cell cycle arrest and/or apoptosis. MDM2 antagonists, therefore, can offer a novel approach to cancer therapy as single agents or in combination with a broad spectrum of other antitumor therapies. The feasibility of this strategy has been shown by the use of different _2_ macromolecular tools for inhibition of MDM2-p53 interaction (e.g. antibodies, antisense oligonucleotides, peptides). MDM2 also binds E2F through a conserved binding region as p53 and activates E2F-dependent transcription of cyclin A, suggesting that antagonists might have effects in p53 mutant cells.
Wells et al. J. Org. Chem., 1972, 37, 2158-2161, report synthesis of imidazolines.
Hunter et al., Can. J. Chem., 1972, Vol. 50, pgs. 669-77, report the preparation of amarine and isoamarine compounds which had previously been studied for chemiluminescence (McCapra et al. Photochem. and Photobiol. 1965, 4, 1111-1121). Zupanc et al.
Bull. Soc.
Cl2em. er Tech. (Yugoslavia) 1980-81, 27/28, 71-80, report the use of triaryl imidazolines as starting materials in the preparation of EDTA derivatives. EP 363 061 to Matsumoto reports imidazoline derivatives useful as immunomodulators. The compounds were indicated to have low toxicity. Treatment and/or prevention of rheumatoid arthritis, multiple sclerosis, systemic lupus, erythemathodes, and rheumatic fever were implicated.
WO 00/78725 to Choueiry et al. report a method for making substituted amidine compounds, and indicate that imidazoline-type compounds may be useful in the treatment of diabetes or related diseases involving impaired glucose disposal.
The present invention provides at least one compound selected from a compound of formula I
X~
H Xs N
N \ CF3 H R
XZ
wherein Xl and XZ are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of I
~ ~ ~ O=S=O
w ~ O Rz~N~O N- 'O N_ 'O
R~ I ~ R3 , , HN~ and Rs Ra R/vS
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R~, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHZ-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
RS is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, SOz-Rl~ and lower alkyl substituted by a substituent selected from R15 and C(O)-Rls;
R6 is selected from the group consisting of Lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower allzyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
L~~ is selected from the group consisting of cyano, hydroxy, Iower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOZNHZ, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CHZ-R9 and CHz-Rlo;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rll;
Rla is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-Iower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, OXO, and lower alkyl substituted with-OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl _g_ substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOZ-NHz, SOZ-N-lower alkyl, heteroaryl, heterocycle;
Rl6 is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkoxy, N-lower alkenyl N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH~, C(O)-N-Lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(O)-NHZ, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, triffuoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In one embodiment, the present invention provides at least one compound selected from a compound of formula I
X
XZ I
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of ~ ~ ~ O=S=O
O R~~N~O N- 'O N- 'O
s R, I r Rs ~ , HN~ and R
Ra R5 wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
Rz is selected from hydrogen and methyl;
R3 is selected from the group consisting of heteroaryl, heterocycle, and CHZ-R~;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHz-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-Rlz, C(O)-R13, SOZ-Ri4 and lower alkyl substituted by a subsdtuent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-Iower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, lower allcoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOzNH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NHZ and C(O)-NH-lower alkyl, CHI-R9 and CHz-RIO;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkOXya C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rln Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NHZ, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and triffuoromethyl;
R12 is selected from the group consisting of lower alkox y, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(Q)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, and oxo;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
Rls is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOZ-NH2, SOZ-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHz, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(~)-NHz C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In preferred embodiments, the two hydrogen of the imadazoline ring are in a cis configuration to each other. The compound may be in a racemic form and may be optically active. The compound maybe an isomer.
The present invention provides cis-imidazolines which are small molecule inhibitors of the MDM2-p53 interaction. In cell-free and cell-based assays, compounds of the present invention are shown to inhibit the interaction of MDM2 protein with a p53-like peptide with a potency that is approximately 100 fold greater than a p53-derived peptide. In cell-based assays, these compounds demonstrate mechanistic activity.
Incubation of cancer cells with wild-type p53 leads to accumulation of pS3 protein, induction of p53-regulated p21 gene, and cell cycle arrest in G1 and G2 phase, resulting in potent antiproliferative activity against wild-type p53 cells in vitro. In contrast, these activities were not observed in cancer cells with mutant p53 at comparable compound concentrations. Therefore, the activity of MDM2 antagonists is likely linked to its mechanism of action. These compounds can be potent and selective anticancer agents.
The present invention provides at least one compound selected from a compound selected from a compound of formula I
H Xs N
N \ CF3 / R
X~
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of w O RZ~N~O N- 'O N- 'O O-S=O
R~ I i R3 ~ , HN,( J and Rs Ra R~''S
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHZ, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen, methyl and lower alkoxy;
_1g_ R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R~, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHz-N-lower alkyl, CHZ-heterocycle, CHZ-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C ( S )-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, SOz-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-Rls;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, Iower alkoxy, heteroaryl, hetero cycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SOZNHz, lower alkoxy and hydroxy;
R$ is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NHz and C(O)-NH-lower alkyl, CHz-R9 and CHz-Rio;
R9 is selected from the group consisting of NHz, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O )-NH-Rl i;
Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-Iower alkyl, C(O)-NHz, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Ril is selected from lower alkyl, and Iower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
Rlz is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-Iower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, and lower alkyl substituted with -OC(O)CH3;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, triffuoromethyl, N-lower alkyl, SOZ-lower alkyl, C(O)-lower alkyl, SOz-NHz, SOz-N-lower alkyl, heteroaryl, heterocycle;
RI6 is selected from the group consisting of lower alkoxy, NHz, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by RIB, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
RIB is selected from the group consisting of C(O)-lower alkyl, C(O)-NHz, C(O)-N-lower alkyl, hydroxy, oxo and Iower alkyl substituted by hydroxy; and Rl$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In one embodiment, the present invention provides at least one compound selected from a compound of formula I
X
wherein Xl and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of I
~ O RZ~N~O N- 'O N- 'O O=S=O
i R~ I ~ Rs , H ~ and Rs Ra R
wherein Rl is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHZ, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
RZ is selected from hydrogen and methyl;
R3 is selected from the group consisting of heteroaryl, heterocycle, and CH2-R~;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CHZ-N-lower alkyl, CHZ-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CHz-Riz, C(O)-R13, S02-Ri4 and lower alkyl substituted by a substituent selected from R15 and C(O)-Rl~;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R~ is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of S02NH2, lower alkoxy and hydroxy;
R$ is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the gxoup consisting of oxo, C(O)-NHZ and C(O)-NH-lower alkyl, CHZ-R9 and CH2-Rio;
R9 is selected from the group consisting of NHZ, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-Rl l;
Rlo is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-Iower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
Rll is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
Rlz is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by Rl~;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo;
Rl4 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NHz, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
Ri5 is selected from the group consisting of Iower alkoxy, cyano, trifluoromethyl, N-lower alkyl, S02-lower alkyl, C(O)-lower alkyl, SO2-NH2, SOZ-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHZ, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, triffuoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
Rl~ is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and RI$ is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
In preferred embodiments, the two hydrogen of the imadazoline ring are in a cis configuration to each other. The compound may be in a racemic form and may be optically active. The compound may be an isomer.
In another preferred embodiment, Xi and Xz are both chloro; X3 is ethoxy or isopropoxy.
In another preferred embodiment, the trifluoromethyl group is para to the imidazoline ring. The trifluoromethyl group is meta to the imidazoline ring.
The R group is preferred to be C(O)-phenyl-CHZ-Rl, C(O)-NRZR3, C(O)-piperidine substituted by R4, and C(O)-piperazine substituted by R5, SOZ-R6.
In a further preferred embodiment, Xl and XZ are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is para to the imidazoline ring, and R
is C(O)-piperidine substituted by R4.
In yet another preferred embodiment, Xl and X2 are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is para to the imidazoline ring, and R
is C(O)-piperazine substituted by R5.
In yet another preferred embodiment, Xl and X2 are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is ineta to the imidazoline ring, and R
is C(O)-~~iperidine substituted by R4.
In yet another preferred embodiment, Xl and Xa are chloro, X3 is ethoxy or .sopropoxy, the trifluoromethyl group is meta to the imidazoline ring, and R
is C(O)-~iperazine substituted by R5.
In a further preferred embodiment, R5 is lower alkyl substituted by R15.
In yet another preferred embodiment, piperazine is substituted by oxo and lower alkyl substituted by Rls.
In yet another preferred embodiment, Rls is selected from the group consisting of -SOZ-methyl, hydroxy and lower alkoxy.
"Alkoxy" denotes -O-alkyl.
"Alkyl" denotes a straight-chained or branched saturated aliphatic hydrocarbon.
"Lower alkyl" groups denote C1-C6 alkyl groups and include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2-butyl, pentyl, hexyl, and the like. Generally, lower alkyl is preferably C1-C4 alkyl, and more preferably CI-C3 alkyl.
"Aryl" means a monovalent, monocyclic or bicyclic, aromatic carbocyclic hydrocarbon radical, preferably a 6-10 member aromatic ring system. Preferred aryl groups include, but are not limited to, phenyl, naphthyl, tolyl, and xylyl.
"Cycloalkyl" means a non-aromatic, partially or completely saturated monovalent cyclic hydrocarbon radical containing 3 to 8 atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
"Effective amount" means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
"Halogen" means fluorine, chlorine, bromine or iodine, preferably bromine or chlorine.
"Hetero atom" means an atom selected from N, O and S.
"Heteroaryl" means an aromatic heterocyclic ring system containing up to two rings. Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyridine, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole and tetrazolyl.
"Heterocycle" or "heterocyclyl" means a saturated or partially unsaturated, non-aromatic cyclic radical of 3 to 8 ring atoms in which from one to 3 ring atoms are hetero atoms selected from nitxogen, oxygen, S(O)n (where n is an integer from 0 to
2), or a combination thereof, the remaining ring atoms being C. Examples of preferred heterocycles are piperidine, piperazine, pyrrolidine, morpholine, indoline, tetrahydropyranyl, thiomorpholino, pentamethylene sulfide, and pentamethylene sulfone.
"ICSO" refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity. ICSO can be measured, ir2ter alia, as is described subsequently.
"Lower alkyl" alone or in conjunction with another term, e.g. lower alkyl-heterocycle, denotes a straight-chain or branched saturated aliphatic hydrocarbon having 1 to 6, preferably 1 to 4, carbon atoms. Typical lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2-butyl, pentyl, hexyl and the like.
"Lower alkoxy" refers to any of the above lower alkyl groups attached to an oxygen atom. Typical lower alkoxy groups include methoxy, ethoxy, propyloxy or propoxy, butyloxy and the like.
"Oxo" means =O.
"Pharmaceutically acceptable ester" refers to a conventionally esterified compound of formula I having a carboxyl group, which esters retain the biological effectiveness and properties of the compounds of formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid.
Information concerning esters and the use of esters for the delivery of pharmaceutical compounds is available in Design of Prodrugs. Bundgaard H ed.
(Elsevier, 1985). See also, H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109; Krogsgaard-Larsen, et. al., Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-19I.
"Pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical arid chemical stability, hygroscopicity, flowability and solubility of compounds.
See, e.g., H.
Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed.
1995) at pp. 196 and 1456-1457.
"Pharmaceutically acceptable," such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
"Substituted," as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options.
"Therapeutically effective amount" means an amount of at least one designated compound, that significantly inhibits proliferation and/or prevents differentiation of a human tumor cell, including human tumor cell lines.
Compounds of the present invention as exemplified advantageously show IC50s from about 70 r~M to about 100 ~M.
The compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
A therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is within the skill in the art.
The therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage will be adjusted to the individual requirements in each particular case including the specific compounds) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg, a daily dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 1,000 mg, should be appropriate, although the upper limit may be exceeded when indicated.
The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.
Synthesis The compounds of formula I can be prepared according to scheme I.
Scheme I
Xz r \ , NHz CN HN O~- I ~ ~NHz Xz i
"ICSO" refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity. ICSO can be measured, ir2ter alia, as is described subsequently.
"Lower alkyl" alone or in conjunction with another term, e.g. lower alkyl-heterocycle, denotes a straight-chain or branched saturated aliphatic hydrocarbon having 1 to 6, preferably 1 to 4, carbon atoms. Typical lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2-butyl, pentyl, hexyl and the like.
"Lower alkoxy" refers to any of the above lower alkyl groups attached to an oxygen atom. Typical lower alkoxy groups include methoxy, ethoxy, propyloxy or propoxy, butyloxy and the like.
"Oxo" means =O.
"Pharmaceutically acceptable ester" refers to a conventionally esterified compound of formula I having a carboxyl group, which esters retain the biological effectiveness and properties of the compounds of formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid.
Information concerning esters and the use of esters for the delivery of pharmaceutical compounds is available in Design of Prodrugs. Bundgaard H ed.
(Elsevier, 1985). See also, H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109; Krogsgaard-Larsen, et. al., Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-19I.
"Pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical arid chemical stability, hygroscopicity, flowability and solubility of compounds.
See, e.g., H.
Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed.
1995) at pp. 196 and 1456-1457.
"Pharmaceutically acceptable," such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
"Substituted," as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options.
"Therapeutically effective amount" means an amount of at least one designated compound, that significantly inhibits proliferation and/or prevents differentiation of a human tumor cell, including human tumor cell lines.
Compounds of the present invention as exemplified advantageously show IC50s from about 70 r~M to about 100 ~M.
The compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
A therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is within the skill in the art.
The therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage will be adjusted to the individual requirements in each particular case including the specific compounds) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg, a daily dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 1,000 mg, should be appropriate, although the upper limit may be exceeded when indicated.
The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.
Synthesis The compounds of formula I can be prepared according to scheme I.
Scheme I
Xz r \ , NHz CN HN O~- I ~ ~NHz Xz i
3 Xs HCI, EtOH ~ X3 Xz / 3 \ I X
I/ N
CF3 CF3 CIH ~ H \ CF3
I/ N
CF3 CF3 CIH ~ H \ CF3
4 CI Xz CI
CI I / O=S=O
J
X then amine X then amine z r Xs ~ X
\ N s CF3 \ N ~ CF3 O __ X ~ / O ~S O
7 Xz Rs '1 The benzonitrile 1, prepared according to the procedure provided by Harrison, C.
R., et al. WO 9203421, is converted to the ethyl benzimidate 2 using HCl gas in ethanol.
Condensation of the imidate 2 with the 1,2-diamine 3 is carried out in ethanol at 40-100 °C in the presence of a base such as triethylamine.
The rneso-1,2-diamines of formula 3 are known compounds and prepared according to the literature procedures (see Jennerwein, M. et al. Cancer Res.
Clin. Oncol.
1988, 114, 347-58; Vogtle, F.; Goldschmitt, E. Chem. Ber. 1976, 109, 1-40).
As set forth in scheme I, the compound of formula 7 can be prepared from compound 4 by the reaction with the benzoyl chloride 5 in the presence of a base such triethylamine, then with an amine in a solvent such as dimethylformamide.
As set forth in scheme I, the compound of formula 8 can be prepared from compound 4 by the reaction with the sulfonyl chloride 6 in the presence of a base such triefihylamine, then with an amine in a solvent such as dimethylformamide.
The compound of formula 4 can be converted to the compound of formula 9 using phosgene in the presence of a base such as triethylamine (scheme 2). The compounds 10, 1 l, or 12 can then be obtained by the reaction of 9 with a suitable amine group (a known compounds or a compound prepared by known methods).
Scheme II
Xz i Xz i Xz Xs _ ~ ~ Xs _ ~ ~ Xs N N N
--~
N ~ GF3 w N \ CF w N \ CF
X I / 4 X I / C~~o 9 3 X I / iN~O 10 z z z Rz R
Xz r X
Xs N
w N \ CF3 ;.F3 ~O
Xz ~~ 11 Xz Ra H Rs If it is desired, the R4 and R5 groups of in the compounds 11 and 12 can be functionalized further as illustrated in scheme 3.
Scheme III
X X X
X~ X; X2 9 i3 ~ 14 N
W
X X
Xa Xz X
2 i 15 ~ Xa HZN ~ LG ~ N ,.
LG: Leaving group ~ N ~ CF
~O
X N
z z As set forth in scheme III, the compound of formula 9 can react with an appropriately protected piperazine to afford a compound of formula 13 after deprotection. A compound of 13 is then reacted with WX (e.g. X = halide, Ms, Ts, epoxide, alkene, or acyl, etc.) to give a compound of formula 14.
As set forth in scheme III, the compound of formula 9 can react with an appropriately protected piperidine to afford a compound of formula I5 after deprotection. A compound of 15 is then reacted with WX (e.g. X = halide, or aryl, etc.) to give a compound of formula 16.
As set forth in scheme III, a compound of formula 17 can be prepared from compound 9 by the reaction with 4-hydroxyethylpiperidine and triethylamine, followed by the conversion of the hydroxyl group to a suitable leaving group (LG) such as Y-N
H
toluenemethylsulfonate. Compound 18 can be prepared from compound 17 by displacing the leaving group with an amine.
If it is desired to prepare a compound of formula 11 or 12 wherein the starting material is not commercially available, many synthetic methods known in the art can be employed. A representative process for synthesizing piperazin-2-one is provided in the examples. The following schemes illustrate some of these methods.
A compound of formula 21 (W can be any suitable group as defined in R5) can be prepared by alkylation of an appropriately protected compound of formula 19 with WX
(X could be any suitable leaving group such as Cl, Br, I) using conventional methods (scheme IV). The amide anion is generated by a base such as sodium hydride.
The reaction typically is carried out in dimethylformamide.
Scheme IV
O p O
/---~ WX, base ~--~ Deprotect Prot-N~ H ------~- prot-N'~N-W -----~- HN~ N-W
A compound of formula 24 (W can be any suitable group as defined in R5) can be prepared by reacting of an appropriately protected compound of formula 19 with WX (X
could be any suitable leaving group such as Cl, Br, I), epoxide, or allzene using conventional methods (scheme V).
Scheme V
/~ WX, base ~ Deprotect /-1 Prot- ~NH or -- Prot-N N-W ---~ H ~N-W
U
epoxide 22 or alkene 23 24 The following examples illustrate preferred methods for synthesizing the compounds of the present invention. Structural formulas follow. With regard to structural formulas, it is understood that oxygen and nitrogen atoms with available electrons have a hydrogen bound thereto, as indicated by compound name. These examples and preparations are illustrative and are not intended to be limiting. It should be understood that there may be other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.
The compounds synthesized in these examples are racemic. The enantiomers of the compounds of interest can be separated using chiral column chromatography (e.g.
ChiralPak~ AD, ChiralPak~ OD, etc). One enanatiomer is shown to be more potent in our in vitro assay than the other.
Example 1 d,5-Bis-(4-chloro-phen~)-2-(2-ethox~4-triffuorometh T~1-phenyl)-4,5-dihydro-1H
imidazole c1 N
~~F
H ~ / F
CI
To a solution of 2-nitro-4-trifluoromethyl-benzonitrile (71.7 g, 318.5 mmol) in anhydrous ethanol (400 mL) at room temperature was added sodium ethoxide (238 mL, 637 mmol, 21% solution in ethanol) dropwise over a period of 30 min. The reaction mixture was stirred at room temperature for 1 h. Water ( 1 L) was added, and the mixture was stirred for 15 min. The solids were filtered off, washed with water, and dried in the vacuume oven (40 °C) overnight to give 2-ethoxy-4-trifluoromethyl-benzonitrile (64 g, 93% yield).
2-Ethoxy-4-triffuoromethyl-benzonitrile (64 g) was dissolved in 750 mL of anhydrous ethanol. The solution was cooled to 0 °C and saturated with hydrogen chloride gas. The reaction flask was then sealed with a Teflon stopper and stirred at room temperature for 11 d. The progress of the reaction was checked every few days, and the solution was saturated again with hydrogen chloride gase. Nitrogen gas was bubbled through the solution to remove excess hydrogen chloride gas. The solvent was removed and the residue was triturated in diethyl ether to afford ethyl 2-ethoxy-4-trifluoromethyl-benzimidate hydrochloride (59.5 g, 67% yield) as white solids.
A solution of meso-1,2-bis-(4-chloro-phenyl)-ethane-1,2-diamine (50.16 g, 178.4 mmol, prepared according to the procedure described by Jennerwein, M. et al.
Cancer Res. Clin. Oncol. 1988,114, 347-58; Vogtle, F.; Goldschmitt, E. Chem. Ber.
1976,109, 1-40), ethyl 2-ethoxy-4-trifluoromethyl-benzimidate hydrochloride (59_g, 178.4 mmol), and triethylamine (49.7 mL, 356.8 mmol) in ethanol (700 mL) was heated at reflex for 4 h. The solvent was removed, and the residue was taken in ethyl acetate (800 mL) and saturated solution of sodium carbonate (300 mL). The layers were separated, and the product was extracted with ethyl acetate ( 1 x 200 mL). The organic layers were washed with brine ( 1 x 100 mL) and dried over anhydrous magnesium sulfate. The solids were then filtered off, and the filtrate was concentrated in vacuo. Purification of the crude residue by flash column chromatography (60 A silica gel) eluting with 50%
ethyl acetate in hexanes yielded 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (64.47 g, 75% yield) as yellow solids.
Example 2 In an analogous manner as described in example 1, there were obtained:
4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole m N
~~-~--~-F
I ~ H \ / F
CI
4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-1 H-imidazole c1, ~. I
N
N
I / H F
CI F F
Example 3 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dih, imidazole-1-carbonyl chloride c1 r.
N
~~~-(~F
I w N \ I F
CI
To a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (46 g, 95.97 mmol, example 1) and triethylamine (66.9 mL, 479.9 mmol) in methylene chloride (2 L) cooled to 0 °C was added phosgene ( 124.3 mL, 239.9 mmol, ~20% solution in toluene) dropwise over a period of 30 min. The reaction mixture was stirred at room temperature for 1 h. Nitrogen gas was bubbled through the reaction mixture to remove excess phosgene. The reaction mixture was concentrated to dryness, and the residue was dried in vacuo for 1 h to give 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (51 g, 98% yield) as off white solids. The product was used without further purification.
Example 4 In an analogous manner as described in example 3, there were obtained:
4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride c1 N
~~-~--~F
N ~ / F
CIO
CI
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride c1 ~
y o N
~N
/ F
CI I CI~C F F
Example 5 The following general procedure was used for the reaction of the 1-carbonyl chloride 9 (examples 3 and 4) with the commercially available amine.
A solution of the 1-carbonyl chloride 9 (1 eq., prepared according the procedure described in example 3) in methylene chloride was added to a solution of the amine ( 1-2 eq.) and triethylamine in methylene chloride. The reaction mixture was stirred at room temperature for 1 h. The reaction was worked up with aqueous sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with water and brine, and dried over anhydroud sodium sulfate. The solids were filtered off, and the filtrate was concentrated in vacuo. Purification of the crude residue by flash column chromatography gave the desired urea product.
Example 6 X4,5-Bis-(4-chloro-phen 1y )2-2-~2-ethoxy-4-trifluorometh,~Tl=phenyl)-4,5-dihydro imidazol-1- 1~f4-(propane-2-sulfonyl)-piperazin-1-~]~-methanone A solution of 1-BOC-piperazine (0.617 mmol) and diisopropylethylamine (0.679 mmol) in 0.5 mL of methylene chloride was added to a 4 mL vial. Propane-2-sulfonyl chloride (0.679mmol) was added to the vial, and the reaction mixture was shaken overnight at room temperature. When the reaction was complete, it was diluted with 1.5 mL of methylene chloride and extracted with 1 mL of 1N solution of hydrogen chloride followed by 1 mL of 10% potassium carbonate solution. The organic layer was concentrated in vacuo. The residue was dissolved in 0.5 mL of tetrahydrofuran and 4M
solution of hydrogen chloride in dioxane (0.5 mL). The solution was shaken overnight at room temperature then concentrated ire vacuo to give 1-(propane-2-sulfonyl)-piperazine.
1-(Propane-2-sulfonyl)-piperazine (0.0286 mrnol) was dissolved in 0.25 mL of methylene chloride and added to a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (0.024 mmol, , example 3) and diisopropylethylamine (0.072 rnmol) in 0.25 mL of methylene chloride in a 4 rnL vial. The vial was capped and shaken overnight at room temperature.
The reaction mixture was diluted with 1 mL of methylene chloride and 1 mL of water. The vial was agitated and centrifuged. The organic layer was transferred to a 4 mL
vial and concentrated in vacuo to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone. LR-MS (M+H)~= 697.4.
Example 7A
1-Ben2X1-4-[4,5-bis-(4-chloro-nhenvll-2 ~2-ethoxy-4-trifluoromethvl-nhenyl~-4,5 dihvdro-imidazole-1-caxbonvl]-piperazin-2-one hydrochloride Sodium hydride ($0 mg, 2.0 mmol, 60a/o in mineral oil) was added to a solution of 4-tent butyloxycarbonyl-piperazin-2-one (200 mg,1.0 mraol) in dimethylformamide (5.0 mL) at 0 aC. The reaction was stirred at 0 °C for 0.5 h. To this mixture was added benzyl bromide (300 uL, 2.5 mmol) and the reaction was stirred for 2 h at room temperature.
The reaction mixture was quenched with a dilute aqueous solution of sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with brine and dried over anhydrous sodium sulfate. Purification of the crude residue by chromatography over silica gel using 30% ethyl acetate in hexane gave 4-tent bntyloxycarbonyl-2 benzyl-piperazin-2-one (174 mg, 60 °r6 yield).
Hydrochloric acid {0.25 mL,1.00 mmol, 4 M in 1,4-dioxane) was added to a solution of 4-tent butyloJCycarbonyl-2-benzyl-piperazin-2-one ( 17~ mg, 0.60 mmol) in 1,4-dioxane ( L0 mh). The lmixCure was stirred overnight The reaction was concentrated to give 2-benzyl-piperazin-2-one hydxochloride as an off white solid (130 mg, 97 r6 yield).
4,5-Bis-(4-chlorv-phenyl)-2-{2-ethoxy 4-tri$uoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (example 3) was reacted with 2 benzyl-piperazin-2-one hydrochloride easing the procedure as desrn-bed in example 5 to give 4-j4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-carbonylJ-1-benzyl-piperazin-2-vne. It was then dissolved in dilute hydrochloric acid {0.5 N,1 mL) and lyophilized to give 4-[4,5-bis-(4-cbloro-phenyl)-2-(2-ethoxy txifluoromethyl-phenyl)-4,5-dihydro-imidazole-carbonyl]-1-benzyl-piperazin-Z-one hydrochloride as an off white powder (65mg; 89% yield). LR MS (APCI): 695.6 j(M+~)+].
f 4 5-Bis-!4-chloro-phenyl)-2-f 2-ethoxy-~4-trifluoromethyl-phenyD-4.5-dihydro imidazol- -1- 1-f4-lmorpholine-4-sulfon~piperazin-1-yll-methanone RECTIFIED SHEET (RULE 91 ) The triffate salt of the methyIated sulfuryldiimidazole (3.14 g, 8.04 mmol ) was solved in acetonitrile. 1-Boc-piperazine (1.0 g, 5.37 mmol) and diisopropylethyIamine :q.) were added at once. The reaction mixture was stirred at room temperature rrnight. It was diluted with ethyl acetate and washed with water. The organic layers ve dried, filtered, and concentrated irt vacuo to give a viscous_oil (2.6 g).
Purification he oil by flash chromatography gave 4-(2-methyl-imidazole-I-sulfonyl)-piperazine-1-ooxylic acid tert-butyl ester (1.4 g, 79% yield). LR-MS: 331 j(M+H)~].
A solution.of4-(2-methyl-imidazole-1-sulfonyl)-piperazine-1-carboxylic acid tert-yl ester ( L4 g, 4.24 mmol) in methylene chloride was cooled in an ice bath, and uoromethanesulfonic acid methyl ester (0.56 mL, 4.9 mmol) was added via a pipet.
'x stirring at ice temperature for 3 h, the solvent was evaporated to give 4-(2-rnethyl-dazole-1-sulfonyl)-piperazine-1-carboxylic acid tert-butyl estex triffate salt as yellow ds.
A solution of the triffate salt (60 rng, 0.12 mmol), morpholine (31.7 mg, 0.36 Col) and 63 uL of diisopropylethylamine (0..36 mmol) .in 0.25 mL of acetonitrile was ~ed at ambient temperature overnight. The reaction was diluted with I rnL of hylene chloride and 0.5 mL of 1.0 M hydrochloric acid. . The organic phase was red through a small pad of silica gel and the solvent evaporated to yield 4-~rpholine-4-sulfonyl)-piperazine-1-carbo~cylic acid tert-butyl ester (39 mg, 95%). LR-336 [(M+H)~].
4-(Morpholine-4-sulfonyl)-piperazine-I-carboxylic acid tert-butyl ester (39 mg) dissolved in 4 mL of dioxane, and 4mL of 4.0 M hydrochloric acid in dioxane was :d. After standiizg overnight at ambient temperature, the solvent was removed to 4-(piperazine-I-sulfonyl)-morpholine hydrochloride as a white solid.
4-(Piperazine-I-sulfonyl)-rnorpholine hydrochloride (0.042 mmol) was suspended .ethylene chloride, and 400 uL of diisopropylethylamine was added. The rxiixture was ~d to 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-azole-I-carbonyl chloride (i0 mg, 0.019 mmol, example 3), and the reaction ure was allowed to stand overnight. It was diluted with mefihylene chloride and ied v~ith water. The organic layer was evaporated, and the residue purified by flash matography using ethyl acetate and hexanes to give [4,5-bis-(4-chloro-phenyl)-2-(2-RECTIFIED SHEET (RULE 9'I) ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(morpholine-4-sulfonyl)-piperazin-1-yl]-methanone (9.0 mg). LR-MS: 740.2 [(M+H)~].
Example 8A
~4-f4,5-Bis-(4-chloro-phmyl)-2-(2-ethoxy-4-trifluorometh T~l-phen~)-4,5-dihydro imidazole-1-carbonyl]-piperazin-1-~propionitrile hydrochloride aH
Phosgene (3.8 mL, 7.22 mmol, 1.9 M in toluene) was added dropwise to a cooled (0 °C) mixture of triethylamine (1.3 mL, 9.62 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluro-phenyl)-4,5-dihydro-1H-imidazole (1.15 g, 2.41 mmol) in methylene chloride (20 mL). The reaction mixture was stirred for 0.5 h at 0 °C, and the solvent was evaporated. The residue was kept under high vacuum for 30 min and dissolved in methylene chloride (20 mL). The solution was added dropwise to a cooled (0 °C) solution of 4-tert-butyloxycarbonylpiperazine (0.90 g, 4.81 mmol) in methylene chloride ( 16 mL). After 1 h, the reaction was worked up with aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using 50% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-tert-butyloxycarbonylpiperazin-1-yl]-methanone as a yellow foam (1.30 g, 78%).
Hydrochloric acid ( 10 mL, 40 mmol, 4 M in 1,4-dioxane) was added to a cooled (0 °C) solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-tert-butyloxycarbonylpiperazin-1-yl]-methanone in 1,4-dioxane ( 10 mL). The mixture was stirred at room temperature overnight.
Evaporation of the solvent gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(piperazin-1-yl)-methanone hydrochloride as an off white solid ( 1.10 g, 98 % yield).
2-Bromopropionitrile ( 10 uL, 0.120 mmol) was added to a mixture of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[piperazin-1-yl]-methanone hydrochloride and diisopropylethylamine (42 uL, 0.240 mmol) in dimethylformamide (1.0 mL). The reaction was stirred at room temperature overnight. Evaporation of the solvent and purification of the crude residue by flash chromatography over silica gel using 1-2% methanol in methylene chloride gave 3-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-propionitrile, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give 3-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-propionitrile hydrochloride as an off white powder (20mg, 39% yield). LR-MS
(APCI): 644.4 [(M+H)+].
Example SB
2-14- f 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorometh,~l-phen,~l)-4,5 dihydro-imidazole-1-carbonill-piperazin-1-yl)-N-methyl-acetamide A solution of chloroacetylchloride (8.85 mmol) in 10 mL of methylene chloride was cooled to approximately -40°C in a sealed 40 mL vial. Methylamine ( 18.6 mmol, 9.3 mL
of a 2M in tetrahydrofuran) was added in a portion-wise fashion via a syringe through a pierceable septum to the stirring solution. The reaction was stirred for 1 h at reduced temperature. The solution was then made acidic with 1N hydrochloric acid and then diluted with 10 mL of methylene chloride. The vial was agitated and centrifuged. The organic layer was transferred to 40 mL vials and concentrated in vacuo to give 2-chloro-N,N-dimethyl-acetamide.
2-Chloro-N,N-dimethyl-acetamide (0.0I94 mmol) in dimethylformamide (0.25 mL) was pipeted into a 4 mL vial containing a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (0.0169mmo1, example 1) and diisopropylethylamine (0.0194mmol) in 0.25 mL of dimethylformamide. The vial was capped and heated to 65°C for 2 d. The reaction was diluted with 1.5 mL of methylene chloride and 0.5 mL of water. The vial was agitated and centrifuged.
The organic layer was transferred to a 4 mL vial and concentrated in vacuo to give 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide. LR-MS: 663 [(M+H)~].
Exarn~le 9 1 ~4 f 4,5-Bis-(4-chloro-phen,~l)-2-(2-ethoxY-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-~l~-2-dimethylamino-ethanone [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (372 mg, 0.63 mmol, example 8A) and diisopropylethylamine (230 uL, 1.32 mmol) were dissolved in methylene chloride (4 mL) and cooled to ice temperature. Chloroacetyl chloride ( 100 uL,1.26 mmol) in methylene chloride ( 1 mL) was added dropwise and this mixture was stirred for 30 min at ice temperature. The reaction was diluted with methylene chloride and washed with water.
The organic layers were dried over anhydrous magnesium sulfate. The solids were filtered off, and the filtrate was concentrated. Purification of the crude material by flash chromatography using ethyl acetate and hexanes gave 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-chloro-ethanone ( 193 mg, 0.29 mmol).
To a solution of 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-chloro-ethanone (9.65 mg) and diisopropylethylamine (5 uL) was added dimethylamine (50 uL, 2.0M
solution in tetrahydrofuran). The reaction mixture was capped and heated at 60 °C overnight. It was diluted with methylene chloride and washed with water. The organic layer was concentrated to dryness to give 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-dimethylamino-ethanone (9.17 mg, 92% yield). LR-MS: 677.3 [(M+H)+].
Example 10 4-f4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuorometh TAI-phen Iy )4,5-dihydro-imidazole-1-carbonyll-piperazine-1-carbothioic acid meth lamide [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (279 mg, 0.47 mmol, example 8A) was dissolved in methylene chloride (3 mL) and methylisothiocyanate (64 uL) was added.
After stirring 3 h, the reaction mixture was concentrated to dryness.
Purification of the crude residue by flash chromatography (silica gel) eluting with ethyl acetate and hexanes gave 4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid methylamide (195 mg). LR-MS:
664.4 [(M+H)+].
Example I I
4-~4-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorometh ~~l-phenyl)-4,5 dihydro-imidazole-1-carbonyll -piperazine-1-carbon,~piperazin-2-one [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (50 mg, 0.085 mmol, example 8A) was dissolved in methylene chloride (1 mL) and cooled in an ice bath. Phosgene (250 uL, 20% solution in toluene)) was added, and the mixture was stirred for 30 min.
The solvent was evaporated and the residue was taken in methylene chloride. One third of this solution (0.028 mmol) was treated with 2-piperazinone (8.5 mg) and diisopropylethylamine (15 u1). The mixture was sonicated to aid in dissolving the amine and allowed to stand at ambient temperature overnight. It was diluted with methylene chloride and washed with water. The organic portion was separated and evaporated to give the crude urea. Purification of the crude urea by flash chromatography (silica gel) using ethyl acetate and hexanes gave 4-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazine-1-carbonyl}-piperazin-2-one (9.0 mg). LR-MS: 718.4 [(M+H)+].
Example 12 j4,5-Bis-(4-chloro=phen~)-2-(2-ethoxy-4-trifluorometh T~l-phenyl)-4,5-dihydro imidazol-1-~l - C4-(2-methanesulfon~,~l-eth~piperazin-1-yll -methanone hydrochloride GH
Methyl vinyl sulfone ( 11 uL, 0.125 mmol) was added to a mixture of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[piperazin-1-yl]-methanone (40 mg, 0.064 mmol, example 8A), and diisopropylethylamine (35 uL, 0.205 mmol) in anhydrous dimethylformamide (1.0 mL).
The reaction was stirred overnight. Evaporation of the solvent and flash chromatography of the residue over silica gel using 0-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[ 4-(2-(methylsulfone)ethyl)-piperazin-1-yl]-methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4;5-dihydro-imidazol-1-yl]-[ 4-(2-(methylsulfone)ethyl)-piperazin-1-yl]-methanone hydrochloride as an off white powder (28 mg, 80%). LR-MS (APCI): 697.7 [(M+H)+].
Example 13A
4-11-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxX-4-trifluorometh ~~1-phenyl)-4,5 dihydro-imidazole-1-carbonyl-piperidin-4- l~meth~piperazin-2-one hydrochloride aH
Phosgene (1.8 mL, 3.6 mmol, 1.9 M in toluene) was added dropwise to a cooled (0 °C) solution of triethylamine (0.57 mL, 4.0 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuro-phenyl)-4,5-dihydro-1H-imidazole (550 mg, 1.2 mmol, example 1) in methylene chloride (5.0 mL). The reaction mixture was stirred for 0.5 h at 0 °C. The solvent was removed under reduced pressure. The residue was kept under high vacuum for 30 min and dissolved in methylene chloride (5.0 mL). Triethylamine (0.170, 1.2 mmol) and 4-(hydroxymethyl)piperidine (0.50 g, 4.4 mmol) were added. After 1 h, the reaction was worked up with aqueous sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvents and flash chromatography of the residue over silica geI using 1-4% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yI] - [4-hydroxymethyl-piperidin-1-yl]-methanone (560 mg, 79%).
To a cooled (0 °C) solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-hydroxy methyl-piperidin-I-yI]-methanone (60 mg, 0.096 mmol) in methylene chloride (2 mL) was added carbon tetrabromide ( 70 mg, 0.210 mmol) followed by triphenyl phosphine (55 mg, 0.21 mmol). The reaction mixture was stirred at ambient temperature for 2.5 h. The reaction was diluted with water and extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using I-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-I-yl]-[4-bromomethyl-piperidin-1-yl]-methanone (50 mg, 76%). , Piperazine-2-one (2I mg, 0.21 mmol) was added to a solution ~[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-bromomethyl-piperidin-1-yl]-methanone (48 mg, 0.07 mmol) in anhydrous dimethylforrnamide (2.0 mL). The mixture was stirred overnight at 70 °C. The reaction mixture was cooled to ambient temperature and partitioned between methylene chloride and a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with methylene chloride and the combined organic extracts were washed with brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using 1-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperazin-2-one-4-yl-methyl)-piperidin-1-y1]-methanone, which was dissolved in dilute hydrochloric acid (0.5 N,1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperazin-2-one-4-yl-methyl)-piperidin-1-yl]-methanone hydrochloride as an off white powder (23 mg, 45%). LR-MS (APCI): 702.4 [(M+H)+].
Example 13B
f4,5-Bis-(4-chloro-phenyl)-2-(2-ethox~-4-trifluorometh~l-phen, l~dih, dro-, imidazol-1-ell-f4-(3,3,3-trifluoro-2-h droxy-propel)-piperazin-1-yll-methanone hydrochloride 1,1,I-trifluoro-2,3-epoxypropane (9 uL, 0.10 mmol) was added to a mixture of (4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[piperazin-1-yl]-methanone (30 mg, 0.048 mmol) and triethylamine (20 uL, 0.144 mmol) in anhydrous methanol (1.0 mL). The reaction was stirred overnight.
Evaporation of the solvent and chromatography of the residue over silica gel using 0-5%
methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4, 5-dihydro-imidazol-1-yl] - [4- (2-hydroxy-2-trifluoromethyethyl)-piperazin-1-ylJ-methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-(2-hydroxy-2-trifluoromethyethyl)-piperazin-1-yl]-methanone hydrochloride as an off white powder (38 mg, 84%). LR-MS (APCI): 703.5 [(M+H)+].
Example 14 I4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluorometh~l-phenyl)-4,5-dih~ro imidazol-1-ell-d4-f4-(2-h d~ro_x~eth~)-piperazin-1-, lmethyll-phenyll methanone hydrochloride GH
4-Chloromethylbenzoyl chloride (140 mg, 0.74 mmol) was added to a cooled solution of triethylamine (0.20 mL, 1.44 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-1H-imidazole (300 mg, 0.61 mmol).
The reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with methylene chloride and washed with water and brine, and dried over anhydrous sodium sulfate. The solvents were removed under reduced pressure and flash chromatography of the residue over silica gel using 10-25% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-I-yl]-(4-chloromethyl-phenyl)-methanone (330 mg, 84%).
4-(2-Hydroxyethyl)-piperazine (10 uL, 0.08 mmol) was added to a solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-chloromethyl-phenyl)-methanone (20 mg, 0.03 mmol) and diisopropylethylamine (7 uL, 0.04 mmol) in anhydrous dimethylformamide (1.0 mL). The mixture was stirred overnight at 80 °C. Evaporation of the solvent and chromatography of the residue over silica geI using I-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-{ (4-(2-hydroxyethyl)piperazine-1-yl)methyl}phenyl]methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-{ (4-(2-hydroxyethyl)piperazine-1-yl)methyl}phenyl]methanone hydrochloride as a off white powder (21 mg, 98%). LR-MS (APCI): 726.1 [(M+H)~].
Example 15 4-~2-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethox-y-4-triffuoromethyl-phenyl)-4,5 dih~dro-imidazole-1-sulfon~Tl -ethyl}-morpholine hydrochloride aH
2-Chloroethylsulfonyl chloride (0.26 mL, 2.5 mmol) was added to a cooled (0 °C) solution of triethylamine (0.24 mL,1.67 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (400 mg, 0834 mmol, example 1) in methylene chloride (20 mL). The reaction mixture was stirred at room temperature for 3 h and quenched with saturated aqueous ammonium chloride. The aqueous phase was extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. The solvents were removed under reduced pressure and purification of the crude residue by flash chromatography over silica gel using 10-50% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[vinyl]sulfone (220 mg, 46%).
Morpholine ( 19 uL, 0.22 mmol) was added to a solution of [4,5-bis-(4-chloro-phenyl) -2- ( 2-ethoxy-4-trifluoromethyl-phenyl) -4,5-dihydro-imidazol-1-yl] -[vinyl]sulfone (40 mg, 0.07 mmol) in benzene (2.0 mL). The mixture was stirred overnight at 50 °C. Evaporation of the solvents and chromatography of the residue over silica gel using 50-80% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[2-(morpholine-1-yl)ethyl]sulfone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give 4-{2-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl]-morpholine hydrochloride as an off white powder (25 mg). LR-MS: 656.2 [(M+H)+].
Example 16 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluor~methyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-4-carboxylic acid methyl ester was prepared in an analogous manner as described in example 5. LR-MS: 648.3 [(M+H)~].
Example 17 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid cyanomethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 575.2 [(M+H)+].
Example 18 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 648.3 j(M+H)+].
Example 19 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidine-3-carboxylic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 662.3 [(M+H)~].
Example 20 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [1,3]dioxolan-2-ylmethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 622.2 [(M+H)+].
Example 21 4,5-Bis-(4-chloro-phenyl)-2-(2-efihoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-hydroxy-propyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 580.2 [(M+H)+].
Examule 22 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)+].
Example 23 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-pyridin-2-yI-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 627.2 [(M+H)+).
Example 24 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (furan-2-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 602.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,S-dihydro-imidazole-1-carboxylic acid (pyridin-3-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 613.2 [(M+H)+].
Example 25 Example 26 _57_ I-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one was prepared in an analogous manner as described in example 5. LR-MS: 722.3 [
(M+H)+] .
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-( I-methyl-pyrrolidin-3-yl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 619.3 [(M+H)+].
Examt~le 28 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-2-carboxylic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 662.3 [(M+H)+].
Example 27 Example 29 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyrimidin-2-yl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 669.3 [(M+H)+].
Example 30 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 3-methoxy-benzylamide was prepared in an analogous manner as described in example 5. LR-MS: 642.2 [(M+H)+].
Example 31 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 566.2 [(M+H)+].
Example 32 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 580.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-1-methyl-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 594.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)~].
Example 33 Example 34 Example 35 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-cyano-ethyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 589.2 [(M+H)+].
Example 36 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-pyridin-2-yl-amide was prepared in an analogous manner as described in example 5. LR-MS: 613.47 [(M+H)t].
Example 37 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)+].
Example 38 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid furan-2-ylmethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 616.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-benzyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 642.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 4-sulfamoyl-benzylamide was prepared in an analogous manner as described in example 5. LR-MS: 691.2 [(M+H)+].
Example 39 Example 40 Example 41 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 566.2 [ (M+H)+] .
Example 42 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-imidazol-1-yl-propyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 630.3 ((M+H)~].
Example 43 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-pyrrolidine-2-carboxylic acid methyl ester was prepared in an analogous manner as described in example 5. LR-MS: 634.2 [(M+H)+].
Examule 44 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethos.y-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-pyrrolidin-1-yI-propyl)-piperazin-I-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702.5 [(M+H)+].
Example 45 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 684.5 (M+).
Example 46 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-yl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 667.8 [(M+H)+].
Example 47 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(2,3-dihydro-benzo [ 1,4] dioxine-2-carbonyl)-piperazin-1-yl] --methanone was prepared in an analogous manner as described in example 5. LR-MS:
752.9 [(M+H)+].
Example 48 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-pipexazin-1-yl}-1-piperidin-1-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 715.9 [(M+H)+].
Example 49 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 704 [(M+H)+].
Example 50 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 716 [(M+H)+].
Example 51 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dipropylamino-propyl)-piperazin-1-yl]-rnethanone was prepared in an analogous manner as described in example 5. LR-MS: 732 [(M+H)+].
Example 52 Example 53 6-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-pipexazin-1-yl}-nicotinonitrile was prepared in an analogous manner as described in example 5. LR-MS: 692.9 [(M+H)'~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl}-[4-(3-dimethylamino-propyl)-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 675.9 [(M+H)'~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylj-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone was pxepared in an analogous manner as descxibed in example 5. LR-MS: 682.4 [(M+H)t].
Example 54 Example 55 Example 56 {4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 676.9 [ (M+H)~] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-ethoxy-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 662.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diisopropylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 7I$ [(M+H)+].
Example 59 Example 57 Example 58 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 661.9 [ (M+H)+] .
Example 60 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 688.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorornethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 718 [(M+H)+).
Example 61 Examine 62 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-diethylamino-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 704 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 688 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-caxbonyl]-piperazin-Z-yl}-N,N-dimethyl-acetamide was prepared in an analogous manner as described in example 5. LR-MS: 676.3 [(M+H)t].
Exam 1e 63 Example 64 Example 65 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 69:8.9 [(M+H)~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-~-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diethylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 690 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-~-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 735.9 [(M+H)+].
Example 66 Example G7 Example 68 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methoxy-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 662.9 [(M+H)+J.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-pyrrolidin-1-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 701.9 [(M+H)+].
o~, [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702 [(M+H)+].
Example 69 Example 70 Example 71 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-ylmethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 675 [(M+H)~].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-nicotinonitrile was prepared in an analogous manner as described in example 5. LR-MS: 692.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-phenyl-piperidin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 665.9 [(M+H)+].
Example 72 Example 73 Examine 74 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-piperidin-1-yl-ethyl)-piperazin-I-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702.5 [(M+H)+].
Example 75 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methylamide was prepared in an analogous manner as described in example 5. LR-MS: 535.5 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 579.9 [(M+H)+].
Example 76 Example 77 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone as prepared in an analogous manner as described in example 5. LR-MS: 669.4 [(M+H)fi].
Example 78 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-amide was prepared in an analogous manner as described in example 5. LR-MS: 551.8 [(M+H)+].
Example 79 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid ethoxy-amide was prepared in an analogous manner as described in example 5. LR-MS: 565.9 [(M+H)+].
Example 80 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2,5-dimethoxy-phenyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 657.9 [(M+H)~].
Example 81 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 718.4 [(M+H)+]
Example 82 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethoxy-phenyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 727 [(M+H)+].
CIH
Example 83 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methoxy-ethanone hydrochloride was prepared in an analogous manner as described in example 5. LR-MS: 663.4 [(M+H)+].
Example 84 aH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone hydrochloride was prepared in an analogous manner as described in example 5. LR-MS: 685.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid bis-(2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 638.3 [(M+H)+].
Example 85 Example 86 _77_ 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-propyl-benzenesulfonyl)-piperazin-1-yl]-methanonewas prepared in an analogous manner as described in example 6. LR-MS: 773.5 [ (M+H)+] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-carbonyl)-piperazin-1-ylJ-methanone was prepared in an analogous manner as described in example 6. LR-MS: 701.4 [(M+H)+].
Example 88 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]- [4-( 1,5-dimethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 713.4 [(M+H)~"].
Example 87 Example 89 _78_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro.-imidazol-1-yl] - [4-(5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS:
783.50 [(M+H)+].
Acetic acid 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1,1-dirnethyl-2-oxo-ethyl ester was prepared in an analogous manner as described in example 6. LR-MS:
719.5 [ (M+H)+] .
Example 91 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 685.4 [(M+H)+].
Example 90 Example 92 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyridine-4-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 696.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 701.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-sulfonyl)-piperazin-1-yl]-methanone was 'prepared in an analogous manner as described in example 6. LR-MS: 737.4 [(M+H)+].
Example 95 Example 93 Example 94 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(4-methyl- [ 1,2,3] thiadiazole-5-carbonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 717.4 [(M+H)t].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-(2,4-dimethyl-thiazole-5-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 766.4 [(M+H)+].
Example 97 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 714.5 [(M+H)+].
Example 96 Example 98 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 737.3 [(M+H)+].
Example 99 [4,5- .Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 769.3 (M+).
Example 100 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-[4-(2,5-dimethyl-furan-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 713.5 [(M+H)+].
Example 101 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-( 1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 749.4 [ (M+H)+] .
Example 102 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl]-2-methoxy-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 663.4 [(M+H)+].
Example 103 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 805.3 (M~).
Example 104 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-thiophen-2-yl-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 715.4 [(M+H)+].
Example 105 1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 744.5 [(M+H)+]
Example 106 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid dimethylamide was prepared in an analogous manner as described in example 6. LR-MS: 698.4 [(M+H)+].
Example 107 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(butane-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 711.4 [(M+H)+].
Example 10~
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-thiophene-2-carboxylic acid methyl ester was prepared in an analogous manner as described in example 6. LR-MS:
795.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-chloro-thiophene-2-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 771.3 [(M+H)t].
Example 109 Example 110 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-triffuoromethanesulfonyl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 6. LR-MS: 723.4 [(M+H)+].
Example 111 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 750.4 [(M+H)+].
Examule 112 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-methoxy-ethyl)-piperazin-2-one was prepared in an analogous manner as described in example 7. LR-MS: 663.2 [(M+H)+].
aH
Example 113 4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-morpholin-4-yl-ethyl)-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 7. LR-MS: 718.4 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid amide was prepared in an analogous manner as described in example 7. LR-MS: 670.3 [(M+H)+].
Example 115 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid methylamide was prepared in an analogous manner as described in example 7. LR-MS: 684.2 [(M+H)+].
Example 114 Example 116 _87_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyrrolidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 724.3 [ (M+H)+] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 738.3 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid isobutyl-amide was prepared in an analogous manner as described in example 7. LR-MS: 726.3 [(M+H)+].
Example 117 Example 118 Example 119 - 88 _ 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 728.2 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid bis-(2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 786.3 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (tetrahydro-furan-2-ylmethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 754.3 [ (M+H)+] .
Examule 122 Example 120 Example 121 _89_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-hydroxy-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 754.3 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -{4- [4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl] -piperazin-1-yl}-methanone was prepared in an analogous manner as described in example 7. LR-MS:
783.3 [(M+H)+].
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-1-yl)-ethanone was prepared in an analogous manner as described in example 7. LR-MS: 781.3 [(M+H)+].
Example 125 Example 123 Example 124 4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-2-one was prepared in an analogous manner as described in example 7. LR-MS: 753.2 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-dimethylamino-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 741.2 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 7. LR-MS: 807.3 [ (M+H)+] .
Example 128 Example 126 Example 127 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2,2,2-trifluoro-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 752.2 [(M+H)~].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-cyano-ethyl)-methyl-amide was prepared in an analogous manner as described in example 7. LR-MS: 737.3 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,3,3-trifluoro-propyl)-piperazin-1-yl]-rnethanone hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 687.5 [(M+H)+].
CIH
Example 129 Example 130 Example 131 {4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetonitrile hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 630.2 [(M+H)+].
CIH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 649.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-pneny)-~-~~-etnoxy-4-trirluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-1-methyl-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
720.5 [(M+H)+].
Example 132 Examule 133 Example 134 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 706.4 [(M+H)~].
N-Benzyloxy-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 754.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 678.4 [(M+H)+].
Examule 135 Example 136 Examule 137 2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-ethoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.4 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(5-methyl-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
742.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-trifluoromethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
784.5 [ (M+H)+] .
Example 138 Example 139 Example 140 2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-N-propyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 690.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isopropyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-rnethoxy-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.5 [(M+H)+].
Example 141 Example 142 Examule 143 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-(2-cyano-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 715.5 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-cyanomethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 701.5 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 732.5 [ (M+H)+] .
Examule 144 Examine 145 Example 146 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-hydroxy-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
706.5 [(M+H)+].
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isobutyl-acetarnide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 764.5 [ (M+H)+] .
Example 147 Example 148 Examule 149 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-I-yl}-1-thiomorpholin-4-yl-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 734.5 [(M+H)+]
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-furan-2-ylmethyl-N-methyl-acetamide was prepared in an analogous-manner as described in example 8. LR-MS:
742.5 [(M+H)+].
Example 151 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-[ 1,3] dioxolan-2-ylmethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
748.4 [(M+H)+].
Examule 150 Example 152 1-(4-Acetyl-piperazin-1-yl)-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 759.5 [ (M+H)+] .
1-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 8. LR-MS:
815.6 [(M+H)+].
Example 154 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-I-yl}-N-cyclopropyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 688.4 [(M+H)+J.
Exam 1p a 153 Example 155 4-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-I-yl}-acetyl)-piperazin-2-one was prepared in an analogous manner as described in example 8. LR-MS: 731.5 [(M+H)~].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-N-(2,2,2-trifluoro-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 730.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl)-piperazin-1-yl}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 648.4 [(M+H)+].
Examule 158 Example 156 Example 157 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-diethyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
Example 159 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methyl-allyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 702.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-irnidazole-1-carbonyl]-piperazin-1-yl}-N-( 1-hydroxymethyl-3-methyl-butyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
748.5 [ (M+H)+] .
Example 160 Example 161 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1- [4-(2-hydroxy-ethyl)-piperidin-1-yl] -ethanone was prepared in an analogous manner as described in example 8. LR-MS:
760.50 [(M+H)+].
Example 162 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-hydroxymethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
746.50 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1-( 1,4-dioxa-8-aza-spiro [4.5]
dec-8-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
774.50 [ (M+H)+] .
Example 163 Example 164 1-( {4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 8. LR-MS:
[ (M+H)+] .
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. hR-MS:
732.5 [ (M+H)+] .
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(3-hydroxy-propyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 706.30 [(M+H)+].
Examule 167 Example 165 Example 166 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 676.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-1-methyl-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
734.5 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 720.5 [ (M+H)+] .
Example 168 Example 169 Example 170 N-Benzyloxy-2-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 768.5 [(M+H)+]
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.4 [(M+H)+]
2-{ 1-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(5-methyl-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
756.5 [ (M+H)+] .
Example 171 Example 172 Example 173 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(4-triffuoromethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
798.5 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-propyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-N-methyl-acetamide was prepared in an analogous mannei as described in example 8. LR-MS: 706.4 [ (M+H)+] .
Example 176 Example 174 Example 175 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(Z-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-cyano-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
729.5 [(M+H)tJ. .
Example 177 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-cyanomethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
715.5 [(M+H)t].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
746.5 [(M+H)~].
Example 179 Example 178 2-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-ylamino }-N-(2-hydroxy-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
720.4 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-I-carbonyl]-piperidin-4-ylamino}-N-isobutyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 718.5 [(M+H)+].
2-{ I- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 662.4 [(M+H)+].
Example 180 Example 181 Example 182 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2,2,2-trifluoro-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
744.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trilluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methyl-allyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 716.5 [(M+H)+].
2-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(1-hydroxymethyl-3-rnethyl-butyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 762.6 [(M+H)+].
GH
Exarnnle 183 Example 184 Examule 185 - llo -2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid dimethylamide hydrochloride was prepared in an analogous manner as described in example 8.
LR-MS:
726.2 [(M+H)+].
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-ethanesulfonic acid amide hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 698.1 [ (M+H)+] .
2-(4-Acetyl-piperazin-1-yl)-N-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetaxnide was prepared in an analogous manner as described in example 9. LR-MS: 773.4 [(M+H)~]
Examule I86 Example 287 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-oxo-piperazin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 745.4 [(M+H)t].
1-( { 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-ylcarbamoyl}-methyl)-piperidine-4-carboxylic acid amide was prepared in an analogous manner as described in example 9.
LR-MS: 773.4 [(M+H)+].
Example 188 Example 189 Example 190 1-({ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 9.
LR-MS: 773.4 [(M+H)~].
1-({ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 9. LR-MS: 829.5 [(M+H)+].
N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-hydroxy-piperidin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 746.4 [ (M+H)+] .
Example 191 Examule 192 Example 193 N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS:
760.7 [ (M+H)+] .
Example 194 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-yl}-2-[bis-(2-hydroxy-ethyl)-amino]
-acetamide was prepared in an analogous mariner as described in example 9. LR-MS:
750.4 [(M+H)+].
Example 195 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-( 1,4-dioxa-8-aza-spiro [4.5]
dec-8-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS:
788.4 [(M+H)+]. Example 196 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-yl}-2- [bis-(2-methoxy-ethyl)-amino] -acetamide was prepared in an analogous manner as described in example 9. LR-MS:
778.4 [ (M+H)+] .
N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-( [ 1,3] dioxolan-2-ylmethyl-methyl-amino)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 762.4 [(M+H)+].
N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-methylamino-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 676.4 [(M+H)+]. .
Example 197 Examule 198 Example 199 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-dimethylamino-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 690.4 [(M+H)+].
2-Amino-N-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 662 [(M+H)t].
2-(4-Acetyl-piperazin-1-yl)-1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 759.4 [ (M+H)+] .
Example 202 Example 200 Example 201 4-(2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperazin-2-one was prepared in an analogous manner as described in example 9. LR-MS: 732.2 [(M+H)+].
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-4-carboxylic acid amide was prepared in an analogous manner as described in example 9. LR-MS:
759.4 [(M+H)+].
1-(2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 9. LR-MS:
759.4 [ (M+H)+] .
Example 203 Example 204 Example 205 1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 9. LR-MS: 815.6 [(M+H)+].
Example 206 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-dimethylamino-ethylamino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
719.7 [ (M+H)+] .
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-[methyl-( 1-methyl-pyrrolidin-3-yl)-amino]-ethanone was prepared in an analogous manner as described in example 9.
LR-MS: 745.6 [(M+H)+].
Examt~le 207 Example 208 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-y1}-2-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 732.6 [(M+H)+].
Example 209 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-hydroxy-ethylarnino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 692.3 [(M+H)+].
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-Example 210 ethanone was prepared in an analogous manner as described in example 9. LR-MS:
746.4 [ (M+H)+] .
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
736.4 [(M+H)+].
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-methoxy-ethylamino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 706.3 [ (M+H)+] .
Example 211 Example 212 Example 213 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-methoxy-ethyl)-amino]-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
764.4 [(M+H)~].
1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-( [ 1,3] dioxolan-2-ylmethyl-methyl-amino)-ethanone was prepared in an analogous manner as described in example 9.
LR-MS: 74.6 [ (M+H)+] .
Example 215 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methylamino-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 662.1 [(M+H)+].
Example 214 Example 216 1-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidin-4-yl}-3-methyl-thiourea was prepared in an analogous manner as described in example 10. LR-MS: 678.3 [(M+H)+].
Example 217 1-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidin-4-yl}-3-phenyl-thiourea was prepared in an analogous manner as described in example 10. LR-MS: 740.3 [(M+H)~J.
Examule 218 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazine-1-carbothioic acid phenylamide was prepared in an analogous manner as described in example 10. LR-MS: 726.3 [(M+H)+].
Example 219 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carb~nyl]-piperazine-1-carbonyl}-piperidine-4-carboxylic acid amide was prepared in an analogous rrzanner'as described in example 11. LR-MS:
745.5 [(M+H)t].
3-Oxo-piperazine-1-carboxylic acid {1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide was prepared in an analogous manner as described in example 11. LR-MS: 732.4 [(M+H)+).
Piperidine-1,4-dicarboxylic acid 4-amide 1-({1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide) was prepared in an analogous manner as described in example 11. LR-MS:
759.5 [ (M+H)+] .
Example 220 Example 221 Example 222 3-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,1-dimethyl-urea was prepared in an analogous manner as described in example 11. LR-MS: 676.4 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-piperidin-1-yl)-methanone hydrochloride was prepared in an analogous manner as described in example 13. LR-MS: 688.4 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -{4- [4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl] -phenyl}-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 741.6 [ (M+H)+] .
aH
Example 223 Example 224 Example 225 [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 763.3 [ (M+H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 62.3 [(M+H)+].
Example 227 aH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 695.3 [(M+H)+].
Example 228 aH
Example 226 [4-(4-Amino-piperidin-1-ylmethyl)-phenyl]-[4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 709.3 [(M+H)+J.
Examule 229 aH
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-1-yl)-ethanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 737.3 [(M+H)~].
aH
N-( 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperidin-4-yl)-acetamide hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 751.4 [(M+H)~].
Examine 231 GH
Example 230 4-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 709.3 [(M+H)~].
Example 232 CIH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(2-hydroxymethyl-piperidin-1-ylmethyl)-phenyl] -methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 724.3 [(M+H)+].
CIH
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 738.3 [(M+H)+].
GH
Examule 233 Example 234 [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 696.3 [ (M+H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 749.4 [ (M~H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 668.1 [(M+H)+].
GH
Example 235 Examule 236 Examule 237 4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 695.3 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone was prepared in an analogous manner as described in example 14. LR-MS: 682.3 [(M+H)+].
aH
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 724.3 [(M+H)+].
GN
Example 238 Example 239 Example 240 4-{2- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 669.2 [(M+H)+].
CIH
Ha( {2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-diethyl-amine hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 642.2 [(M+H)+].
GH
2-(4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-1-yl)-ethanol hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 699.3 [(M+H)+]
Example 243 In Vitro Assay Example 241 Example 242 The ability of the compounds to inhibit the interaction between p53 and MDM2 proteins was measured by an HTRF (homogeneous time-resolved fluorescence) assay in which recombinant GST-tagged MDM2 binds to a peptide that resembles the MDM2-interacting region of p53 (Lane et al.). Binding of GST-MDM2 protein and p53-peptide (biotinylated on its N-terminal end) is registered by the FRET (fluorescence resonance energy transfer) between Europium (Eu)-labeled anti-GST antibody and streptavidin-conjugated Allophycocyanin (APC).
Test is performed in black flat-bottom 384-well plates (Costar) in a total volume of 40 uL containing:90 nM biotinylate peptide, 160 ng/ml GST-MDM2, 20 nM
streptavidin-APC (PerkinElmerWallac), 2 nM Eu-labeled anti-GST-antibody (PerkinElmerWallac), 0.2% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT) and 20 mM Tris-borate saline (TBS) buffer as follows: Add 10 uL of GST-MDM2 (640 ng/ml working solution) in reaction buffer to each well. Add 10 uL diluted compounds ( 1:5 dilution in reaction buffer) to each well, mix by shaking. Add 20 uL
biotinylated p53 peptide ( 180 nM working solution) in reaction buffer to each well and mix on shaker.
Incubate at 37°C for 1 h. Add 20 uL streptavidin-APC and Eu-anti-GST
antibody mixture (6 nM Eu-anti-GST and 60 nM streptavidin-APC working solution) in TBS
buffer with 0.2% BSA, shake at room temperature for 30 minutes and read using a TRF-capable plate reader at 665 and 615 nm (Victor 5, Perkin ElmerWallac). If not specified, the reagents were purchased from Sigma Chemical Co.
ICSOS showing biological activity that applies to compounds of the subject matter of this invention ranges from about 0.020 uM to about 5 uM. Specific data for some examples are as follows:
Example ICSO (~.M) 6 0.100 16 1.740 26 0.800 36 4.260 176 0.021
CI I / O=S=O
J
X then amine X then amine z r Xs ~ X
\ N s CF3 \ N ~ CF3 O __ X ~ / O ~S O
7 Xz Rs '1 The benzonitrile 1, prepared according to the procedure provided by Harrison, C.
R., et al. WO 9203421, is converted to the ethyl benzimidate 2 using HCl gas in ethanol.
Condensation of the imidate 2 with the 1,2-diamine 3 is carried out in ethanol at 40-100 °C in the presence of a base such as triethylamine.
The rneso-1,2-diamines of formula 3 are known compounds and prepared according to the literature procedures (see Jennerwein, M. et al. Cancer Res.
Clin. Oncol.
1988, 114, 347-58; Vogtle, F.; Goldschmitt, E. Chem. Ber. 1976, 109, 1-40).
As set forth in scheme I, the compound of formula 7 can be prepared from compound 4 by the reaction with the benzoyl chloride 5 in the presence of a base such triethylamine, then with an amine in a solvent such as dimethylformamide.
As set forth in scheme I, the compound of formula 8 can be prepared from compound 4 by the reaction with the sulfonyl chloride 6 in the presence of a base such triefihylamine, then with an amine in a solvent such as dimethylformamide.
The compound of formula 4 can be converted to the compound of formula 9 using phosgene in the presence of a base such as triethylamine (scheme 2). The compounds 10, 1 l, or 12 can then be obtained by the reaction of 9 with a suitable amine group (a known compounds or a compound prepared by known methods).
Scheme II
Xz i Xz i Xz Xs _ ~ ~ Xs _ ~ ~ Xs N N N
--~
N ~ GF3 w N \ CF w N \ CF
X I / 4 X I / C~~o 9 3 X I / iN~O 10 z z z Rz R
Xz r X
Xs N
w N \ CF3 ;.F3 ~O
Xz ~~ 11 Xz Ra H Rs If it is desired, the R4 and R5 groups of in the compounds 11 and 12 can be functionalized further as illustrated in scheme 3.
Scheme III
X X X
X~ X; X2 9 i3 ~ 14 N
W
X X
Xa Xz X
2 i 15 ~ Xa HZN ~ LG ~ N ,.
LG: Leaving group ~ N ~ CF
~O
X N
z z As set forth in scheme III, the compound of formula 9 can react with an appropriately protected piperazine to afford a compound of formula 13 after deprotection. A compound of 13 is then reacted with WX (e.g. X = halide, Ms, Ts, epoxide, alkene, or acyl, etc.) to give a compound of formula 14.
As set forth in scheme III, the compound of formula 9 can react with an appropriately protected piperidine to afford a compound of formula I5 after deprotection. A compound of 15 is then reacted with WX (e.g. X = halide, or aryl, etc.) to give a compound of formula 16.
As set forth in scheme III, a compound of formula 17 can be prepared from compound 9 by the reaction with 4-hydroxyethylpiperidine and triethylamine, followed by the conversion of the hydroxyl group to a suitable leaving group (LG) such as Y-N
H
toluenemethylsulfonate. Compound 18 can be prepared from compound 17 by displacing the leaving group with an amine.
If it is desired to prepare a compound of formula 11 or 12 wherein the starting material is not commercially available, many synthetic methods known in the art can be employed. A representative process for synthesizing piperazin-2-one is provided in the examples. The following schemes illustrate some of these methods.
A compound of formula 21 (W can be any suitable group as defined in R5) can be prepared by alkylation of an appropriately protected compound of formula 19 with WX
(X could be any suitable leaving group such as Cl, Br, I) using conventional methods (scheme IV). The amide anion is generated by a base such as sodium hydride.
The reaction typically is carried out in dimethylformamide.
Scheme IV
O p O
/---~ WX, base ~--~ Deprotect Prot-N~ H ------~- prot-N'~N-W -----~- HN~ N-W
A compound of formula 24 (W can be any suitable group as defined in R5) can be prepared by reacting of an appropriately protected compound of formula 19 with WX (X
could be any suitable leaving group such as Cl, Br, I), epoxide, or allzene using conventional methods (scheme V).
Scheme V
/~ WX, base ~ Deprotect /-1 Prot- ~NH or -- Prot-N N-W ---~ H ~N-W
U
epoxide 22 or alkene 23 24 The following examples illustrate preferred methods for synthesizing the compounds of the present invention. Structural formulas follow. With regard to structural formulas, it is understood that oxygen and nitrogen atoms with available electrons have a hydrogen bound thereto, as indicated by compound name. These examples and preparations are illustrative and are not intended to be limiting. It should be understood that there may be other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.
The compounds synthesized in these examples are racemic. The enantiomers of the compounds of interest can be separated using chiral column chromatography (e.g.
ChiralPak~ AD, ChiralPak~ OD, etc). One enanatiomer is shown to be more potent in our in vitro assay than the other.
Example 1 d,5-Bis-(4-chloro-phen~)-2-(2-ethox~4-triffuorometh T~1-phenyl)-4,5-dihydro-1H
imidazole c1 N
~~F
H ~ / F
CI
To a solution of 2-nitro-4-trifluoromethyl-benzonitrile (71.7 g, 318.5 mmol) in anhydrous ethanol (400 mL) at room temperature was added sodium ethoxide (238 mL, 637 mmol, 21% solution in ethanol) dropwise over a period of 30 min. The reaction mixture was stirred at room temperature for 1 h. Water ( 1 L) was added, and the mixture was stirred for 15 min. The solids were filtered off, washed with water, and dried in the vacuume oven (40 °C) overnight to give 2-ethoxy-4-trifluoromethyl-benzonitrile (64 g, 93% yield).
2-Ethoxy-4-triffuoromethyl-benzonitrile (64 g) was dissolved in 750 mL of anhydrous ethanol. The solution was cooled to 0 °C and saturated with hydrogen chloride gas. The reaction flask was then sealed with a Teflon stopper and stirred at room temperature for 11 d. The progress of the reaction was checked every few days, and the solution was saturated again with hydrogen chloride gase. Nitrogen gas was bubbled through the solution to remove excess hydrogen chloride gas. The solvent was removed and the residue was triturated in diethyl ether to afford ethyl 2-ethoxy-4-trifluoromethyl-benzimidate hydrochloride (59.5 g, 67% yield) as white solids.
A solution of meso-1,2-bis-(4-chloro-phenyl)-ethane-1,2-diamine (50.16 g, 178.4 mmol, prepared according to the procedure described by Jennerwein, M. et al.
Cancer Res. Clin. Oncol. 1988,114, 347-58; Vogtle, F.; Goldschmitt, E. Chem. Ber.
1976,109, 1-40), ethyl 2-ethoxy-4-trifluoromethyl-benzimidate hydrochloride (59_g, 178.4 mmol), and triethylamine (49.7 mL, 356.8 mmol) in ethanol (700 mL) was heated at reflex for 4 h. The solvent was removed, and the residue was taken in ethyl acetate (800 mL) and saturated solution of sodium carbonate (300 mL). The layers were separated, and the product was extracted with ethyl acetate ( 1 x 200 mL). The organic layers were washed with brine ( 1 x 100 mL) and dried over anhydrous magnesium sulfate. The solids were then filtered off, and the filtrate was concentrated in vacuo. Purification of the crude residue by flash column chromatography (60 A silica gel) eluting with 50%
ethyl acetate in hexanes yielded 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (64.47 g, 75% yield) as yellow solids.
Example 2 In an analogous manner as described in example 1, there were obtained:
4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole m N
~~-~--~-F
I ~ H \ / F
CI
4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-1 H-imidazole c1, ~. I
N
N
I / H F
CI F F
Example 3 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dih, imidazole-1-carbonyl chloride c1 r.
N
~~~-(~F
I w N \ I F
CI
To a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (46 g, 95.97 mmol, example 1) and triethylamine (66.9 mL, 479.9 mmol) in methylene chloride (2 L) cooled to 0 °C was added phosgene ( 124.3 mL, 239.9 mmol, ~20% solution in toluene) dropwise over a period of 30 min. The reaction mixture was stirred at room temperature for 1 h. Nitrogen gas was bubbled through the reaction mixture to remove excess phosgene. The reaction mixture was concentrated to dryness, and the residue was dried in vacuo for 1 h to give 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (51 g, 98% yield) as off white solids. The product was used without further purification.
Example 4 In an analogous manner as described in example 3, there were obtained:
4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride c1 N
~~-~--~F
N ~ / F
CIO
CI
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride c1 ~
y o N
~N
/ F
CI I CI~C F F
Example 5 The following general procedure was used for the reaction of the 1-carbonyl chloride 9 (examples 3 and 4) with the commercially available amine.
A solution of the 1-carbonyl chloride 9 (1 eq., prepared according the procedure described in example 3) in methylene chloride was added to a solution of the amine ( 1-2 eq.) and triethylamine in methylene chloride. The reaction mixture was stirred at room temperature for 1 h. The reaction was worked up with aqueous sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with water and brine, and dried over anhydroud sodium sulfate. The solids were filtered off, and the filtrate was concentrated in vacuo. Purification of the crude residue by flash column chromatography gave the desired urea product.
Example 6 X4,5-Bis-(4-chloro-phen 1y )2-2-~2-ethoxy-4-trifluorometh,~Tl=phenyl)-4,5-dihydro imidazol-1- 1~f4-(propane-2-sulfonyl)-piperazin-1-~]~-methanone A solution of 1-BOC-piperazine (0.617 mmol) and diisopropylethylamine (0.679 mmol) in 0.5 mL of methylene chloride was added to a 4 mL vial. Propane-2-sulfonyl chloride (0.679mmol) was added to the vial, and the reaction mixture was shaken overnight at room temperature. When the reaction was complete, it was diluted with 1.5 mL of methylene chloride and extracted with 1 mL of 1N solution of hydrogen chloride followed by 1 mL of 10% potassium carbonate solution. The organic layer was concentrated in vacuo. The residue was dissolved in 0.5 mL of tetrahydrofuran and 4M
solution of hydrogen chloride in dioxane (0.5 mL). The solution was shaken overnight at room temperature then concentrated ire vacuo to give 1-(propane-2-sulfonyl)-piperazine.
1-(Propane-2-sulfonyl)-piperazine (0.0286 mrnol) was dissolved in 0.25 mL of methylene chloride and added to a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (0.024 mmol, , example 3) and diisopropylethylamine (0.072 rnmol) in 0.25 mL of methylene chloride in a 4 rnL vial. The vial was capped and shaken overnight at room temperature.
The reaction mixture was diluted with 1 mL of methylene chloride and 1 mL of water. The vial was agitated and centrifuged. The organic layer was transferred to a 4 mL
vial and concentrated in vacuo to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone. LR-MS (M+H)~= 697.4.
Example 7A
1-Ben2X1-4-[4,5-bis-(4-chloro-nhenvll-2 ~2-ethoxy-4-trifluoromethvl-nhenyl~-4,5 dihvdro-imidazole-1-caxbonvl]-piperazin-2-one hydrochloride Sodium hydride ($0 mg, 2.0 mmol, 60a/o in mineral oil) was added to a solution of 4-tent butyloxycarbonyl-piperazin-2-one (200 mg,1.0 mraol) in dimethylformamide (5.0 mL) at 0 aC. The reaction was stirred at 0 °C for 0.5 h. To this mixture was added benzyl bromide (300 uL, 2.5 mmol) and the reaction was stirred for 2 h at room temperature.
The reaction mixture was quenched with a dilute aqueous solution of sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with brine and dried over anhydrous sodium sulfate. Purification of the crude residue by chromatography over silica gel using 30% ethyl acetate in hexane gave 4-tent bntyloxycarbonyl-2 benzyl-piperazin-2-one (174 mg, 60 °r6 yield).
Hydrochloric acid {0.25 mL,1.00 mmol, 4 M in 1,4-dioxane) was added to a solution of 4-tent butyloJCycarbonyl-2-benzyl-piperazin-2-one ( 17~ mg, 0.60 mmol) in 1,4-dioxane ( L0 mh). The lmixCure was stirred overnight The reaction was concentrated to give 2-benzyl-piperazin-2-one hydxochloride as an off white solid (130 mg, 97 r6 yield).
4,5-Bis-(4-chlorv-phenyl)-2-{2-ethoxy 4-tri$uoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (example 3) was reacted with 2 benzyl-piperazin-2-one hydrochloride easing the procedure as desrn-bed in example 5 to give 4-j4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-carbonylJ-1-benzyl-piperazin-2-vne. It was then dissolved in dilute hydrochloric acid {0.5 N,1 mL) and lyophilized to give 4-[4,5-bis-(4-cbloro-phenyl)-2-(2-ethoxy txifluoromethyl-phenyl)-4,5-dihydro-imidazole-carbonyl]-1-benzyl-piperazin-Z-one hydrochloride as an off white powder (65mg; 89% yield). LR MS (APCI): 695.6 j(M+~)+].
f 4 5-Bis-!4-chloro-phenyl)-2-f 2-ethoxy-~4-trifluoromethyl-phenyD-4.5-dihydro imidazol- -1- 1-f4-lmorpholine-4-sulfon~piperazin-1-yll-methanone RECTIFIED SHEET (RULE 91 ) The triffate salt of the methyIated sulfuryldiimidazole (3.14 g, 8.04 mmol ) was solved in acetonitrile. 1-Boc-piperazine (1.0 g, 5.37 mmol) and diisopropylethyIamine :q.) were added at once. The reaction mixture was stirred at room temperature rrnight. It was diluted with ethyl acetate and washed with water. The organic layers ve dried, filtered, and concentrated irt vacuo to give a viscous_oil (2.6 g).
Purification he oil by flash chromatography gave 4-(2-methyl-imidazole-I-sulfonyl)-piperazine-1-ooxylic acid tert-butyl ester (1.4 g, 79% yield). LR-MS: 331 j(M+H)~].
A solution.of4-(2-methyl-imidazole-1-sulfonyl)-piperazine-1-carboxylic acid tert-yl ester ( L4 g, 4.24 mmol) in methylene chloride was cooled in an ice bath, and uoromethanesulfonic acid methyl ester (0.56 mL, 4.9 mmol) was added via a pipet.
'x stirring at ice temperature for 3 h, the solvent was evaporated to give 4-(2-rnethyl-dazole-1-sulfonyl)-piperazine-1-carboxylic acid tert-butyl estex triffate salt as yellow ds.
A solution of the triffate salt (60 rng, 0.12 mmol), morpholine (31.7 mg, 0.36 Col) and 63 uL of diisopropylethylamine (0..36 mmol) .in 0.25 mL of acetonitrile was ~ed at ambient temperature overnight. The reaction was diluted with I rnL of hylene chloride and 0.5 mL of 1.0 M hydrochloric acid. . The organic phase was red through a small pad of silica gel and the solvent evaporated to yield 4-~rpholine-4-sulfonyl)-piperazine-1-carbo~cylic acid tert-butyl ester (39 mg, 95%). LR-336 [(M+H)~].
4-(Morpholine-4-sulfonyl)-piperazine-I-carboxylic acid tert-butyl ester (39 mg) dissolved in 4 mL of dioxane, and 4mL of 4.0 M hydrochloric acid in dioxane was :d. After standiizg overnight at ambient temperature, the solvent was removed to 4-(piperazine-I-sulfonyl)-morpholine hydrochloride as a white solid.
4-(Piperazine-I-sulfonyl)-rnorpholine hydrochloride (0.042 mmol) was suspended .ethylene chloride, and 400 uL of diisopropylethylamine was added. The rxiixture was ~d to 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-azole-I-carbonyl chloride (i0 mg, 0.019 mmol, example 3), and the reaction ure was allowed to stand overnight. It was diluted with mefihylene chloride and ied v~ith water. The organic layer was evaporated, and the residue purified by flash matography using ethyl acetate and hexanes to give [4,5-bis-(4-chloro-phenyl)-2-(2-RECTIFIED SHEET (RULE 9'I) ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(morpholine-4-sulfonyl)-piperazin-1-yl]-methanone (9.0 mg). LR-MS: 740.2 [(M+H)~].
Example 8A
~4-f4,5-Bis-(4-chloro-phmyl)-2-(2-ethoxy-4-trifluorometh T~l-phen~)-4,5-dihydro imidazole-1-carbonyl]-piperazin-1-~propionitrile hydrochloride aH
Phosgene (3.8 mL, 7.22 mmol, 1.9 M in toluene) was added dropwise to a cooled (0 °C) mixture of triethylamine (1.3 mL, 9.62 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluro-phenyl)-4,5-dihydro-1H-imidazole (1.15 g, 2.41 mmol) in methylene chloride (20 mL). The reaction mixture was stirred for 0.5 h at 0 °C, and the solvent was evaporated. The residue was kept under high vacuum for 30 min and dissolved in methylene chloride (20 mL). The solution was added dropwise to a cooled (0 °C) solution of 4-tert-butyloxycarbonylpiperazine (0.90 g, 4.81 mmol) in methylene chloride ( 16 mL). After 1 h, the reaction was worked up with aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using 50% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-tert-butyloxycarbonylpiperazin-1-yl]-methanone as a yellow foam (1.30 g, 78%).
Hydrochloric acid ( 10 mL, 40 mmol, 4 M in 1,4-dioxane) was added to a cooled (0 °C) solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-tert-butyloxycarbonylpiperazin-1-yl]-methanone in 1,4-dioxane ( 10 mL). The mixture was stirred at room temperature overnight.
Evaporation of the solvent gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(piperazin-1-yl)-methanone hydrochloride as an off white solid ( 1.10 g, 98 % yield).
2-Bromopropionitrile ( 10 uL, 0.120 mmol) was added to a mixture of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[piperazin-1-yl]-methanone hydrochloride and diisopropylethylamine (42 uL, 0.240 mmol) in dimethylformamide (1.0 mL). The reaction was stirred at room temperature overnight. Evaporation of the solvent and purification of the crude residue by flash chromatography over silica gel using 1-2% methanol in methylene chloride gave 3-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-propionitrile, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give 3-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-propionitrile hydrochloride as an off white powder (20mg, 39% yield). LR-MS
(APCI): 644.4 [(M+H)+].
Example SB
2-14- f 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorometh,~l-phen,~l)-4,5 dihydro-imidazole-1-carbonill-piperazin-1-yl)-N-methyl-acetamide A solution of chloroacetylchloride (8.85 mmol) in 10 mL of methylene chloride was cooled to approximately -40°C in a sealed 40 mL vial. Methylamine ( 18.6 mmol, 9.3 mL
of a 2M in tetrahydrofuran) was added in a portion-wise fashion via a syringe through a pierceable septum to the stirring solution. The reaction was stirred for 1 h at reduced temperature. The solution was then made acidic with 1N hydrochloric acid and then diluted with 10 mL of methylene chloride. The vial was agitated and centrifuged. The organic layer was transferred to 40 mL vials and concentrated in vacuo to give 2-chloro-N,N-dimethyl-acetamide.
2-Chloro-N,N-dimethyl-acetamide (0.0I94 mmol) in dimethylformamide (0.25 mL) was pipeted into a 4 mL vial containing a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (0.0169mmo1, example 1) and diisopropylethylamine (0.0194mmol) in 0.25 mL of dimethylformamide. The vial was capped and heated to 65°C for 2 d. The reaction was diluted with 1.5 mL of methylene chloride and 0.5 mL of water. The vial was agitated and centrifuged.
The organic layer was transferred to a 4 mL vial and concentrated in vacuo to give 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide. LR-MS: 663 [(M+H)~].
Exarn~le 9 1 ~4 f 4,5-Bis-(4-chloro-phen,~l)-2-(2-ethoxY-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-~l~-2-dimethylamino-ethanone [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (372 mg, 0.63 mmol, example 8A) and diisopropylethylamine (230 uL, 1.32 mmol) were dissolved in methylene chloride (4 mL) and cooled to ice temperature. Chloroacetyl chloride ( 100 uL,1.26 mmol) in methylene chloride ( 1 mL) was added dropwise and this mixture was stirred for 30 min at ice temperature. The reaction was diluted with methylene chloride and washed with water.
The organic layers were dried over anhydrous magnesium sulfate. The solids were filtered off, and the filtrate was concentrated. Purification of the crude material by flash chromatography using ethyl acetate and hexanes gave 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-chloro-ethanone ( 193 mg, 0.29 mmol).
To a solution of 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-chloro-ethanone (9.65 mg) and diisopropylethylamine (5 uL) was added dimethylamine (50 uL, 2.0M
solution in tetrahydrofuran). The reaction mixture was capped and heated at 60 °C overnight. It was diluted with methylene chloride and washed with water. The organic layer was concentrated to dryness to give 1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-dimethylamino-ethanone (9.17 mg, 92% yield). LR-MS: 677.3 [(M+H)+].
Example 10 4-f4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuorometh TAI-phen Iy )4,5-dihydro-imidazole-1-carbonyll-piperazine-1-carbothioic acid meth lamide [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (279 mg, 0.47 mmol, example 8A) was dissolved in methylene chloride (3 mL) and methylisothiocyanate (64 uL) was added.
After stirring 3 h, the reaction mixture was concentrated to dryness.
Purification of the crude residue by flash chromatography (silica gel) eluting with ethyl acetate and hexanes gave 4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid methylamide (195 mg). LR-MS:
664.4 [(M+H)+].
Example I I
4-~4-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorometh ~~l-phenyl)-4,5 dihydro-imidazole-1-carbonyll -piperazine-1-carbon,~piperazin-2-one [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-piperazin-1-yl-methanone (50 mg, 0.085 mmol, example 8A) was dissolved in methylene chloride (1 mL) and cooled in an ice bath. Phosgene (250 uL, 20% solution in toluene)) was added, and the mixture was stirred for 30 min.
The solvent was evaporated and the residue was taken in methylene chloride. One third of this solution (0.028 mmol) was treated with 2-piperazinone (8.5 mg) and diisopropylethylamine (15 u1). The mixture was sonicated to aid in dissolving the amine and allowed to stand at ambient temperature overnight. It was diluted with methylene chloride and washed with water. The organic portion was separated and evaporated to give the crude urea. Purification of the crude urea by flash chromatography (silica gel) using ethyl acetate and hexanes gave 4-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazine-1-carbonyl}-piperazin-2-one (9.0 mg). LR-MS: 718.4 [(M+H)+].
Example 12 j4,5-Bis-(4-chloro=phen~)-2-(2-ethoxy-4-trifluorometh T~l-phenyl)-4,5-dihydro imidazol-1-~l - C4-(2-methanesulfon~,~l-eth~piperazin-1-yll -methanone hydrochloride GH
Methyl vinyl sulfone ( 11 uL, 0.125 mmol) was added to a mixture of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[piperazin-1-yl]-methanone (40 mg, 0.064 mmol, example 8A), and diisopropylethylamine (35 uL, 0.205 mmol) in anhydrous dimethylformamide (1.0 mL).
The reaction was stirred overnight. Evaporation of the solvent and flash chromatography of the residue over silica gel using 0-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[ 4-(2-(methylsulfone)ethyl)-piperazin-1-yl]-methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4;5-dihydro-imidazol-1-yl]-[ 4-(2-(methylsulfone)ethyl)-piperazin-1-yl]-methanone hydrochloride as an off white powder (28 mg, 80%). LR-MS (APCI): 697.7 [(M+H)+].
Example 13A
4-11-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxX-4-trifluorometh ~~1-phenyl)-4,5 dihydro-imidazole-1-carbonyl-piperidin-4- l~meth~piperazin-2-one hydrochloride aH
Phosgene (1.8 mL, 3.6 mmol, 1.9 M in toluene) was added dropwise to a cooled (0 °C) solution of triethylamine (0.57 mL, 4.0 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuro-phenyl)-4,5-dihydro-1H-imidazole (550 mg, 1.2 mmol, example 1) in methylene chloride (5.0 mL). The reaction mixture was stirred for 0.5 h at 0 °C. The solvent was removed under reduced pressure. The residue was kept under high vacuum for 30 min and dissolved in methylene chloride (5.0 mL). Triethylamine (0.170, 1.2 mmol) and 4-(hydroxymethyl)piperidine (0.50 g, 4.4 mmol) were added. After 1 h, the reaction was worked up with aqueous sodium bicarbonate and extracted with methylene chloride. The organic extracts were washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvents and flash chromatography of the residue over silica geI using 1-4% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yI] - [4-hydroxymethyl-piperidin-1-yl]-methanone (560 mg, 79%).
To a cooled (0 °C) solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-hydroxy methyl-piperidin-I-yI]-methanone (60 mg, 0.096 mmol) in methylene chloride (2 mL) was added carbon tetrabromide ( 70 mg, 0.210 mmol) followed by triphenyl phosphine (55 mg, 0.21 mmol). The reaction mixture was stirred at ambient temperature for 2.5 h. The reaction was diluted with water and extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using I-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-I-yl]-[4-bromomethyl-piperidin-1-yl]-methanone (50 mg, 76%). , Piperazine-2-one (2I mg, 0.21 mmol) was added to a solution ~[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-bromomethyl-piperidin-1-yl]-methanone (48 mg, 0.07 mmol) in anhydrous dimethylforrnamide (2.0 mL). The mixture was stirred overnight at 70 °C. The reaction mixture was cooled to ambient temperature and partitioned between methylene chloride and a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with methylene chloride and the combined organic extracts were washed with brine, and dried over anhydrous sodium sulfate. Evaporation of the solvents and chromatography of the residue over silica gel using 1-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperazin-2-one-4-yl-methyl)-piperidin-1-y1]-methanone, which was dissolved in dilute hydrochloric acid (0.5 N,1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperazin-2-one-4-yl-methyl)-piperidin-1-yl]-methanone hydrochloride as an off white powder (23 mg, 45%). LR-MS (APCI): 702.4 [(M+H)+].
Example 13B
f4,5-Bis-(4-chloro-phenyl)-2-(2-ethox~-4-trifluorometh~l-phen, l~dih, dro-, imidazol-1-ell-f4-(3,3,3-trifluoro-2-h droxy-propel)-piperazin-1-yll-methanone hydrochloride 1,1,I-trifluoro-2,3-epoxypropane (9 uL, 0.10 mmol) was added to a mixture of (4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[piperazin-1-yl]-methanone (30 mg, 0.048 mmol) and triethylamine (20 uL, 0.144 mmol) in anhydrous methanol (1.0 mL). The reaction was stirred overnight.
Evaporation of the solvent and chromatography of the residue over silica gel using 0-5%
methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4, 5-dihydro-imidazol-1-yl] - [4- (2-hydroxy-2-trifluoromethyethyl)-piperazin-1-ylJ-methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-(2-hydroxy-2-trifluoromethyethyl)-piperazin-1-yl]-methanone hydrochloride as an off white powder (38 mg, 84%). LR-MS (APCI): 703.5 [(M+H)+].
Example 14 I4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluorometh~l-phenyl)-4,5-dih~ro imidazol-1-ell-d4-f4-(2-h d~ro_x~eth~)-piperazin-1-, lmethyll-phenyll methanone hydrochloride GH
4-Chloromethylbenzoyl chloride (140 mg, 0.74 mmol) was added to a cooled solution of triethylamine (0.20 mL, 1.44 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-1H-imidazole (300 mg, 0.61 mmol).
The reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with methylene chloride and washed with water and brine, and dried over anhydrous sodium sulfate. The solvents were removed under reduced pressure and flash chromatography of the residue over silica gel using 10-25% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-I-yl]-(4-chloromethyl-phenyl)-methanone (330 mg, 84%).
4-(2-Hydroxyethyl)-piperazine (10 uL, 0.08 mmol) was added to a solution of [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-chloromethyl-phenyl)-methanone (20 mg, 0.03 mmol) and diisopropylethylamine (7 uL, 0.04 mmol) in anhydrous dimethylformamide (1.0 mL). The mixture was stirred overnight at 80 °C. Evaporation of the solvent and chromatography of the residue over silica geI using I-5% methanol in methylene chloride gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-{ (4-(2-hydroxyethyl)piperazine-1-yl)methyl}phenyl]methanone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[4-{ (4-(2-hydroxyethyl)piperazine-1-yl)methyl}phenyl]methanone hydrochloride as a off white powder (21 mg, 98%). LR-MS (APCI): 726.1 [(M+H)~].
Example 15 4-~2-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethox-y-4-triffuoromethyl-phenyl)-4,5 dih~dro-imidazole-1-sulfon~Tl -ethyl}-morpholine hydrochloride aH
2-Chloroethylsulfonyl chloride (0.26 mL, 2.5 mmol) was added to a cooled (0 °C) solution of triethylamine (0.24 mL,1.67 mmol) and 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (400 mg, 0834 mmol, example 1) in methylene chloride (20 mL). The reaction mixture was stirred at room temperature for 3 h and quenched with saturated aqueous ammonium chloride. The aqueous phase was extracted with methylene chloride. The organic extracts were washed with water, brine, and dried over anhydrous sodium sulfate. The solvents were removed under reduced pressure and purification of the crude residue by flash chromatography over silica gel using 10-50% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[vinyl]sulfone (220 mg, 46%).
Morpholine ( 19 uL, 0.22 mmol) was added to a solution of [4,5-bis-(4-chloro-phenyl) -2- ( 2-ethoxy-4-trifluoromethyl-phenyl) -4,5-dihydro-imidazol-1-yl] -[vinyl]sulfone (40 mg, 0.07 mmol) in benzene (2.0 mL). The mixture was stirred overnight at 50 °C. Evaporation of the solvents and chromatography of the residue over silica gel using 50-80% ethyl acetate in hexanes gave [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -[2-(morpholine-1-yl)ethyl]sulfone, which was dissolved in dilute hydrochloric acid (0.5 N, 1 mL) and lyophilized to give 4-{2-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl]-morpholine hydrochloride as an off white powder (25 mg). LR-MS: 656.2 [(M+H)+].
Example 16 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluor~methyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-4-carboxylic acid methyl ester was prepared in an analogous manner as described in example 5. LR-MS: 648.3 [(M+H)~].
Example 17 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid cyanomethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 575.2 [(M+H)+].
Example 18 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 648.3 j(M+H)+].
Example 19 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidine-3-carboxylic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 662.3 [(M+H)~].
Example 20 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [1,3]dioxolan-2-ylmethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 622.2 [(M+H)+].
Example 21 4,5-Bis-(4-chloro-phenyl)-2-(2-efihoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-hydroxy-propyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 580.2 [(M+H)+].
Examule 22 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)+].
Example 23 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-pyridin-2-yI-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 627.2 [(M+H)+).
Example 24 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (furan-2-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 602.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,S-dihydro-imidazole-1-carboxylic acid (pyridin-3-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 613.2 [(M+H)+].
Example 25 Example 26 _57_ I-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one was prepared in an analogous manner as described in example 5. LR-MS: 722.3 [
(M+H)+] .
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-( I-methyl-pyrrolidin-3-yl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 619.3 [(M+H)+].
Examt~le 28 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-2-carboxylic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 662.3 [(M+H)+].
Example 27 Example 29 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyrimidin-2-yl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 669.3 [(M+H)+].
Example 30 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 3-methoxy-benzylamide was prepared in an analogous manner as described in example 5. LR-MS: 642.2 [(M+H)+].
Example 31 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 566.2 [(M+H)+].
Example 32 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 580.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-1-methyl-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 594.2 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)~].
Example 33 Example 34 Example 35 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-cyano-ethyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 589.2 [(M+H)+].
Example 36 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-pyridin-2-yl-amide was prepared in an analogous manner as described in example 5. LR-MS: 613.47 [(M+H)t].
Example 37 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.3 [(M+H)+].
Example 38 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid furan-2-ylmethyl-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 616.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-benzyl)-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 642.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 4-sulfamoyl-benzylamide was prepared in an analogous manner as described in example 5. LR-MS: 691.2 [(M+H)+].
Example 39 Example 40 Example 41 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-methyl-amide was prepared in an analogous manner as described in example 5. LR-MS: 566.2 [ (M+H)+] .
Example 42 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-imidazol-1-yl-propyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 630.3 ((M+H)~].
Example 43 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-pyrrolidine-2-carboxylic acid methyl ester was prepared in an analogous manner as described in example 5. LR-MS: 634.2 [(M+H)+].
Examule 44 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethos.y-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-pyrrolidin-1-yI-propyl)-piperazin-I-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702.5 [(M+H)+].
Example 45 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 684.5 (M+).
Example 46 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-yl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 667.8 [(M+H)+].
Example 47 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(2,3-dihydro-benzo [ 1,4] dioxine-2-carbonyl)-piperazin-1-yl] --methanone was prepared in an analogous manner as described in example 5. LR-MS:
752.9 [(M+H)+].
Example 48 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-pipexazin-1-yl}-1-piperidin-1-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 715.9 [(M+H)+].
Example 49 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 704 [(M+H)+].
Example 50 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 716 [(M+H)+].
Example 51 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide was prepared in an analogous manner as described in example 5. LR-MS: 633.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dipropylamino-propyl)-piperazin-1-yl]-rnethanone was prepared in an analogous manner as described in example 5. LR-MS: 732 [(M+H)+].
Example 52 Example 53 6-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-pipexazin-1-yl}-nicotinonitrile was prepared in an analogous manner as described in example 5. LR-MS: 692.9 [(M+H)'~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl}-[4-(3-dimethylamino-propyl)-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 675.9 [(M+H)'~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylj-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone was pxepared in an analogous manner as descxibed in example 5. LR-MS: 682.4 [(M+H)t].
Example 54 Example 55 Example 56 {4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetic acid ethyl ester was prepared in an analogous manner as described in example 5. LR-MS: 676.9 [ (M+H)~] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-ethoxy-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 662.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diisopropylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 7I$ [(M+H)+].
Example 59 Example 57 Example 58 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 661.9 [ (M+H)+] .
Example 60 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 688.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluorornethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 718 [(M+H)+).
Example 61 Examine 62 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-diethylamino-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 704 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 688 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-caxbonyl]-piperazin-Z-yl}-N,N-dimethyl-acetamide was prepared in an analogous manner as described in example 5. LR-MS: 676.3 [(M+H)t].
Exam 1e 63 Example 64 Example 65 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 69:8.9 [(M+H)~].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-~-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diethylamino-ethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 690 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-~-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 735.9 [(M+H)+].
Example 66 Example G7 Example 68 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methoxy-propyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 662.9 [(M+H)+J.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-pyrrolidin-1-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 701.9 [(M+H)+].
o~, [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702 [(M+H)+].
Example 69 Example 70 Example 71 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-ylmethyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 675 [(M+H)~].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-nicotinonitrile was prepared in an analogous manner as described in example 5. LR-MS: 692.9 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-phenyl-piperidin-1-yl)-methanone was prepared in an analogous manner as described in example 5. LR-MS: 665.9 [(M+H)+].
Example 72 Example 73 Examine 74 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-piperidin-1-yl-ethyl)-piperazin-I-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 702.5 [(M+H)+].
Example 75 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methylamide was prepared in an analogous manner as described in example 5. LR-MS: 535.5 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 579.9 [(M+H)+].
Example 76 Example 77 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone as prepared in an analogous manner as described in example 5. LR-MS: 669.4 [(M+H)fi].
Example 78 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-amide was prepared in an analogous manner as described in example 5. LR-MS: 551.8 [(M+H)+].
Example 79 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid ethoxy-amide was prepared in an analogous manner as described in example 5. LR-MS: 565.9 [(M+H)+].
Example 80 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2,5-dimethoxy-phenyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 657.9 [(M+H)~].
Example 81 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone was prepared in an analogous manner as described in example 5. LR-MS: 718.4 [(M+H)+]
Example 82 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethoxy-phenyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 5. LR-MS: 727 [(M+H)+].
CIH
Example 83 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methoxy-ethanone hydrochloride was prepared in an analogous manner as described in example 5. LR-MS: 663.4 [(M+H)+].
Example 84 aH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone hydrochloride was prepared in an analogous manner as described in example 5. LR-MS: 685.3 [(M+H)+].
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid bis-(2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 5. LR-MS: 638.3 [(M+H)+].
Example 85 Example 86 _77_ 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-propyl-benzenesulfonyl)-piperazin-1-yl]-methanonewas prepared in an analogous manner as described in example 6. LR-MS: 773.5 [ (M+H)+] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-carbonyl)-piperazin-1-ylJ-methanone was prepared in an analogous manner as described in example 6. LR-MS: 701.4 [(M+H)+].
Example 88 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]- [4-( 1,5-dimethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 713.4 [(M+H)~"].
Example 87 Example 89 _78_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro.-imidazol-1-yl] - [4-(5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS:
783.50 [(M+H)+].
Acetic acid 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1,1-dirnethyl-2-oxo-ethyl ester was prepared in an analogous manner as described in example 6. LR-MS:
719.5 [ (M+H)+] .
Example 91 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 685.4 [(M+H)+].
Example 90 Example 92 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyridine-4-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 696.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 701.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-sulfonyl)-piperazin-1-yl]-methanone was 'prepared in an analogous manner as described in example 6. LR-MS: 737.4 [(M+H)+].
Example 95 Example 93 Example 94 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(4-methyl- [ 1,2,3] thiadiazole-5-carbonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 717.4 [(M+H)t].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-(2,4-dimethyl-thiazole-5-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 766.4 [(M+H)+].
Example 97 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 714.5 [(M+H)+].
Example 96 Example 98 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 737.3 [(M+H)+].
Example 99 [4,5- .Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 769.3 (M+).
Example 100 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-[4-(2,5-dimethyl-furan-3-carbonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 713.5 [(M+H)+].
Example 101 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-( 1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 6. LR-MS: 749.4 [ (M+H)+] .
Example 102 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl]-2-methoxy-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 663.4 [(M+H)+].
Example 103 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 805.3 (M~).
Example 104 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-thiophen-2-yl-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 715.4 [(M+H)+].
Example 105 1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 6. LR-MS: 744.5 [(M+H)+]
Example 106 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid dimethylamide was prepared in an analogous manner as described in example 6. LR-MS: 698.4 [(M+H)+].
Example 107 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(butane-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 711.4 [(M+H)+].
Example 10~
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-thiophene-2-carboxylic acid methyl ester was prepared in an analogous manner as described in example 6. LR-MS:
795.4 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-chloro-thiophene-2-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 771.3 [(M+H)t].
Example 109 Example 110 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-triffuoromethanesulfonyl-piperazin-1-yl)-methanone was prepared in an analogous manner as described in example 6. LR-MS: 723.4 [(M+H)+].
Example 111 [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 6. LR-MS: 750.4 [(M+H)+].
Examule 112 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-methoxy-ethyl)-piperazin-2-one was prepared in an analogous manner as described in example 7. LR-MS: 663.2 [(M+H)+].
aH
Example 113 4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-morpholin-4-yl-ethyl)-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 7. LR-MS: 718.4 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid amide was prepared in an analogous manner as described in example 7. LR-MS: 670.3 [(M+H)+].
Example 115 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid methylamide was prepared in an analogous manner as described in example 7. LR-MS: 684.2 [(M+H)+].
Example 114 Example 116 _87_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyrrolidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 724.3 [ (M+H)+] .
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 738.3 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid isobutyl-amide was prepared in an analogous manner as described in example 7. LR-MS: 726.3 [(M+H)+].
Example 117 Example 118 Example 119 - 88 _ 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 728.2 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid bis-(2-methoxy-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 786.3 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (tetrahydro-furan-2-ylmethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 754.3 [ (M+H)+] .
Examule 122 Example 120 Example 121 _89_ [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-hydroxy-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone was prepared in an analogous manner as described in example 7. LR-MS: 754.3 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -{4- [4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl] -piperazin-1-yl}-methanone was prepared in an analogous manner as described in example 7. LR-MS:
783.3 [(M+H)+].
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-1-yl)-ethanone was prepared in an analogous manner as described in example 7. LR-MS: 781.3 [(M+H)+].
Example 125 Example 123 Example 124 4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-2-one was prepared in an analogous manner as described in example 7. LR-MS: 753.2 [(M+H)+].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-dimethylamino-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 741.2 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-piperazin-1-yl] -methanone was prepared in an analogous manner as described in example 7. LR-MS: 807.3 [ (M+H)+] .
Example 128 Example 126 Example 127 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2,2,2-trifluoro-ethyl)-amide was prepared in an analogous manner as described in example 7. LR-MS: 752.2 [(M+H)~].
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-cyano-ethyl)-methyl-amide was prepared in an analogous manner as described in example 7. LR-MS: 737.3 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,3,3-trifluoro-propyl)-piperazin-1-yl]-rnethanone hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 687.5 [(M+H)+].
CIH
Example 129 Example 130 Example 131 {4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetonitrile hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 630.2 [(M+H)+].
CIH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 649.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-pneny)-~-~~-etnoxy-4-trirluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-1-methyl-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
720.5 [(M+H)+].
Example 132 Examule 133 Example 134 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 706.4 [(M+H)~].
N-Benzyloxy-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 754.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 678.4 [(M+H)+].
Examule 135 Example 136 Examule 137 2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-ethoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.4 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(5-methyl-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
742.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-trifluoromethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
784.5 [ (M+H)+] .
Example 138 Example 139 Example 140 2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-N-propyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 690.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isopropyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-rnethoxy-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.5 [(M+H)+].
Example 141 Example 142 Examule 143 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-(2-cyano-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 715.5 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-cyanomethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 701.5 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 732.5 [ (M+H)+] .
Examule 144 Examine 145 Example 146 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-hydroxy-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
706.5 [(M+H)+].
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isobutyl-acetarnide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 764.5 [ (M+H)+] .
Example 147 Example 148 Examule 149 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-I-yl}-1-thiomorpholin-4-yl-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 734.5 [(M+H)+]
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-furan-2-ylmethyl-N-methyl-acetamide was prepared in an analogous-manner as described in example 8. LR-MS:
742.5 [(M+H)+].
Example 151 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-[ 1,3] dioxolan-2-ylmethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
748.4 [(M+H)+].
Examule 150 Example 152 1-(4-Acetyl-piperazin-1-yl)-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone was prepared in an analogous manner as described in example 8. LR-MS: 759.5 [ (M+H)+] .
1-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 8. LR-MS:
815.6 [(M+H)+].
Example 154 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-I-yl}-N-cyclopropyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 688.4 [(M+H)+J.
Exam 1p a 153 Example 155 4-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-I-yl}-acetyl)-piperazin-2-one was prepared in an analogous manner as described in example 8. LR-MS: 731.5 [(M+H)~].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-N-(2,2,2-trifluoro-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 730.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl)-piperazin-1-yl}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 648.4 [(M+H)+].
Examule 158 Example 156 Example 157 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-diethyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
Example 159 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methyl-allyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 702.5 [(M+H)+].
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-irnidazole-1-carbonyl]-piperazin-1-yl}-N-( 1-hydroxymethyl-3-methyl-butyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
748.5 [ (M+H)+] .
Example 160 Example 161 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1- [4-(2-hydroxy-ethyl)-piperidin-1-yl] -ethanone was prepared in an analogous manner as described in example 8. LR-MS:
760.50 [(M+H)+].
Example 162 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-hydroxymethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
746.50 [ (M+H)+] .
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-1-( 1,4-dioxa-8-aza-spiro [4.5]
dec-8-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
774.50 [ (M+H)+] .
Example 163 Example 164 1-( {4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 8. LR-MS:
[ (M+H)+] .
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. hR-MS:
732.5 [ (M+H)+] .
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(3-hydroxy-propyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 706.30 [(M+H)+].
Examule 167 Example 165 Example 166 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 676.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-1-methyl-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
734.5 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 720.5 [ (M+H)+] .
Example 168 Example 169 Example 170 N-Benzyloxy-2-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 768.5 [(M+H)+]
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 692.4 [(M+H)+]
2-{ 1-(4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(5-methyl-furan-2-ylmethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
756.5 [ (M+H)+] .
Example 171 Example 172 Example 173 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(4-triffuoromethyl-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
798.5 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-propyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 704.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-N-methyl-acetamide was prepared in an analogous mannei as described in example 8. LR-MS: 706.4 [ (M+H)+] .
Example 176 Example 174 Example 175 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(Z-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-cyano-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
729.5 [(M+H)tJ. .
Example 177 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-cyanomethyl-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
715.5 [(M+H)t].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 8. LR-MS:
746.5 [(M+H)~].
Example 179 Example 178 2-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-ylamino }-N-(2-hydroxy-ethyl)-N-methyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
720.4 [ (M+H)+] .
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-I-carbonyl]-piperidin-4-ylamino}-N-isobutyl-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 718.5 [(M+H)+].
2-{ I- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 662.4 [(M+H)+].
Example 180 Example 181 Example 182 2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2,2,2-trifluoro-ethyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS:
744.5 [(M+H)+].
2-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trilluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methyl-allyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 716.5 [(M+H)+].
2-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(1-hydroxymethyl-3-rnethyl-butyl)-acetamide was prepared in an analogous manner as described in example 8. LR-MS: 762.6 [(M+H)+].
GH
Exarnnle 183 Example 184 Examule 185 - llo -2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid dimethylamide hydrochloride was prepared in an analogous manner as described in example 8.
LR-MS:
726.2 [(M+H)+].
2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazin-1-yl}-ethanesulfonic acid amide hydrochloride was prepared in an analogous manner as described in example 8. LR-MS: 698.1 [ (M+H)+] .
2-(4-Acetyl-piperazin-1-yl)-N-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetaxnide was prepared in an analogous manner as described in example 9. LR-MS: 773.4 [(M+H)~]
Examule I86 Example 287 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-oxo-piperazin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 745.4 [(M+H)t].
1-( { 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-ylcarbamoyl}-methyl)-piperidine-4-carboxylic acid amide was prepared in an analogous manner as described in example 9.
LR-MS: 773.4 [(M+H)+].
Example 188 Example 189 Example 190 1-({ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 9.
LR-MS: 773.4 [(M+H)~].
1-({ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 9. LR-MS: 829.5 [(M+H)+].
N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-hydroxy-piperidin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 746.4 [ (M+H)+] .
Example 191 Examule 192 Example 193 N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS:
760.7 [ (M+H)+] .
Example 194 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-yl}-2-[bis-(2-hydroxy-ethyl)-amino]
-acetamide was prepared in an analogous mariner as described in example 9. LR-MS:
750.4 [(M+H)+].
Example 195 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-( 1,4-dioxa-8-aza-spiro [4.5]
dec-8-yl)-acetamide was prepared in an analogous manner as described in example 9. LR-MS:
788.4 [(M+H)+]. Example 196 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-yl}-2- [bis-(2-methoxy-ethyl)-amino] -acetamide was prepared in an analogous manner as described in example 9. LR-MS:
778.4 [ (M+H)+] .
N-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-( [ 1,3] dioxolan-2-ylmethyl-methyl-amino)-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 762.4 [(M+H)+].
N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-methylamino-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 676.4 [(M+H)+]. .
Example 197 Examule 198 Example 199 N-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-dimethylamino-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 690.4 [(M+H)+].
2-Amino-N-{ 1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide was prepared in an analogous manner as described in example 9. LR-MS: 662 [(M+H)t].
2-(4-Acetyl-piperazin-1-yl)-1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 759.4 [ (M+H)+] .
Example 202 Example 200 Example 201 4-(2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperazin-2-one was prepared in an analogous manner as described in example 9. LR-MS: 732.2 [(M+H)+].
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-4-carboxylic acid amide was prepared in an analogous manner as described in example 9. LR-MS:
759.4 [(M+H)+].
1-(2-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid amide was prepared in an analogous manner as described in example 9. LR-MS:
759.4 [ (M+H)+] .
Example 203 Example 204 Example 205 1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid diethylamide was prepared in an analogous manner as described in example 9. LR-MS: 815.6 [(M+H)+].
Example 206 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-dimethylamino-ethylamino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
719.7 [ (M+H)+] .
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-[methyl-( 1-methyl-pyrrolidin-3-yl)-amino]-ethanone was prepared in an analogous manner as described in example 9.
LR-MS: 745.6 [(M+H)+].
Examt~le 207 Example 208 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-y1}-2-(3-hydroxy-piperidin-1-yl)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 732.6 [(M+H)+].
Example 209 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-hydroxy-ethylarnino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 692.3 [(M+H)+].
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-Example 210 ethanone was prepared in an analogous manner as described in example 9. LR-MS:
746.4 [ (M+H)+] .
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
736.4 [(M+H)+].
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-methoxy-ethylamino)-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 706.3 [ (M+H)+] .
Example 211 Example 212 Example 213 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-methoxy-ethyl)-amino]-ethanone was prepared in an analogous manner as described in example 9. LR-MS:
764.4 [(M+H)~].
1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-2-( [ 1,3] dioxolan-2-ylmethyl-methyl-amino)-ethanone was prepared in an analogous manner as described in example 9.
LR-MS: 74.6 [ (M+H)+] .
Example 215 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methylamino-ethanone was prepared in an analogous manner as described in example 9. LR-MS: 662.1 [(M+H)+].
Example 214 Example 216 1-{ 1- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidin-4-yl}-3-methyl-thiourea was prepared in an analogous manner as described in example 10. LR-MS: 678.3 [(M+H)+].
Example 217 1-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperidin-4-yl}-3-phenyl-thiourea was prepared in an analogous manner as described in example 10. LR-MS: 740.3 [(M+H)~J.
Examule 218 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonylJ-piperazine-1-carbothioic acid phenylamide was prepared in an analogous manner as described in example 10. LR-MS: 726.3 [(M+H)+].
Example 219 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carb~nyl]-piperazine-1-carbonyl}-piperidine-4-carboxylic acid amide was prepared in an analogous rrzanner'as described in example 11. LR-MS:
745.5 [(M+H)t].
3-Oxo-piperazine-1-carboxylic acid {1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide was prepared in an analogous manner as described in example 11. LR-MS: 732.4 [(M+H)+).
Piperidine-1,4-dicarboxylic acid 4-amide 1-({1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide) was prepared in an analogous manner as described in example 11. LR-MS:
759.5 [ (M+H)+] .
Example 220 Example 221 Example 222 3-{ 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,1-dimethyl-urea was prepared in an analogous manner as described in example 11. LR-MS: 676.4 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-piperidin-1-yl)-methanone hydrochloride was prepared in an analogous manner as described in example 13. LR-MS: 688.4 [(M+H)+].
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -{4- [4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl] -phenyl}-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 741.6 [ (M+H)+] .
aH
Example 223 Example 224 Example 225 [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 763.3 [ (M+H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 62.3 [(M+H)+].
Example 227 aH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 695.3 [(M+H)+].
Example 228 aH
Example 226 [4-(4-Amino-piperidin-1-ylmethyl)-phenyl]-[4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-ylJ-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 709.3 [(M+H)+J.
Examule 229 aH
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-1-yl)-ethanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 737.3 [(M+H)~].
aH
N-( 1-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperidin-4-yl)-acetamide hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 751.4 [(M+H)~].
Examine 231 GH
Example 230 4-{4- [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 709.3 [(M+H)~].
Example 232 CIH
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] - [4-(2-hydroxymethyl-piperidin-1-ylmethyl)-phenyl] -methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 724.3 [(M+H)+].
CIH
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 738.3 [(M+H)+].
GH
Examule 233 Example 234 [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 696.3 [ (M+H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 749.4 [ (M~H)+] .
GH
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 668.1 [(M+H)+].
GH
Example 235 Examule 236 Examule 237 4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 14. LR-MS: 695.3 [(M+H)+].
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone was prepared in an analogous manner as described in example 14. LR-MS: 682.3 [(M+H)+].
aH
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride was prepared in an analogous manner as described in example 14.
LR-MS: 724.3 [(M+H)+].
GN
Example 238 Example 239 Example 240 4-{2- [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-2-one hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 669.2 [(M+H)+].
CIH
Ha( {2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-diethyl-amine hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 642.2 [(M+H)+].
GH
2-(4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-1-yl)-ethanol hydrochloride was prepared in an analogous manner as described in example 15. LR-MS: 699.3 [(M+H)+]
Example 243 In Vitro Assay Example 241 Example 242 The ability of the compounds to inhibit the interaction between p53 and MDM2 proteins was measured by an HTRF (homogeneous time-resolved fluorescence) assay in which recombinant GST-tagged MDM2 binds to a peptide that resembles the MDM2-interacting region of p53 (Lane et al.). Binding of GST-MDM2 protein and p53-peptide (biotinylated on its N-terminal end) is registered by the FRET (fluorescence resonance energy transfer) between Europium (Eu)-labeled anti-GST antibody and streptavidin-conjugated Allophycocyanin (APC).
Test is performed in black flat-bottom 384-well plates (Costar) in a total volume of 40 uL containing:90 nM biotinylate peptide, 160 ng/ml GST-MDM2, 20 nM
streptavidin-APC (PerkinElmerWallac), 2 nM Eu-labeled anti-GST-antibody (PerkinElmerWallac), 0.2% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT) and 20 mM Tris-borate saline (TBS) buffer as follows: Add 10 uL of GST-MDM2 (640 ng/ml working solution) in reaction buffer to each well. Add 10 uL diluted compounds ( 1:5 dilution in reaction buffer) to each well, mix by shaking. Add 20 uL
biotinylated p53 peptide ( 180 nM working solution) in reaction buffer to each well and mix on shaker.
Incubate at 37°C for 1 h. Add 20 uL streptavidin-APC and Eu-anti-GST
antibody mixture (6 nM Eu-anti-GST and 60 nM streptavidin-APC working solution) in TBS
buffer with 0.2% BSA, shake at room temperature for 30 minutes and read using a TRF-capable plate reader at 665 and 615 nm (Victor 5, Perkin ElmerWallac). If not specified, the reagents were purchased from Sigma Chemical Co.
ICSOS showing biological activity that applies to compounds of the subject matter of this invention ranges from about 0.020 uM to about 5 uM. Specific data for some examples are as follows:
Example ICSO (~.M) 6 0.100 16 1.740 26 0.800 36 4.260 176 0.021
Claims (52)
1. At least one compound selected from a compound of formula I
wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, and lower alkyl substituted with-OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino, and trifluoromethyl heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl, and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, and lower alkyl substituted with-OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino, and trifluoromethyl heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl, and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
2. The compound of claim 1, wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen and methyl;
83 is selected from the group consisting of heteroaryl, heterocycle, and CH2-R7;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, and lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHa, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen and methyl;
83 is selected from the group consisting of heteroaryl, heterocycle, and CH2-R7;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl and NH-C(O)-R8;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, and lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterecycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxy and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy and cyano, heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NHa, N-lower alkyl, N-lower alkoxy, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
3. The compound of claim 1 wherein the two hydrogen of the imadazoline ring are in a cis configuration to each other.
4. The compound of claim 1 wherein the compound is in a racemic form.
5. The compound of claim 1 wherein the compound is optically active.
6. The compound of claim 1 wherein the compound is an isomer.
7. The compound of claim 1 wherein X1 and X2 are both chloro.
8. The compound of claim 1 wherein X3 is selected from ethoxy and isopropoxy.
9. The compound of claim 1 wherein the trifluoromethyl substituent is para to the imidazoline ring.
10. The compound of claim 1 wherein the trifluoromethyl substituent is meta to the imidazoline ring.
11. The compound of claim 1 wherein R is C(O)-phenyl-CH2-R1.
12. The compound of claim 1 wherein R is C(O)-NR2R3.
l3.The compound of claim 1 wherein R is C(O)-piperidine substituted by R4.
l4.The compound of claim 1 wherein R is C(O)-piperazine substituted by R5.
15. The compound of claim 1 wherein R is SO2-R6.
16. The compound of claim 1 wherein both X1 and X2 are chloro, X3 is selected from ethoxy and isopropoxy, the trifluoromethyl group is pare to the imidazoline ring, and R is C(O)-piperidine substituted by R4.
17. The compound of claim 1 wherein both X1 and X2 are chloro, X3 is selected from ethoxy and isopropoxy, the trifluoromethyl group is pare to the imidazoline ring, and R is C(O)-piperazine substituted by R5.
18. The compound of claim 1 wherein both X1 and X2 are chloro, X3 is selected from ethoxy and isopropoxy, the trifluoromethyl group is mete to the imidazoline ring, and R is C(O)-piperidine substituted by R4.
19. The compound of claim 1 wherein X1, X2 are chloro, X3 is ethoxy or isopropoxy, the trifluoromethyl group is mete to the imidazoline ring, and R
is C(O)-piperazine substituted by R5.
is C(O)-piperazine substituted by R5.
20. The compound of claim 1 wherein R5 is lower alkyl substituted by R15.
21. The compound of claim 1 wherein piperazine is substituted by oxo and lower alkyl substituted by R15.
22. The compound of claim 1 wherein R15 is selected from -SO2-methyl, hydroxy and lower alkoxy.
23. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone;
1-Benzyl-4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(morpholine-4-sulfonyl)-piperazin-1-yl]-methanone;
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-propionitrile hydrochloride;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-dimethylamino-ethanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid methylamide;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperazin-2-one;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone hydrochloride;
and 4-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylmethyl}-piperazin-2-one hydrochloride.
1-Benzyl-4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(morpholine-4-sulfonyl)-piperazin-1-yl]-methanone;
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-propionitrile hydrochloride;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-dimethylamino-ethanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid methylamide;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperazin-2-one;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone hydrochloride;
and 4-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylmethyl}-piperazin-2-one hydrochloride.
24. The compound of claim 1 which is seleted from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,3,3-trifluoro-2-hydroxy-propyl)-piperazin-1-yl]-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-methanone hydrochloride;
4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-morpholine hydrochloride;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-4-carboxylic acid methyl ester;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid cyanomethyl-methyl-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(1,4-dioxa-8-aza-spiro [4.5] dec-8-yl)-methanone;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-3-carboxylic acid ethyl ester;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [1,3]dioxolan-2-ylmethyl-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-hydroxy-propyl)-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-methanone hydrochloride;
4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-morpholine hydrochloride;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-4-carboxylic acid methyl ester;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid cyanomethyl-methyl-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(1,4-dioxa-8-aza-spiro [4.5] dec-8-yl)-methanone;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-3-carboxylic acid ethyl ester;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [1,3]dioxolan-2-ylmethyl-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-hydroxy-propyl)-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide.
25. The compound of claim 1 which is selected from 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-pyridin-2-yl-ethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (furan-2-ylmethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (pyridin-3-ylmethyl)-amide;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazole-1-carboxylic acid methyl-(1-methyl-pyrrolidin-3-yl)-amide;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-2-carboxylic acid ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyrimidin-2-yl-piperazin-1-yl)-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 3-methoxy-benzylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-methyl-amide.
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (furan-2-ylmethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (pyridin-3-ylmethyl)-amide;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazole-1-carboxylic acid methyl-(1-methyl-pyrrolidin-3-yl)-amide;
1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidine-2-carboxylic acid ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyrimidin-2-yl-piperazin-1-yl)-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 3-methoxy-benzylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-ethyl)-methyl-amide.
26. The compound of claim 1 which is selected from 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-1-methyl-ethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-cyano-ethyl)-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-pyridin-2-yl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid furan-2-ylmethyl-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-benzyl)-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 4-sulfamoyl-benzylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-methyl-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-imidazol-1-yl-propyl)-amide.
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-cyano-ethyl)-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-pyridin-2-yl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid furan-2-ylmethyl-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-hydroxy-benzyl)-methyl-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid 4-sulfamoyl-benzylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-methyl-amide; and 4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (3-imidazol-1-yl-propyl)-amide.
27. The compound of claim 1 which is selected from 1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-pyrrolidine-2-carboxylic acid methyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-pyrrolidin-1-yl-propyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-yl-piperazin-1-yl)-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,3-dihydro-benzo[1,4]dioxine-2-carbonyl)-piperazin-1-yl]-methanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-piperidin-1-yl-ethanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dipropylamino-propyl)-piperazin-1-yl]-methanone.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-pyrrolidin-1-yl-propyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-yl-piperazin-1-yl)-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,3-dihydro-benzo[1,4]dioxine-2-carbonyl)-piperazin-1-yl]-methanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-piperidin-1-yl-ethanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dipropylamino-propyl)-piperazin-1-yl]-methanone.
28. The compound of claim 1 which is selected from 6-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-nicotinonitrile;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dimethylamino-propyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone;
{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetic acid ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-ethoxy-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diisopropylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-diethylamino-propyl)-piperazin-1-yl]-methanone.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-dimethylamino-propyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone;
{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetic acid ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-ethoxy-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diisopropylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-diethylamino-propyl)-piperazin-1-yl]-methanone.
29. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl]-methanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diethylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-( 5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl] -methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methoxy-propyl)-piperazin-1-yl]-methanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-pyrrolidin-1-yl-ethanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-ylmethyl)-piperazin-1-yl]-methanone; and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-nicotinonitrile.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-diethylamino-ethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-( 5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl] -methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methoxy-propyl)-piperazin-1-yl]-methanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-pyrrolidin-1-yl-ethanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(tetrahydro-furan-2-ylmethyl)-piperazin-1-yl]-methanone; and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-nicotinonitrile.
30. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-phenyl-piperidin-1-yl)-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid ethoxy-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2,5-dimethoxy-phenyl)-amide;
2-[4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethoxy-phenyl)-piperazin-1-yl]-methanone.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methylamide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2-methoxy-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid methoxy-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid ethoxy-amide;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid (2,5-dimethoxy-phenyl)-amide;
2-[4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethoxy-phenyl)-piperazin-1-yl]-methanone.
31. The compound of claim 1 which is selected from 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methoxy-ethanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone hydrochloride;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid bis-(2-methoxy-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-propyl-benzenesulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazol-1-yl]-[4-(1,5-dimethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazol-1-yl]-[4-(5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl)-piperazin-1-yl]-methanone;
Acetic acid 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-3-carbonyl)-piperazin-1-yl]-methanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyridine-4-carbonyl)-piperazin-1-yl] -methanone.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone hydrochloride;
4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carboxylic acid bis-(2-methoxy-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-propyl-benzenesulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazol-1-yl]-[4-(1,5-dimethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro imidazol-1-yl]-[4-(5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl)-piperazin-1-yl]-methanone;
Acetic acid 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(furan-3-carbonyl)-piperazin-1-yl]-methanone; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyridine-4-carbonyl)-piperazin-1-yl] -methanone.
32. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,4-dimethyl-thiazole-5-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dimethyl-furan-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperazin-1-yl]-methanone;
and 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methoxy-ethanone.
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-2-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,4-dimethyl-thiazole-5-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(thiophene-3-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dimethyl-furan-3-carbonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperazin-1-yl]-methanone;
and 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methoxy-ethanone.
33. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2,5-dichloro-thiophene-3-sulfonyl)-piperazin-1-yl]-methanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-thiophen-2-yl-ethanone;
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidin-1-yl)-ethanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid dimethylamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(butane-1-sulfonyl)-piperazin-1-yl]-methanone;
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-thiophene-2-carboxylic acid methyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-chloro-thiophene-2-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-trifluoromethanesulfonyl-piperazin-1-yl)-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-1-yl]-methanone; and 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-methoxy-ethyl)-piperazin-2-one.
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-thiophen-2-yl-ethanone;
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-triffuoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidin-1-yl)-ethanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid dimethylamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(butane-1-sulfonyl)-piperazin-1-yl]-methanone;
3-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-thiophene-2-carboxylic acid methyl ester;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(5-chloro-thiophene-2-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-trifluoromethanesulfonyl-piperazin-1-yl)-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-1-yl]-methanone; and 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-methoxy-ethyl)-piperazin-2-one.
34. The compound of claim 1 which is selected from 4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-1-(2-morpholin-4-yl-ethyl)-piperazin-2-one hydrochloride;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid methylamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyrrolidine-1-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperidine-1-sulfonyl)-piperazin-1-yl]-methanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid isobutyl-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-methoxy-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid bis-(2-methoxy-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (tetrahydro-furan-2-ylmethyl)-amide;
and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-hydroxy-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone.
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid methylamide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(pyrrolidine-1-sulfonyl)-piperazin-1-yl]-methanone;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(piperidine-1-sulfonyl)-piperazin-1-yl]-methanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid isobutyl-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-methoxy-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid bis-(2-methoxy-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (tetrahydro-furan-2-ylmethyl)-amide;
and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-hydroxy-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone.
35. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-{4- [4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl] -piperazin-1-yl}-methanone;
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-1-yl)-ethanone;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-2-one;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-dimethylamino-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2,2,2-trifluoro-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-cyano-ethyl)-methyl-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,3,3-trifluoro-propyl)-piperazin-1-yl]-methanone hydrochloride;
{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetonitrile hydrochloride; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone hydrochloride.
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-1-yl)-ethanone;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonyl}-piperazin-2-one;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-dimethylamino-ethyl)-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-piperazin-1-yl]-methanone;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2,2,2-trifluoro-ethyl)-amide;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-sulfonic acid (2-cyano-ethyl)-methyl-amide;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3,3,3-trifluoro-propyl)-piperazin-1-yl]-methanone hydrochloride;
{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetonitrile hydrochloride; and [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone hydrochloride.
36. The compound of claim 1 which is selected from 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-1-methyl-ethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-ethyl)-acetamide;
N-Benzyloxy-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-ethoxy-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(5-methyl-furan-2-ylmethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-trifluoromethyl-piperidin-1-yl)-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-propyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isopropyl-N-methyl-acetamide;
and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-N-methyl-acetamide.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-ethyl)-acetamide;
N-Benzyloxy-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-ethoxy-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(5-methyl-furan-2-ylmethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-trifluoromethyl-piperidin-1-yl)-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-propyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isopropyl-N-methyl-acetamide;
and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-N-methyl-acetamide.
37. The compound of claim 1 which is selected from 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-cyano-ethyl)-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-cyanomethyl-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(3-hydroxy-piperidin-1-yl)-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-hydroxy-ethyl)-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isobutyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxy-ethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-thiomorpholin-4-yl-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-furan-2-ylmethyl-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-[1,3]dioxolan-2-ylmethyl-N-methyl-acetamide; and 1-(4-Acetyl-piperazin-1-yl)-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4 trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-cyanomethyl-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(3-hydroxy-piperidin-1-yl)-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-hydroxy-ethyl)-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isobutyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxy-ethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-thiomorpholin-4-yl-ethanone;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-furan-2-ylmethyl-N-methyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-[1,3]dioxolan-2-ylmethyl-N-methyl-acetamide; and 1-(4-Acetyl-piperazin-1-yl)-2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4 trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone.
38. The compound of claim 1 which is selected from 1-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid diethylamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-cyclopropyl-acetamide;
4-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperazin-2-one;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2,2,2-trifluoro-ethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-diethyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methyl-allyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(1-hydroxymethyl-3-methyl-butyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-ethanone; and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-hydroxymethyl-piperidin-1-yl)-ethanone.
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1-yl}-N-cyclopropyl-acetamide;
4-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperazin-2-one;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2,2,2-trifluoro-ethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-diethyl-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methyl-allyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(1-hydroxymethyl-3-methyl-butyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-ethanone; and 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(4-hydroxymethyl-piperidin-1-yl)-ethanone.
39. The compound of claim 1 which is selected from 2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-(1,4-dioxa-8-aza-spiro [4.5]
dec-8-yl)-ethanone;
1-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid amide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(3-hydroxy-propyl)-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-1-methyl-ethyl)-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-ethyl)-acetamide;
N-Benzyloxy-2-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-acetamide; and 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(5-methyl-furan-2-ylmethyl)-acetamide.
dec-8-yl)-ethanone;
1-({4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetyl)-piperidine-3-carboxylic acid amide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(3-hydroxy-propyl)-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-1-methyl-ethyl)-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methoxy-ethyl)-acetamide;
N-Benzyloxy-2-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-acetamide; and 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5 dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(5-methyl-furan-2-ylmethyl)-acetamide.
40. The compound of claim 1 which is selected from 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(4-trifluoromethyl-piperidin-1-yl)-ethanone;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-propyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-cyano-ethyl)-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-cyanomethyl-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(3-hydroxy-piperidin-1-yl)-ethanone;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-hydroxy-ethyl)-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-isobutyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl)-piperidin-4-ylamino}-acetamide; and 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2,2,2-trifluoro-ethyl)-acetamide.
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-propyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-methoxy-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-cyano-ethyl)-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-cyanomethyl-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-1-(3-hydroxy-piperidin-1-yl)-ethanone;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-hydroxy-ethyl)-N-methyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-isobutyl-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl)-piperidin-4-ylamino}-acetamide; and 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2,2,2-trifluoro-ethyl)-acetamide.
41. The compound of claim 1 which is selected from 2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(2-methyl-allyl)-acetamide;
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(1-hydroxymethyl-3-methyl-butyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid dimethylamide hydrochloride;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid amide hydrochloride;
2-(4-Acetyl-piperazin-1-yl)-N-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-oxo-piperazin-1-yl)-acetamide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-4-carboxylic acid amide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid amide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid diethylamide; and N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-hydroxy-piperidin-1-yl)-acetamide.
2-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylamino}-N-(1-hydroxymethyl-3-methyl-butyl)-acetamide;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid dimethylamide hydrochloride;
2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanesulfonic acid amide hydrochloride;
2-(4-Acetyl-piperazin-1-yl)-N-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-oxo-piperazin-1-yl)-acetamide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-4-carboxylic acid amide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid amide;
1-({1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-ylcarbamoyl}-methyl)-piperidine-3-carboxylic acid diethylamide; and N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(3-hydroxy-piperidin-1-yl)-acetamide.
42. The compound of claim 1 which is selected from N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-[bis-(2-methoxy-ethyl)-amino]-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-([1,3] dioxolan-2-ylmethyl-methyl-amino)-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-methylamino-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-dimethylamino-acetamide;
2-Amino-N-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide;
2-(4-Acetyl-piperazin-1-yl)-1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone;
and 4-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperazin-2-one.
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-[bis-(2-methoxy-ethyl)-amino]-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-([1,3] dioxolan-2-ylmethyl-methyl-amino)-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-methylamino-acetamide;
N-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-2-dimethylamino-acetamide;
2-Amino-N-{1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide;
2-(4-Acetyl-piperazin-1-yl)-1-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone;
and 4-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperazin-2-one.
43. The compound of claim 1 wherein the compound is selected from 1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-4-carboxylic acid amide;
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid amide;
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid diethylamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-dimethylamino-ethylamino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(3-hydroxy-piperidin-1-yl)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-hydroxy-ethylamino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-ethanone; and 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-methoxy-ethylamino)-ethanone.
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid amide;
1-(2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-oxo-ethyl)-piperidine-3-carboxylic acid diethylamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-dimethylamino-ethylamino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(3-hydroxy-piperidin-1-yl)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-hydroxy-ethylamino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(4-hydroxymethyl-piperidin-1-yl)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-hydroxy-ethyl)-amino]-ethanone; and 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-(2-methoxy-ethylamino)-ethanone.
44. The compound of claim 1 which is selected from 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-[bis-(2-methoxy-ethyl)-amino]-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-([1,3]dioxolan-2-ylmethyl-methyl-amino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methylamino-ethanone;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-3-methyl-thiourea;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-3-phenyl-thiourea;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid phenylamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidine-4-carboxylic acid amide;
3-Oxo-piperazine-1-carboxylic acid {1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide;
Piperidine-1,4-dicarboxylic acid 4-amide 1-({1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide); and 3-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,1-dimethyl-urea.
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-([1,3]dioxolan-2-ylmethyl-methyl-amino)-ethanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-2-methylamino-ethanone;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-3-methyl-thiourea;
1-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-3-phenyl-thiourea;
4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbothioic acid phenylamide;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazine-1-carbonyl}-piperidine-4-carboxylic acid amide;
3-Oxo-piperazine-1-carboxylic acid {1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide;
Piperidine-1,4-dicarboxylic acid 4-amide 1-({1-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-amide); and 3-{1-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-1,1-dimethyl-urea.
45. The compound of claim 1 which is selected from [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-piperidin-1-yl)-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-phenyl)-methanone hydrochloride;
[4-(4-Amino-piperidin-1-ylmethyl)-phenyl]-[4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -methanone hydrochloride;
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-1-yl)-ethanone hydrochloride;
N-(1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperidin-4-yl)-acetamide hydrochloride;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride; and [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-hydroxymethyl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride.
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-piperazin-1-ylmethyl-phenyl)-methanone hydrochloride;
[4-(4-Amino-piperidin-1-ylmethyl)-phenyl]-[4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl] -methanone hydrochloride;
1-(4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-1-yl)-ethanone hydrochloride;
N-(1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperidin-4-yl)-acetamide hydrochloride;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride; and [4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-hydroxymethyl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride.
46. The compound of claim 1 which is selected from 1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride;
4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-2-one hydrochloride;
{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-diethyl-amine hydrochloride; and 2-(4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-1-yl)-ethanol hydrochloride.
[4,5-Bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-phenyl]-methanone hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-diethylaminomethyl-phenyl)-methanone hydrochloride;
4-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-piperazin-2-one hydrochloride;
[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-morpholin-4-ylmethyl-phenyl)-methanone;
1-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-5-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-benzyl}-pyrrolidine-2-carboxylic acid methyl ester hydrochloride;
4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-2-one hydrochloride;
{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-diethyl-amine hydrochloride; and 2-(4-{2-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-sulfonyl]-ethyl}-piperazin-1-yl)-ethanol hydrochloride.
47. A pharmaceutical composition which comprises at least one compound selected from a compound of formula I
wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, lower alkyl substituted with -OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl;
heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.
wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NH2, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11;
R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, oxo, lower alkyl substituted with -OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl;
heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.
48. Compounds according to anyone of claims 1 to 47 as medicament.
49. Use of a compound of formula I for the preparation of a medicament for the treatment of a disease based on the interaction of MDM2 protein with a p53-like peptide wherein X1 and X2 are halogen;
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHa, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11, R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo, lower alkyl substituted with -OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl;
heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle, and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
X3 is lower alkoxy;
R is selected from the group consisting of wherein R1 is selected from the group consisting of N-lower alkyl, unsubstituted heterocycle and heterocycle substituted by one or more substituents selected from the group consisting of NHa, NH-C(O)-lower alkyl, C(O)-lower alkyl, C(O)-lower alkoxy, oxo, heterocycle, and lower alkyl substituted by hydroxy;
R2 is selected from hydrogen, methyl and lower alkoxy;
R3 is selected from the group consisting of heteroaryl, heterocycle, lower alkyl substituted with R7, aryl, lower alkoxy, and lower alkyl;
R4 is selected from the group consisting of C(O)-lower alkoxy, lower alkoxy, CH2-N-lower alkyl, CH2-heterocycle, CH2-heterocycle substituted by oxo, aryl, NH-C(S)-N-lower alkyl, NH-C(S)-N-aryl, NH-C(O)-R8, N-alkyl substituted by C(O)R16, and trifluoromethyl;
R5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro, C(S)-N-lower alkyl, C(S)-N-aryl, C(O)-CH2-R12, C(O)-R13, SO2-R14 and lower alkyl substituted by a substituent selected from R15 and C(O)-R16;
R6 is selected from the group consisting of lower alkyl substituted by -N-lower alkyl, lower alkyl substituted by heterocycle, lower alkyl substituted by heterocycle substituted by one or two substituents selected from lower alkyl, lower alkyl substituted by hydroxyl lower alkyl substituted by lower alkoxy, and oxo;
R7 is selected from the group consisting of cyano, hydroxy, lower alkoxy, heteroaryl, heterocycle, heterocycle substituted by oxo, N-lower alkyl; and aryl substituted by a substituent selected from the group consisting of SO2NH2, lower alkoxy and hydroxy;
R8 is selected from the group consisting of N-lower alkyl, heterocycle, heterocycle substituted by a substituent selected from the group consisting of oxo, C(O)-NH2 and C(O)-NH-lower alkyl, CH2-R9 and CH2-R10;
R9 is selected from the group consisting of NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, C(O)-NH-lower alkoxy, C(O)-NH-benzyloxy, C(O)-heterocycle substituted by a substituent selected from trifluoromethyl or hydroxyl, and C(O)-NH-R11, R10 is selected from a heterocycle, and heterocycle substituted by one or more groups selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy, hydroxy, lower alkoxy and oxo;
R11 is selected from lower alkyl, and lower alkyl substituted by a substituent selected from the group consisting of alkoxy, heteroaryl substituted by lower alkyl, cyano, and trifluoromethyl;
R12 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from hydroxy and lower alkoxy, heteroaryl, and heterocycle substituted by R17;
R13 is selected from the group consisting of heteroaryl, heteroaryl substituted by one or two substituents selected from the group consisting of lower alkyl, aryl and halogen, heterocycle, heterocycle substituted by one or more substituents selected from the group consisting of lower alkyl, aryl and halogen, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, and oxo, lower alkyl substituted with -OC(O)CH3;
R14 is selected from the group consisting of trifluoromethyl, lower alkyl, aryl substituted by lower alkyl, NH2, N-lower alkyl, N-lower alkyl substituted by a substituent selected from lower alkoxy, cyano, amino and trifluoromethyl;
heteroaryl, heteroaryl substituted by a substituent selected from the group consisting of amino, halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl, heterocycle, and heterocycle substituted by a substituent selected from the group consisting of halogen, hydroxy, oxo, C(O)-lower alkoxy, lower alkyl and lower alkyl substituted by hydroxyl;
R15 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, N-lower alkyl, SO2-lower alkyl, C(O)-lower alkyl, SO2-NH2, SO2-N-lower alkyl, heteroaryl and heterocycle;
R16 is selected from the group consisting of lower alkoxy, NH2, N-lower alkyl, N-lower alkoxy, N-lower alkenyl, N-benzyloxy, N-lower alkyl substituted by R18, heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
R17 is selected from the group consisting of C(O)-lower alkyl, C(O)-NH2, C(O)-N-lower alkyl, hydroxy, oxo and lower alkyl substituted by hydroxy; and R18 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
or a pharamaceutically acceptable salt or ester thereof.
50. Use according to claim 49 wherein the disease are cell proliferative disorders.
51. Use according to claim 49 wherein the disease are solid tumors.
52. The invention as described above.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47935103P | 2003-06-17 | 2003-06-17 | |
US60/479,351 | 2003-06-17 | ||
PCT/EP2004/006176 WO2005003097A1 (en) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaryl-imidazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2528119A1 true CA2528119A1 (en) | 2005-01-13 |
Family
ID=33563793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002528119A Abandoned CA2528119A1 (en) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaryl-imidazolines |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1638942A1 (en) |
JP (1) | JP2006527712A (en) |
KR (1) | KR100768021B1 (en) |
CN (1) | CN100465163C (en) |
AR (1) | AR044703A1 (en) |
AU (1) | AU2004254187A1 (en) |
BR (1) | BRPI0411841A (en) |
CA (1) | CA2528119A1 (en) |
CL (1) | CL2004001484A1 (en) |
MX (1) | MXPA05013279A (en) |
RU (1) | RU2319696C2 (en) |
TW (1) | TW200510387A (en) |
WO (1) | WO2005003097A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1861376A1 (en) * | 2005-03-16 | 2007-12-05 | F. Hoffmann-Roche AG | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments |
EP1960368B1 (en) * | 2005-12-01 | 2015-05-06 | F. Hoffmann-La Roche AG | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
US8114095B2 (en) * | 2006-11-10 | 2012-02-14 | Bausch & Lomb Incorporated | Intraocular lens injection apparatus and method |
WO2008072655A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | Imidazothiazole derivative having 4,7-diazaspiroý2.5¨octane ring structure |
AU2010205201A1 (en) | 2009-01-16 | 2011-08-04 | Daiichi Sankyo Company,Limited | Imidazothiazole derivative having proline ring structure |
IT1396520B1 (en) | 2009-12-10 | 2012-12-14 | Nuovo Pignone Spa | COUPLING FOR ROTOR BALANCING |
US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2030158A1 (en) * | 1989-11-22 | 1991-05-23 | Nahed K. Ahmed | Cancer treatments |
DE10043456A1 (en) * | 2000-09-04 | 2002-03-14 | Merck Patent Gmbh | Use of ectoin or ectoin derivatives to stabilize p53 |
RU2305095C2 (en) * | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Cis-2,4,5-triphenylimidazolines and pharmaceutical composition based on thereof |
-
2004
- 2004-06-08 AU AU2004254187A patent/AU2004254187A1/en not_active Abandoned
- 2004-06-08 MX MXPA05013279A patent/MXPA05013279A/en unknown
- 2004-06-08 CN CNB2004800170350A patent/CN100465163C/en not_active Expired - Fee Related
- 2004-06-08 BR BRPI0411841-3A patent/BRPI0411841A/en not_active IP Right Cessation
- 2004-06-08 WO PCT/EP2004/006176 patent/WO2005003097A1/en active Application Filing
- 2004-06-08 JP JP2006515856A patent/JP2006527712A/en not_active Ceased
- 2004-06-08 KR KR1020057024295A patent/KR100768021B1/en not_active IP Right Cessation
- 2004-06-08 EP EP04739704A patent/EP1638942A1/en not_active Withdrawn
- 2004-06-08 RU RU2006100730/04A patent/RU2319696C2/en not_active IP Right Cessation
- 2004-06-08 CA CA002528119A patent/CA2528119A1/en not_active Abandoned
- 2004-06-11 TW TW093116988A patent/TW200510387A/en unknown
- 2004-06-15 AR ARP040102068A patent/AR044703A1/en not_active Application Discontinuation
- 2004-06-15 CL CL200401484A patent/CL2004001484A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2004254187A1 (en) | 2005-01-13 |
MXPA05013279A (en) | 2006-03-09 |
RU2319696C2 (en) | 2008-03-20 |
AR044703A1 (en) | 2005-09-21 |
EP1638942A1 (en) | 2006-03-29 |
JP2006527712A (en) | 2006-12-07 |
RU2006100730A (en) | 2006-08-10 |
TW200510387A (en) | 2005-03-16 |
WO2005003097A1 (en) | 2005-01-13 |
CN100465163C (en) | 2009-03-04 |
KR100768021B1 (en) | 2007-10-18 |
CL2004001484A1 (en) | 2005-05-27 |
KR20060021902A (en) | 2006-03-08 |
BRPI0411841A (en) | 2006-08-08 |
CN1809538A (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7425638B2 (en) | Cis-imidazolines | |
JP5324586B2 (en) | Chiral cis-imidazoline | |
AU2007207052B2 (en) | CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors | |
AU2006319248B2 (en) | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | |
KR100855929B1 (en) | Novel cis-imidazolines | |
JP4955646B2 (en) | Cis-2,4,5-triaryl-imidazolines and their use as anticancer agents | |
CA2528119A1 (en) | Cis-2,4,5-triaryl-imidazolines | |
EP2125795B1 (en) | Indole derivatives | |
NZ566007A (en) | (Indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor | |
JPH09500124A (en) | N- (piperidinyl-1-alkyl) -substituted cyclohexanecarboxylic acid amides as 5-HT1A receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |